Study Title: 
Sponsor: 
IND Number: 
EudraCT Number: 
Clinical Trials.gov 
Identifier: 
Indication: 
Protocol ID: 
[COMPANY_009] Study Clinical 
Program Manager: 
[COMPANY_009] Medical 
Monitor: 
[COMPANY_009] Study Director: 
Protocol Version/Date: (rJ GILEAU 
CLINICAL STUDY PROTOCOL 
A Phase 3, Randomized, Open-Label Study to Evaluate the Safety 
and Efficacy of Switching from Regimens Consisting of Boosted 
Atazanavir or Damnavir plus either Emtricitabine/Tenofovir or 
Abacavir/Lamivudine to GS-9883/Emtricitabine/T enofovir 
Alafenamide in Virologically Suppressed HN -[ADDRESS_1010920] 
Foster City, CA [ZIP_CODE] 
125589 
2015-004011-20 
Not Available 
HN -1 Infection 
GS-US-380-1878 
Name: 
[CONTACT_10880]: 
Fax: 
Name: 
[CONTACT_10880]: 
Mobile: 
Fax: 
Name: 
[CONTACT_10880]: 
Fax: 
Original: [COMPANY_003] 
[COMPANY_003] 
[COMPANY_003] 
Marshall Fordyce, MD 
[COMPANY_003] 
[COMPANY_003] 
[COMPANY_003] 
[COMPANY_003] 
[COMPANY_003] 
[COMPANY_003] 
[ADDRESS_1010921] or Independent Ethics Committee. The infonnation is only to be used by [CONTACT_580875]. 
You will not disclose any of the infonnation to others without written authorization from 
[COMPANY_009] Sciences, Inc., except to the extent necessaty to obtain infonned consent from those 
persons to whom the dmg may be administered. 
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_1010922] OF IN- TEXT FIGURES ...................................................................................................................................... 5
PROTOCOL SYNOPSIS .............................................................................................................................................. 6
GLOSSARY OF ABBREVIA TIONS AND DEFINITION OF TERMS .................................................................... 12
1.INTRODUCTION .............................................................................................................................................. 15
1.1.Background ............................................................................................................................................ 15
1.2.GS-9883................................................................................................................................................. 16
1.2.1. General Information ............................................................................................................. 16
1.2.2. Preclinical Pharmacology and Toxicology ........................................................................... 16
1.2.3. Clinical Trials of GS -9883................................................................................................... 18
1.3.Information about Emtricitabine (Emtriva®, FTC)................................................................................. 26
1.4.Information about Tenofovir alafenamide (TAF, GS -7340).................................................................. 26
1.4.1. Clinical Trials of Single Agent Tenofovir alafenamide (TAF, GS -7340) 
or Fixed Dose Combination emtricitabine/tenofovir alafenamide 
(FTC/TAF) ........................................................................................................................... 27
1.4.2. Clinical Trials of FTC/TAF as part of 
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) ........................... 28
1.5.Information about GS -9883/emtricitabine/tenofovir alafenamide (GS -9883/F/TAF) ........................... 30
1.5.1. GS-US-141-1233: Stu dy of the Relative Bioavailability of GS -9883, 
FTC, and TAF betw een GS-9883/F/TAF and GS -9883 + F/TAF........................................ [ADDRESS_1010923] Selection ............................................................................................ 39
4.2.Inclusion Criteria .................................................................................................................................... 39
4.3.Exclusion Criteria ................................................................................................................................... 40
5.INVESTIGATIONAL MEDI CINAL PRODUCTS........................................................................................... 42
5.1.Randomization ....................................................................................................................................... 42
5.2.Description and Handling ....................................................................................................................... 42
5.2.1. Formulation.......................................................................................................................... 42
5.2.2. Packaging and Labeling ....................................................................................................... 43
5.2.3. Storage and Handling ........................................................................................................... 43
5.3.Dosage and Administration of GS -9883/Emtricitabine/Tenofovir alafenamide .................................... 43
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_1010924] (IMP) ................................................................. [ADDRESS_1010925] Enrollment and Treatment Assignment ..................................................................................... 47
6.2.Pretreatment Assessments ...................................................................................................................... 47
6.2.1. Screening Visit ..................................................................................................................... 47
6.2.2. Day 1 Assessments ............................................................................................................... 49
6.3.Randomization ....................................................................................................................................... 51
6.4.Treatment Assessments (Week 4 -48).................................................................................................... 51
6.5.Treatment Assessments (Post Week 48) ...............................................................
................................. [ADDRESS_1010926] Study Care ...................................................................................................................................... 59
6.13.Virologic Failure .................................................................................................................................... 59
6.13.1. Management of Virologic Rebound ..................................................................................... 59
6.13.2. Subjects with HIV -1 RNA ≥ 50 copi[INVESTIGATOR_014]/mL at Study Drug 
Discontinuation, or Week 48................................................................................................ [ADDRESS_1010927] -Treatment Exacerbation of Hepatitis B 
Management ................................
......................................................................................... 67
7.5.5. Management of Hyperbilirubinemia .................................................................................... 69
7.5.6. Management of Possible Abacavir Hypersensitivity Reaction ............................................. 70
7.5.7. On-Treatment Hepatitis C M anagement ............................................................................... 70
7.6.Special Situations Reports ...................................................................................................................... 71
7.6.1. Definitions of Special Situations .......................................................................................... 71
7.6.2. Instructions for Reporting Special Situations ....................................................................... 71
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page4 21 October [ZIP_CODE].STATISTICAL CONSIDER ATIONS................................................................................................................ 73
8.1.Analysis Objectives and Endpoints ........................................................................................................ 73
8.1.1. Analysis Objectives .............................................................................................................. 73
8.1.2. Primary Endpoint ................................................................................................................. 73
8.1.3. Secondary Endpoint ............................................................................................................. 73
8.2.Analysis Conventions ............................................................................................................................. 73
8.2.1. Analysis Sets ........................................................................................................................ 73
8.3.Data Handling Conventions ................................................................................................................... 75
8.4.Demographic Data and Baseline Characteristics ................................................................................... 75
8.5.Efficacy Analysis ................................................................................................................................... 75
8.5.1. Primary Analysis ................................
.................................................................................. 75
8.5.2. Secondary Analyses ............................................................................................................. 77
8.6.Safety Analysis ....................................................................................................................................... 77
8.6.1. Extent of Exposure ............................................................................................................... 77
8.6.2. Adverse Events ..................................................................................................................... 77
8.6.3. Laboratory Evalua tions........................................................................................................ 78
8.6.4. Other Safety Evaluations ...................................................................................................... 78
8.7.Pharmacokinetic Analysis ...................................................................................................................... 78
8.8.Patient Reported Outcomes (PRO) ...............................................................
.......................................... [ADDRESS_1010928] (IRB)/Independent Ethics Committee (IEC) 
Review and Approval ........................................................................................................... [ADDRESS_1010929] Accountability and Return ............................................. 83
9.1.8. Inspections ............................................................................................................................ 83
9.1.9. Protocol Compliance ............................................................................................................ 83
9.2.Sponsor Responsibilities ........................................................................................................................ 84
9.2.1. Protocol Modifications ......................................................................................................... 84
9.2.2. Study Report and Publications ............................................................................................. 84
9.3.Joint Investigator/Sponsor Responsibilities ........................................................................................... 84
9.3.1. Payment Reporting ............................................................................................................... 84
9.3.2. Access to Information for Monitoring .................................................................................. 85
9.3.3. Access to Information for Auditing or Inspections .............................................................. 85
9.3.4. Study Discontinuation .......................................................................................................... 85
10.REFERENCES ................................................................................................................................................... 86
11.APPENDICES .................................................................................................................................................... 88
Appendix 1.Investigator Signature [CONTACT_3490] .................................................................................................... 89
Appendix 2.Study Procedures Table .......................................................................................................... 90
Appendix 3.Management of Clinical and Laboratory Adverse Events ...................................................... 94
Appendix 4.GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities ............... 95
Appendix 5.Definitions of Stage 3 Opportunistic Illnesses in HIV (CDC Guidelines) ........................... 119
Appendix 6.Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements ................................................................................................. 121
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_1010930] OF IN -TEXT TABLES
Table1-1. GS-US-141-1218: GS -9883 Mean (%CV) PK Parameters Follow ing Single Doses 
of GS-9883 in Healthy Subjects (GS -9883 PK Analysis Set; Part A: Single Dosing) ...........20
Table1-2. GS-US-141-1218: GS -9883 Plasma Pharmacokinetic Parameters by [CONTACT_10827] -9883 Dose 
Following Multiple -Dose Administration of GS -9883 (Analysis Set: GS -9883 PK 
Part B: Multiple
-Dose)........................................................................................................... 21
Table1
-3. GS-US-141-1218: Statistical Comparison of GS -9883 Pharmacokinetic Parameters 
Following Single -Dose Adm inistration of GS -9883 in the Fasted and Fed States 
(GS-9883 PK Analysis Set) ...............................................................
..................................... 22
Table1-
4. Trough GS -9883 Plasma C oncentrations at Steady State Follow ing GS-9883 
Administration Under Fasting Conditions and Corresponding Protein -Adjusted 
IQ95 Values (GS-9883 PK Analysis Set) ...............................................................
................ 23
Table1-5. GS-US-141-1219: Trough GS -9883 Plasma Concentrat ions at Steady State 
Following GS-9883 Administration Under Fasting Conditions and Corresponding 
Protein-Adjusted IQ 95Values................................................................
................................. 32
Table5
-1. Prior and Concomitant Medications (GS -9883/F/TAF Regimen) .......................................... 44
Table5-2. Prior and Concomitant Medications (Boosted ATV and DRV regimen) ............................... [ADDRESS_1010931] OF IN -TEXT FIGURES
Figure1-1.GS-US-141-1219: Mean and 95% CIs of Change from Ba seline in HIV -1 RNA 
(log10copi[INVESTIGATOR_014]/mL) (PP Analysis Set) ....................................................................................... 23
Figure3-1
.Study Schema ......................................................................................................................... 37
Figure6-1.Virologic Rebound Schema .................................................................................................... 60
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_1010932]
Foster City, CA [ZIP_CODE]
Study Title: A Phase3, Randomized, Open- Label Study  to Evaluate the Safet y 
andEfficacy of Switching from Regimens Consisting of Boosted
Atazanavir or Darunavir plus 
either Emtricitabine/Tenofovir or 
Abacavir/ Lamivudine to GS-9883/ Emtricitabine /Tenofovir 
Alafenamide in Virologically  Suppressed HI V-1 Infected Adults
IND Number:
EudraCT Number:
Clinical Trials.gov 
Identifier:[PHONE_2519]-004011-20
Not Available
Study Centers 
Planned:Approximately  60 centers in North America
Approximately  31 centers in Europe
Approximately  4 centers in AsiaPacific
Objectives: The primary  objective of this study  is as follows:
To evaluate the efficacy  of switching to a fixed dose combination 
(FDC)of GS-9883/emtricitabine /
tenofovir a lafenamide 
(GS-9883/F/TAF)versus continuing on a regimen consisting of 
boosted atazanavir (ATV) or darunavir (DRV) plus either 
emtricitabine/t enofovir 
disoproxil fumarate ( FTC/TDF )or
abacavir/lamivudine ( ABC/3TC) in HIV-1 infected adult subjects 
who are virologically  suppressed as determined by [CONTACT_739909] (HIV-1 RNA ≥ 50copi[INVESTIGATOR_014]/mL )at 
Week 48
The secondary  objective of this study  
is as follows:
To evaluate the safet y and tolerability  of the two treatment groups
through Week 48
Study Design: Randomized, open-label, multicenter, active- controlled study  to 
evaluate the safet y and efficacy of switching to a FDC of 
GS-9883/F/TAF in HIV -1 infected subjects who are virologicall y 
suppressed (HIV -1 RNA < 50 copi[INVESTIGATOR_014]/mL) on a regimen consisting of 
ritonavir (RTV) or cobicistat (COBI) boosted ATV or DRV plus 
either FTC/TDF or ABC/3TC for ≥ 6 months prior to screening.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page7 21 October 2015Subjects who provide written consent and meet all eligibility  criteria 
will be randomized in a 1:1 ra tio toone of the following 
twotreatment groups:
Treatment Group 1: Switch to a FDC of GS-9883/emtricitabine
/tenofovir alafenamide (GS -9883/F/TAF) administered orall y,
oncedailywithout regard to food (n=260)
Treatment Group 2: Remain on current antiretrovira l regimen 
consisting of 
ritonaviror cobicistat boosted ATV or DRVplus either 
FTC/TDF or ABC/3TC administered orally ,once daily  with food 
(n=260)
Investigators must provide a prescription to subjects in Treatment 
Group 2. Subjects in Treatment Group
2 are responsible for obtaining 
their ARV regimen.
Randomization will be stratified b y the prior treatment regimen group 
(i.e., TDF containing regimens [ATV +RTVor ATV+COBI or 
DRV+RTV or DRV+COBI or COBI boosted DRV as fixed dose 
combination plus FTC/TDF] and non- TDF containing regimens 
[ATV+RTV or ATV+COBI or DRV+RTV or DRV+COBI or COBI 
boosted DRV as fixed dose combination plus ABC/3TC]) at 
screening.
Number of Subjects 
Planned:Approximately  520 subjects in total .
Approximately  260subjects in each Treatment Group 1 and 
Treatment Group 2
Target Population: HIV-1 infected subjects 
≥18 years old who are virologically  
suppressed (HIV -1 RNA < 50 copi[INVESTIGATOR_014]/mL) on a sta ble regimen 
containing boosted ATV or DRV plus either FTC/TDF or ABC/3TC 
for 6 months prior to screening and who are INSTI  naive.
Duration of 
Treatment:Duration of this study  is at least 48 weeks.
At the Week 48 Visit, subjects in a country where GS -9883/F/TAF 
FDC is not available will be given the option to receive 
GS-9883/F/TAF FDC foradditional [ADDRESS_1010933].
Subjects who complete the study  through Week 48 Visit anddo not 
further continue participation in the study , will be required to return 
to the clinic 30 day s after Week 48 Visit for a 30 -Day Follow-Up 
Visit
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page8 21 October 2015After Week 48 Visit, subjects in the UnitedKingdom ([LOCATION_006]) will stop 
taking stud y drug and complete a [ADDRESS_1010934] of care.
Diagnosis and Main 
Eligibility  Criteria:Medically  stable HIV -1 infected subjects who meet the following 
criteria:
Currently  receiving  antiretroviral regimen consisting of ritonavir 
or cobicistat bo osted ATV or DRV plus either FTC/TDF or 
ABC/3TC for  6 months preceding the screening visit
Currently  on the first or second antiretroviral regimen with 
documented plasma HIV 1 RNA < 50 copi[INVESTIGATOR_014]/mL on a stable 
regimen (or undetectable HIV- [ADDRESS_1010935] ing to the local 
assay being used if the limit of detection is ≥ 50copi[INVESTIGATOR_014]/mL ) for 
≥6 months preceding the Screening visit.
Prior changes in antiretroviral regimen are onl y allowed due to 
tolerability  issues or for regimen simplification. 
Unconfirmed 
virologic elevation s of≥ 50 copi[INVESTIGATOR_014]/mL  (transient detectable 
viremia, or “blip”) prior to screening areacceptable .(If the lower 
limit of detection of the local HIV -1 RNA assay  is 
<50copi[INVESTIGATOR_014]/mL [e.g., <20 copi[INVESTIGATOR_014]/mL ], the plasma HIV- 1 RNA 
level cannot exceed 50 copi[INVESTIGATOR_014]/mL  on twoconsecutive HIV -1 
RNA tests)
HIV-1 RNA levels < 50 copi[INVESTIGATOR_014]/mL  at Screening Visit
No previous use of an y approved or experimental integrase st rand 
transfer inhibitor (INSTI)
No documented or suspected resistance to FTC, TFV, ABC or 
3TC, including but not limited to the reverse transcriptase 
resistance mutations K65R and M184V/I
Estimated GFR ≥ 50 mL /min according to the Cockcroft -Gault 
formula for creatinine clearance
Study Procedures/
Frequency :After screening procedures, eligible subjects will be randomized 1:1 
to Treatment Group 1 or Treatment Group 2 and treated for 48 weeks. 
For all eligible subjects, blood will be collected at Day  1,Weeks 4, 8, 
12, and then every  12 weeks through Week 48. Laboratory  analyses 
(hematology , chemistry , and urinal ysis), HIV-1 RNA, CD4+ cell 
count, and complete or symptom
-directed phy sical examinations will 
be performed at the Screening, Day  1 and all subsequent study  visits.
Urine will be collected and stored for possible evaluations of renal 
tubularfunction including urine albumin, urine creatinine, urine 
protein, retinol binding protein and beta -2 microglobulin .
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_1010936], Dose, 
and Mode of 
Administration:FDC of GS -9883 50 mg/emtricitabine 200 mg/tenofovir alafenamide 
25mg (GS-9883/F/TAF) administered orall y, once daily without 
regard to food.
Reference Therapy, 
Dose, and Mode of 
Administration:Current antiretroviral drug regimen consisting of ritonavir or 
cobicistat boosted ATV or DRV plus either FTC/TDF or ABC/3TC 
administered orall y,once daily  with food.
Criteria for 
Evaluation:
Safety: Adverse events, clinical laboratory  tests to evaluate the safety  and 
tolerability  of the treatment regimens.
Efficacy: The primary  efficacy endpoint is the proportion of subjects with 
virologic failure (HIV-1 RNA ≥ 50 copi[INVESTIGATOR_014]/mL )at Week48as defined 
by [CONTACT_739910] (US) Food and Drug Administration
[FDA]snapshot algorithm.
The secondary  efficacy endpoint s include:
The proportion of subjects with HIV-1 RNA < 50copi[INVESTIGATOR_014]/mL  at 
Week 48 as 
defined by  [CONTACT_10830]
The changefrom baseline in CD4+ cellcount at Week 48
Pharmacokinetics: An intensive pharmacokinetic (PK) substudy  will be performed at the 
Weeks 4 or 8 visits in a subset of Treatment Group 1 subjects (target 
n=24) at stud y sites able to conduct this testing.
For all subjects in Treatment Group [ADDRESS_1010937] -dose.
For intensive PK substudy, the following PK parameters for GS -9883 
may be explored as applicable:
Cmax, Tmax, Clast, Tlast, Ctau,T1/2, AUC tau,AUC0-last , Vz/F, CL ss/F.
The concentration of GS -9883 may  be summar ized using descriptive 
statistics. The pharmacokinetics of GS -9883 may  be evaluated using 
population approaches. TAF and FTC concentrations may  be 
analyzed and PK parameters may  be summarized as applicable.
GS-9883/F/T AF 
Protocol GS-US-380-1878 
[COMPANY_009] Sciences, Inc. 
Optional Genomic 
Testing: 
Patient Reported 
Outcomes: 
Statistical Methods: 
CONFIDENTIAL PD Final 
Original 
Shmi Fmm 36 Health Smvey (SF-36), HIV Symptoms Distress 
Module Index, Work Productivity and Activity Impailment 
Questionnaii·e (WP AI), and UCLA Sclerode1ma Clinical Trial 
Consortium Gastrointestinal Tract (UCLA SCTC GIT 2.0) will be 
administered at Day 1, Weeks 4, 12 and 48. Visual Analog Scale 
(VAS) Adherence Questionnaii·e will be administered at Day [ADDRESS_1010938] of a non-inferiority evaluation of 
switching to GS-9883/F /TAF versus maintaining an antii·etrovii·al 
dmg regimen consisting of boosted ATV or DRV plus either 
FTCITDF or ABC/3TC (i.e., boosted PI [INVESTIGATOR_574059] 2 nucleoside reverse 
transcriptase inhibitors (NRTis) [boosted PI+ 2 NRTis], with respect 
to the propmiio n of subjects with vii·ologic failme (HIV-1 RNA 
:::: 50 copi[INVESTIGATOR_014]/mL as defmed by [CONTACT_739911]) at Week 48. It will be concluded that GS-9883/F /TAF is 
non-inferior to the boosted PI+ 2 NRTis if the upper bmmd of the 
2-sided 95% confidence interval (CI) of the difference between 
treatment groups (GS-9883/F/TAF-boosted PI+ 2 NRTis) in the 
virologic failme rate is less than 4% (i.e., a mru·gin of 4% is applied to 
non-inferiority assessment). The 2-sided 95% Cis will be constructed 
based on the exact method. 
The propmiion of subjects with HIV -1 RNA < 50 copi[INVESTIGATOR_014]/mL at 
Week 48 as defined by [CONTACT_110091] . The 95% Cis will be constructed in the same manner as 
described for the primruy efficacy endpoint. 
Page 10 21 October 2015 
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page11 21 October 2015The change from base line in CD4+ cell count at Week48 will be 
summarized using descriptive statistics. The differences and the 
associated 95% CIs will be constructed using Analy sis of Variance 
(ANOVA) model, including treatment (GS -9883/F/TAF vs. boosted 
PI + 2 NRTIs ) as a fixed effect in the model.
Adverse events, clinical laboratory  assessments, and pharmacokinetic 
parameters will be summarized using descriptive statistics.
A total of approximately  520 HIV -1 infected subjects, randomized in 
a 1:1 ratio to two treatment groups (260 subjects per treatment g roup), 
achieves at least 90% power to detect a non- inferiority  margin of 4% 
in Week48 virologic failure rate (HIV -1 RNA ≥ 50copi[INVESTIGATOR_014]/mL ) 
difference between the two treatment groups. For sample size and 
power computation, it is assumed that both treatment g roups have a 
virologic failure rate of 2% (based on historical [COMPANY_009] E/C/F/TAF 
and STB studies), that a non -inferiority margin is 4%, and that the 
significance level of the test is at a one- sided 0.025 level.
This study  will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) 
including archiving of essential documents.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page12 21 October 2015GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
C degrees Celsius
F degrees Fahrenheit
ABC/3TC abacavir/lamivudine, EpzicomKivexa
AE adverse event
ALT alanine aminotransferase
ANC absolute neutrophil counts
ARV Antiretroviral
AST aspartate aminotransferase
ATV atazanavir
AUC area under the plasma/serum/peripheral blood mononuclear cell concentration 
versus time curve
BID twice a day 
BUN bloodurea nitrogen
CBC complete blood count
CI confidence interval
CLcr creatinine clearance
Cmax the maximum observed serum/plasma/peripheral blood mononuclear (PBMC) 
concentration of drug
CMH Cochran-Mantel-Haenszel
CNS central nervous system
COBI, /co cobicistat (GS -9350)
Ctau the observed drug concentration at the end of the dosing interval
CPK creatine phosphokinase
CRF case report form(s)
CRO contract (or clinical) research organization 
CYP cytochrome P450
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
DRV darunavir
DSPH Drug Safety and Public Health
DTG dolutegravir , Tivicay
ECG Electrocardiogram
eCRF electronic case report form(s)
eGFR estimated glomerular filtration rate
EVG elvitegravir
E/C/F/TAF elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
E/C/F/TDF elvitegravir/cobicistat/emtricitabine /tenofovir disoproxil fumarate, Stribild
FAS full analysis set
FDA ([LOCATION_002]) Food and Drug Administration
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page13 21 October 2015FDC fixed dose combination
FTC/TAF emtricitabine/tenofovir alafenamide 
FSH follicle-stimulating hormone
FTC, F emtricitabine, Emtriva
GCP Good Clinical Practice (Guidelines)
GGT gamma glutamyl transferase
GLSM geometric least squares mean
GSI [COMPANY_009] Sciences, Inc.
HAART highly active antiretroviral therapy
HBV hepatitis B virus
HBcAb hepatitis B core antibody
HBsAb hepatitis B surface antibody
HBsAg hepatitis B surface antigen
HCV hepatitis C virus
HDPE high-density polyethylene
hERG human Ether -à-go-go-Related Gene
HIV Human Immunodeficiency Virus
HIV Sx HIV Symptoms  Index
IB investigator’s brochure
ICH International Conference on Harmonisation
IDMC Independent Data Monitoring Committee
IND Investigational New Drug (Application)
INSTI integrase strand-transfer inhibitors
IRB institutional review board
IWRS interactive web response system
KS Kaposi’s sarcoma
LDH lactate dehydrogenase
LLN lower limit of the normal range
MedDRA Medical Dictionary for Regulatory Activities
mg Milligram
MH Mantel-Haenszel
min Minute
mmHg millimeters mercury
nM nanoMolar
NNRTI non-nucleoside reverse transcriptase inhibitor
NOAEL no observed adverse effect level
NRTI nucleoside/nucleotide reverse transcriptase inhibitor
P-gp P-glycoprotein
PI [INVESTIGATOR_739894]-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page14 21 October 2015PSQI Pi[INVESTIGATOR_739895]-36 Short Form 36 Health Survey
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction
TAF tenofovir alafenamide 
TDF tenofovir disoproxil fumarate, Viread
TFV-DP tenofovir diphosphate (TFVpp)
tmax the time (observed time point) of C max
TSH thyroid stimulating hormone
UCLA SCTC GIT UCLA Sc leroderma Clinical Trial Consortium Gastrointestinal Tract
UGT1A1 uridine 5' -diphospho -glucuronosyltransferase
UGT uridine glucuronosyltransferase
ULN upper limit of the normal range
US [LOCATION_002]
VAS Visual analog scale
WPAI Work Productivity and Activity Impairment Questionnaire
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page15 21 October [ZIP_CODE]. INTRODUCTION
1.1. Background
Human immunodeficiency virus -1 (HIV-1) infection is a life -threatening and serious disease that 
is of major public health interest around the world. There are approximately  2.4millionpeople in 
North America and Western and Central Europe living with HIV -1 and 36 million people 
worldwide {[ZIP_CODE]}. The infection, if left untreated or suboptimally  treated, is characterized by  
[CONTACT_10832], ultimately  resulting in death. Therapeutic strategies for the 
treatment of HIV -[ADDRESS_1010939] been significantly  advanced by  [CONTACT_739912] y (HAART); the introduction of HAART was associa ted with a dramatic 
decrease in acquired immune deficiency  syndrome (AIDS) -related morbidity  and mortalit y 
{[ZIP_CODE]}, {5125}, {8284}.
The success of potent and well- tolerated ART means that morbidity  and mortality  in the 
HIV-infected population is increasingly  driven by  [CONTACT_105]-AIDS–associated comorbidities. Clinical 
attention has become more focused on the optimization of tolerability , long-term safety , and 
adherence of potent ART regimens {[ZIP_CODE]}. In addition, t here remains a significant medical need 
for new, effective therapi[INVESTIGATOR_10788] , the aging 
HIV-
infected population, ARV resistance, non- HIV comorbidities, and regimen simplification.
For ART- naive HIV -infected patients, current treatment guidelines suggest that initial therapy  
consist of 2 nucleos(t)ide reverse transcriptase inhibitors (N[t]RTI ) and either an integrase 
strand-transfer inhibitor (INSTI) or the boosted protease inhibitor darunavir {[ZIP_CODE]}. 
Virologically  suppressed, HIV -infected patients may  switch from their current regimen because 
of safety or tolerability concerns or for regimen simplification. All patient populations may  
benefit from once -daily fixed-dose combination (FDC) regimens as these have been shown to 
provide increased adherence and improved clinical and virologic outcomes {[ZIP_CODE]}, {[ZIP_CODE]}.
Tenofovir (TFV) is a nucleotide analog that inhibits HI V-1 reverse transcription. While tenofovir 
disoproxil fumarate (TDF), an oral prodrug of 
TFV, is a preferred NtRTI for initial therap y, 
nephrotoxicity  is an identified risk, and reductions in bone mineral densit y (BMD) have been 
shown that are larger than those seen with other NRTI s. Tenofovir alafenamide (TAF) is also an 
oral prodrug of TFV. TAF is more stable in plasma than TDF, provides higher intracellular 
levels of the active phosphory lated metabolite tenofovir diphosphate (TFV -DP), and 
approximately  90% lower circulating levels of TFV relative to TDF at the clinical doses. 
Thedistinct metabolism of TAF offers the potential for an improved clinical profile compared 
withTDF.
GS-[ADDRESS_1010940] a panel of mutant 
viruses with resistance to NRTI s, non-nucleoside reverse- transcriptase inhibitors (NNRTI s), and 
protease inhibitors (PI s).  Integrase mutant viruses that are resistant to the INSTI s raltegravir 
(RAL) and elvitegravir (EV G) remain largel y sensitive to GS -9883.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page16 21 October 2015[COMPANY_009] Sciences [COMPANY_009]) has coformulated GS -9883 with the NRTI  emtricitabine (FTC; F) and 
the NtRTI  tenofovir alafenamide (TAF) into an FDC tablet that is suitable for once -daily use. 
This GS-9883/F/TAF FDC may  provide a potent, convenient, tolerable, and practical regimen 
for the long -term treatment of patients with HIV infection.
1.2. GS-[ADDRESS_1010941] been conducted with GS -9883. These 
include assessments of cytotoxicity , off-target recepto r and ion- channel binding, effects on 
human Ether -à
-go-go-Related Gene (hERG) potassium current and papi[INVESTIGATOR_10789], and in vivo studies in rats and dogs that evaluated effects of GS -9883 on all major 
organ systems. The volume of distribution of GS -9883 ranged between 0.09 and 0.22 L/kg in the 
preclinical species, which indicates that the distribution of GS -9883 is limited to the extracellular 
compartment due to its high binding to plasma proteins. The projected half -life of GS -9883 in 
humans is approximately  20hours based upon the estimates of clearance and volume of 
distribution.
[IP_ADDRESS]. Pharmacology
GS-[ADDRESS_1010942] HIV replicati on in MT4 cells with an EC 50(50% 
effective inhibitory  concentration) value of 1.[ADDRESS_1010943] dividing and non- dividing human 
PBMCs, primary  human hepatocy tes and various non -target human cell lines.
GS-9883 is mainly  metabolized by  [CONTACT_10834] 5' -diphospho -glucuronos yltransferase UGT1A1 and 
secondaril y by [CONTACT_097]3A. GS -9883 does not inhibit major human CYP isoforms or UGT1A1 at 
concentrations up to 25 M. Consequently , GS-9883 is unlikely  to be a clinically  relevant 
inhibitor of these enzymes, and is not expected to inhibit the metabolic clearance of drugs 
metabolized by  [CONTACT_236703]. GS-
9883 only modestly  inhibits renal transporter OCT2 
(IC50=0.42 M). As a result, GS -
[ADDRESS_1010944] the OCT2 -mediated excretion of co -administered 
drugs is considered to be low.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page17 21 October 2015GS-9883 does not activate AhR and onl y weakly activates PXR at concentrations up to 50 M 
(less than 5% and 40% of activation, respectivel y, compared to positive control compound). 
Therefore, GS -[ADDRESS_1010945] as an induc er through PXR -or AhR-mediated 
pathways at the doses and exposure lev els projected in clinical use.
[IP_ADDRESS]. Toxicology
Single oral doses of GS -9883 up to 1000 mg/kg were well -tolerated in rats (AD -141-2286). The 
increase in exposure was limited (< 2- fold) between 100 and 300 mg/kg and similar exposure 
was observed between 300 and 1000 mg/kg suggesting saturation of absorption at 300 mg/kg 
(AUC0-242205 g
h/mL and 1931 gh/mL, respectively ). In monkey s, single oral doses of 
GS-9883 up to 1000 mg/kg were well- tolerated (AD -141-2284). The increase in exposure was 
limited (< 2-fold) between 300 to 1000 mg/kg (AUC 0-[ZIP_CODE]gh/mL and 1078 gh/mL, 
respectivel y).
In 2-week (TX -
141-2029) and 26- week (TX -141-2031) oral toxicity  studies in rats at doses up to 
300 mg/kg/day , GS-9883 was well- tolerated with no GS - 9883-related effects on clinical 
observations, bod y weight, food consumption, ophthalmic examinations, and anatomic 
pathology .  The high dose of 300 mg/kg/day  was considered the maximum feasible dose based 
upon saturation of absorption. The no observed effect level (NOEL) in the 26 -week stud y was 
considered to be the high dose of 300 mg/kg/day.  At the NOEL, GS -9883 exposures in the rat 
were considered to be approximately  12-/31-fold higher (males/females) th an the projected 
steady state human exposure of GS-9883 following administration of GS -9883/F/TAF 
(50/200/25 mg)QD under fed conditions.
In a 39-week study  in monkey s (TX-141-2032), following administration of 1000 mg/kg/day  
(high dose) of GS -[ADDRESS_1010946] 
hyperplasia and minimal or moderate hepatocy te hypertrophy  in both sexes, and minimal 
regenerative h yperplasia and minimal or slight neutrophil infiltrate in males.  The macroscopic 
finding of rou gh surface on the liver in one male administered 1000 mg/kg/day correlated with 
moderate hepatocy te hypertrophy and marked bile duct hyperplasia. A fter a 4-week recovery  
period, GS -9883-related microscopic liver findings included marked bile duct hy perplasia, slight 
hepatocyte hypertrophy, minimal regenerative h yperplasia, and slight lymphocyte infiltrate in 
one male and slight bile duct hy perplasia in one female administered 1000 mg/kg/day , while the 
other two animals in the high dose group had no hepatobi liary findings. Minimally  to mildly  
increased ALT activities (≤ 3.5- fold versus baseline values), likel y associated with liver findings, 
exhibited reversibility . There were no other adverse findings in the study, including clinical 
observations, or effects on body weight, bod y weight change, food consumption, ECGs, 
hematology , coagulation, clinical chemistry , urinalysis, and ophthalmoscopy .
No GS-
9883-related effects were observed in the mid -dose group (200 mg/kg/day ) which was 
considered the no -observed- effect-level (NOEL).  The estimated margin of exposure at the 
NOEL was approximately  4.7-fold based on expected human exposure with the once dail y 
dosing of the GS -9883/F/TAF (50/200/25 mg) tablet.
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_1010947] battery  of in vitro and in vivo studies was performed to assess the genotoxic potential 
of GS-9883. There was no evidence of mutagenic or clastogenic activity  in an in vitro bacterial 
reverse mutation assay  (Study TX-141-2026), a chromosomal aberration assay  in human 
lymphocytes (Study  TX-141-2027), or i n a rat micronucleus test (Stud y TX-141-2029).
1.2.3. Clinical Trials of GS-9883
Clinical trials entailing the use of GS- 9883 include:
GS-US-141-1218, a Phase [ADDRESS_1010948] -in-human, 
single-and multiple -ascending dose stud y evaluating the safet y, tolerability, and PK of oral 
GS-9883 in healthy  subjects and a randomized, open
-label, 2-cohort, 3- period, crossover, PK 
study evaluating the drug interaction potential between F/TAF FDC tablet and GS -9883 in 
healthy subjects (completed)
GS-US-141-1219, a Phase 1b randomized, double -blinded, sequential cohort 
placebo
-controlled study  of the safet y, PK, and antiviral activity  of GS-9883 in HIV -1 
infected subjects study of the pharmacokinetics and antiviral activity  of GS-7340 (8mg, 
25mg, 40mg) in HIV infected subjects (completed)
GS-US-141-1233, a Phase 1,Open -label, Two- Cohort, Multiple -Period, Fixed- Sequence, 
Crossover Study  to Evaluate 1) the Relative Bioavailability  o
f
TwoGS-9883/Emtricit
abine/Tenofovir Alafenamide (75/200/25 mg and 50/200/25 mg)
Fixed-Dose Combination Tablets Versus a GS-9883 (75 mg) Tablet and a 
Emtricitabine/Tenofovir Alafenamide (200/25 mg) Fixed-Dose Combination Tablet 
Administered Simultaneously  and 2) the Effect of Foo d on the Pharmacokinetics of 
GS-9883, Emtricitabine and Tenofovir Alafenamide When Administered as 
GS-9883/Emtricitabine/Tenofovir Alafenam ide (75/200/25 mg and 50/200/25 mg)
Fixed-DoseCombination Tablets(ongoing)
GS-US-141-1479, a Phase 1, open- label, parallel -group, adaptive single - dose study to 
evaluate the PK of GS -9883 in subjects with normal and impaired renal function (completed)
GS-US-141-1480, a Phase [ADDRESS_1010949] of GS
-9883 on the QT/QTc interval in healthy  subjects 
(completed)
GS-US-141-1481, a Phase 1 study  to evaluate the pharmacokinetics, metabolism, and 
excretion of GS -9883 in healthy  subjects (completed)
GS-US-141-1485, a Phase 1 adaptive stud y to evaluate transporter, CYP -mediated and 
UGT1A1 drug-drug interactions between GS -9883 and probe drugs (ongoing)
GS-US-141-1487, a Phase [ADDRESS_1010950] of GS- 9883 on Renal Function as Assessed b y Markers of Glomerular 
Filtration Rate (ongo ing)
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page19 21 October 2015GS-US-311-1790, a Phase 1Randomized, Open Label, Drug Interaction Study  Evaluating the 
Effect of F/TAF FDC Tablet or GS -9883 on the Pharmacokinetics of a Representative 
Hormonal Contraceptive Medication, Norgestimate/Ethiny l Estradiol (ongoing)
GS-US-380-1761, a Phase 1 Study  to Evaluate Pharmacokinetic Drug -Drug Interaction 
Potential between GS -9883/Emtricitabine/Tenofovir Alafenamide Fumarate 
(GS-9883/F/TAF) and Ledipasvir/Sofosbuvir (LDV/SOF) Fixed -Dose Combination (FDC) 
Tablets (ongoing)
GS-US-
141-1475, a Phase 2 Randomized, Double -Blinded Study  of the Safety  and Efficacy  
of GS-9883 + Emtricitabine/Tenofovir Alafenamide Versus 
Dolutegravir +Emtricitabine/Tenofovir Alafenamide in HIV -1 Infected, Antiretroviral 
Treatment -Naive Adults (ongoing)
Pleaserefer to the GS -
9883/F/TAF Investigators’ Brochure for further information about these 
studies.
[IP_ADDRESS]. Phas e [ADDRESS_1010951] of food on the PK of GS- 9883.  
Part D was a randomized, open -label, 
2-cohort, 3- period, crossover PK study  evaluating the drug interaction potential between 
FTC/TAF FDC tablet and GS -9883 in healthy  subjects.
There was no difference in the overall incidence or ty pe of AEs when GS -9883 was administered 
in the fasted and fed states. T here was no difference in the overall incidence of AEs when 
GS-9883 or FTC/TAF was each administered alone or in combination.
No deaths or pregnancies were reported. No Grade 3 or 4 AEs or SAEs, were reported in any  
cohort.
Changesin serum creatinine were observed in this study , presumably  via inhibition of the renal 
transporter OCT2.  
In the MAD cohorts (fasted), serum creatinine change at Day 14 ranged from 
0.05 mg/dL for the 5 mg cohort to 0.18 m g/dL for the 300 mg/dL cohort. In Part D (DDI), 
conducted in the fed state (regular meal), subjects received 100 mg GS- 9883 monotherapy  for 
7days and 100 mg GS -9883 with FTC/TAF for 7 day s, the meanserum creatinine change at 
Day7 was 0.14 mg/dL following GS -9883 and 0.17 mg/d L following GS -9883 + FTC/TAF. All 
changes returned to baseline after discontinuation of GS-9883.
The majority  of laboratory  abnormalities were Grade 1 or Grade 2 in severity . Grade3 laboratory  
abnormalities included 10 subjects with Grade 3 u rine dipstick tests for blood. All of these 
subjects were female, none of the labs were considered b y the Investigator to be clinically 
significant, and all wer e associated with menstruation. No other Grade 3 or 4 laboratory  
abnormalities were observed.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page20 21 October 2015Based on results in study GS- US-141-1218, pharmac okinetic profile of GS -9883 was 
characterized b y rapid absorption with time to peak plasma concentrations (median t max of 
cohorts) ranging between 1 and 4 hours following administration under fasted conditions. 
GS-9883 exposures were appropriatel y dose proportional following single dose 25 -100mg dose 
administration, with decreasing dose proportional at higher doses.  The half -life of GS -9883 was 
approximately  18hours, with no changes observed across studied dose range as evidenced by  
[CONTACT_739913]. A high -fat meal increased AUC infand Cmax (geometric mean, 84% 
and 101%, respectivel y) following 100 mg single dose administration. Steady  state was achieved 
after 4-6days of once daily  dosing of GS -9883 with average accumulation ratios for AU C24hr
of
1.6.
Table1-1. GS-US-141-1218: GS -9883 Mean (%CV) PK Parameters Following 
Single Doses of GS -9883 in Healthy Subjects (GS -9883 PK Analysis 
Set; Part A: Single Dosing)
GS-9883 PK 
Parameter
Mean 
(%CV)5mg
(N=6)25 mg
(N=6)50 mg
(N=6)100 mg
(N=6)300 mg
(N=6)600 mg
(N=6)
Cmax (ng/mL)691.2
(22.1)1618.3
(26.7)3965.0
(40.1)6998.3
(36.1)[ZIP_CODE].0 
(27.1)[ZIP_CODE].0
(7.5)
Tmax(hr)1.25 
(1.00-1.50)2.00
(1.00-3.00)3.00
(1.50-4.00)2.25
(1.50-3.00)3.50
(2.00-6.00)3.5
(2.00-4.00)
AUCinf 
(ng.hr/mL)[ZIP_CODE].7
(25.1)[ZIP_CODE].2 
(21.3)[ZIP_CODE].5 
(29.7)163028.2 
(24.3)355917.3 
(32.9)454446.8 
(19.9)
T1/2 (hr)18.51
(16.81-19.99)18.08
(16.63-19.64)16.72
(15.77-17.11)18.90
(17.96-20.05)18.14
(17.86-20.53)17.89
(16.38-19.52)
T1/2and Tmax: Median (Q1, Q3)
Table1-2presents GS -9883 plasma PK parameters following administration of GS -9883 
(5,25, 50,
100,and 300mg) once daily for 7 days . Following administration of either GS -9883 
(5,25, 50, 100, or300 mg) once daily for 7 days, the PK absorption profile observed on Day s 1 
and 7 was similar to that observed in Part A (SAD). The median T maxvalues ranged from 1.5 to 
2.5hours on Day  1 and 1.5 to 4.0 hours on Day 7. Linearit y was observed comparing GS -9883 
AUCand Cmaxon Days 1 and 7 over the dose range of 25 to 50 mg. Stead y state levels of 
GS-9883 were achieved between Stud y Days 4 to 6 of do sing and maintained through Day 14. 
Accumulation is approximately  1.6-fold, which is consistent with the observed half -life of the 
GS-9883 (approximately  18 hours).
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page21 21 October 2015Table1-2. GS-US-141-1218: GS -9883 Plasma Pharmacokinetic Parameters by 
[CONTACT_10827]-9883 Dose Following Multiple -Dose Administration of GS -9883 
(Analysis Set: GS -9883 PK P art B: Multiple -Dose)
GS-9883 PK Param eter Mean
(%CV)aMultiple-Dose GS-9883
5mg
(N=6)25mg
(N=6)50mg
(N=6)100mg
(N=6)300mg
(N=6)
Day 1AUC0-24 (hr*ng/mL)9033.6
(8.2)27,775.1
(28.3)58,371.4
(18.9)79,773.8
(18.9)180,714.3
(17.6)
Cmax(ng/mL)709.7
(9.5)2220.0
(35.6)4648.3
(18.7)6248.3
(26.8)13,716.7
(19.1)
Tmax(hr)1.50
(1.50, 1.50)1.75
(1.00,3.00)1.50
(1.00, 2.00)2.50
(2.00, 3.00)2.50
(2.00, 4.00)
Day 7AUCtau (hr*ng/mL)14,392.0
(16.7)50,008.2
(26.6)89,710.1
(22.7)126,785.8 
(23.7)277,200.2 
(16.7)
Cmax(ng/mL)982.5
(7.9)3455.0
(24.1)6538.3
(17.6)9396.7
(20.8)19,900.0 
(21.2)
Ctau(ng/mL)400.83
(26.9)1322.00
(27.8)2241.67
(28.2)3145.00 
(26.1)6758.33 
(21.6)
Tmax(hr)1.50
(1.00, 2.00)3.00
(2.00,3.00)1.75
(1.50,2.00)1.75
(1.50,3.00)4.00
(2.00, 4.00)
Accumulation Ratio of AUC (%)160.5
(19.0)182.2
(17.1)154.0
(15.9)158.5
(12.1)157.5
(22.6)
aData are presented as mean (%CV), except for T max, andt½, which are presented as median (Q1, Q3)
Table1-3presents the GLSM ratios and associated 90% CIs for the test (fed) versus reference 
(fasted) treatments for the primary  plasma PK parameters of GS -9883. Administration of a single 
dose of GS -9883 100 mg with food (high
-calorie/high -fat breakf ast) increased the GL SM values 
of Cmaxand AUC inf101% (90% CI of GL SM ratio 165.93% to 242.74%) and 84% (90% CI of 
GLSM ratio 152.05% to 222.59%), respectivel y. There were no apparent changes in clearance 
and t1/2following administration with food, indic ating that food enhanced the bioavailability  of 
GS-9883 by [CONTACT_10837]/or absorption.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page22 21 October 2015Table1-3. GS-US-141-1218: Statistical Comparison of GS -9883 Pharmacokinetic 
Parameters Following Single -Dose Administration of GS -9883 in the 
Fasted and Fed States (GS -9883 PK Analysis Set)
GS-9883 PK Param eter Mean (%CV)
% GLSM Ratio 
(90% CI)Test
GS-9883 100 m g Fed
(n=8)Reference
GS-9883 100 m g Fasted
(n=8)
AUCinf(hr*ng/mL) 214,146.3 (15.9) 117,777.1 (23.3) 183.97 (152.05, 222.59)
AUClast(hr*ng/mL) 209,259.9 (15.1) 115,681.7 (24.0) 183.58 (151.91, 221.86)
Cmax(ng/mL) 11,268.8 (15.1) 5885.0 (34.9) 200.69 (165.93, 242.74)
CI = confidence interval; GLSM = geometric least squares mean
[IP_ADDRESS]. Phase 1b Proof of Concept
The first HIV -1 positive human subjects were dosed in the fasted state with 10 day s of GS-9883 
in study (GS-US-141-1219).  Four cohorts of 5 subjects each were randomized 4:[ADDRESS_1010952] frequentl y reported AEs across all subjects were diarrhea (2 subjects), 
and headache (3subjects).  No other AE was reported in more than [ADDRESS_1010953]. There was no 
increase in the incidence of AEs with increas ing doses of GS -9883.
The majority  of AEs were considered by  [CONTACT_236705]. A total 
of 2subjects expe rienced mild diarrhea that was considered related to study  drug (1 in the 5 mg 
cohort, 1 in the 100 mg cohort).
No deaths or pregnancies were reported. No Grade 3 or 4 AEs, SAEs, or AEs leading to 
discontinuation of study  drug were reported in any  cohort.
The majority  of laboratory  abnormalities were Grade 1 or Grade 2 in severity . No Grade 3 
treatment emergent laboratory abnormalities were observed. Median serum creatinine changes at 
Day 10 were: 0.05 mg/dL (5 mg), 0.04 mg/dL (25 mg), 0.06 mg/dL (50 mg), and 0.15mg/dL 
(100 mg). These changes in serum creatinine appeared to be transient and returned close to 
baseline values on discontinuation of study  drug. One Grade [ADDRESS_1010954]. An adverse event of elevated CK was reported unrelated to
study medication.
Based on PK information collected in study  GS-US-141-1219, which was in line with PK 
observed in stud y GS-US-141-1218, the median IQ for each dose were calculated and ar e 
presented i n the Table below.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page23 21 October 2015Table1-4. Trough GS -9883 Plasma Concentrations at Steady State Following 
GS-9883 Administration Under Fasting Conditions and 
Corresponding Protein -Adjusted IQ 95 Values(GS-9883 PK Analysis 
Set)
GS-9883dose n Median (range) C tau, SS(ng/mL) Median (range) paIQ 95a
5 mg 4 206.5 (146.0 to 342.0) 1.3 (0.9 to 2.1)
25 mg 4 797.5 (714.0 to 1900.0) 4.9 (4.4 to 11.7)
50 mg 4 2170.0 (852.0 to 3020.0) 13.4 (5.3 to 18.6)
100 mg 4 4190.0 (3730.0 to 5970.0) 25.9 (23.0 to 36.9)
a.The protein adjusted IQ 95(paIQ95) value is estimated based on steady -state C tauvalues and the in vitro paIC 95value for 
wild-type HIV-1 (162ng/ml).
The mean and 95% CIs of change from baseline in HIV -1RNA (log 10copi[INVESTIGATOR_014]/mL ) are presented 
in Figure1-1.
Figure1-1. GS-US-141-1219: Mean and 95% CIs of Change from Baseline in 
HIV-1 RNA (log 10copi[INVESTIGATOR_014]/mL) (PP Analysis Set)
NOTE: Baseline value was the last available value collected prior to the time o f the first dose of study drug.

GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page24 21 October 2015Mean viral load change on Day  11 was -2.08 log 10in the 25mg cohort, -2.06 log 10in the 50mg 
cohort, and - 2.43 log 10in the 100 mg cohort. Time weighted average change from base line at 
Day 11 (DAVG11) was - 0.92 log 10in the 5 mg cohort, -1.33 log 10 in the 25 mg 
cohort, -1.37 log10 in the 50 mg cohort and -1.61 log 10 in the 100 mg cohort. Viral suppression 
(HIV-1 RNA < 50copi[INVESTIGATOR_014]/mL ) was ever achieved by  [CONTACT_2054]  (Day17) by 1subject 
(25.0%) in the GS -9883 50mg group and 2 subjects (50%) in the GS -9883 100 mg group.
[IP_ADDRESS]. Summary  of Phase 2 Study  (GS-US-141-1475)
Study GS
-US-141-1475 is an ongoing Phase 2, randomized, double -blind, multicenter, 
active-controlled study  to assess the safety  and efficacy  of a regimen containing 
GS-9883+F/TAF versus dolutegravir (DTG)+F/TAF in HIV -infected, antiretroviral therapy  
(ART)-naive adult subjects. 
Eligible subjects were randomized in a 2:1 ratio to one of the following treatment groups , 
stratified by  [CONTACT_10840]
-1 RNA level ( ≤ 100,000 copi[INVESTIGATOR_014]/mL , 100,000
copi[INVESTIGATOR_014]/mL to
400,000copi[INVESTIGATOR_014]/mL , or > 400,000 copi[INVESTIGATOR_014]/mL) at screening:
Treatment Group 1 : GS-9883 75 mg + F/TAF (200/25 mg) + placebo -to-match DTG 50 mg 
once daily
Treatment Group 2 : DTG 50 mg + F/TAF (200/25 mg) + placebo -to-match GS-
9883 75mg 
once daily
Interim data at Week 12 are summarized below.  Data from the Week 24 primary  endpoint are 
included in the GS -9883/F/TAF Investigator’s Brochure.
[IP_ADDRESS]. Subject Disposition and Baseline Ch aracteristics
A total of 98 subjects were randomized and treated in the study : 65 subjects in the 
GS-9883+F/TAF group and 33 subjects in the DTG+F/TAF group . At the time of the Week 12 
data analysis, 2 subjects (2.0%) had prematurel y discontinued study  treatment, one in each 
treatment group; both subjects were lost to follow-up.
Demographic and baseline characteristics were similar between the 2 treatment groups.
Key baseline disease characteristics (ie, viral load, CD4 cell count, and estimated glomerular 
filtration rate [eGFR] using the Cockcroft -Gault method [eGFR CG]) were similar between the 
2treatment groups. 
Median (Q1, Q3) baseline HIV -1 RNA was 4.45 (3.96, 4.79) log 10copi[INVESTIGATOR_014]/mL , with 82.7% of 
subjects having ≤ 100,000 copi[INVESTIGATOR_014]/mL  at baseline; 5 subje cts had > 400,000 copi[INVESTIGATOR_014]/mL  at 
baseline; 4 of these subjects were randomized to GS -9883+F/TAF and [ADDRESS_1010955] was randomized 
to DTG+F/TAF.
Median (Q1, Q3) baseline CD4 cell count was 444 (316, 595) cells/μL, with 41.8% of 
subjects having ≥ 500 cells/μL  at baseline. Median (Q1, Q3) baseline eGFR CGwas 125.3 
(105.7, 147.0) mL /min.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page25 21 October [ZIP_CODE].2.3.5. Efficacy Results
Virologic success at Week 12 when assessed using the US FDA snapshot algorithm, defined as 
plasma HIV -1 RNA < 50 copi[INVESTIGATOR_014]/mL , was similar between the 2 treatment groups as follows: 
GS-9883+F/TAF 93.8%; DTG+F/TAF 93.9% (stratum-adjusted difference in percentages: 
−1.3%; 95% CI: −12.9% to 10.2%; p= 0.79).
Following initiation of study  drug, the increases from baseline in CD4 cell count were similar 
between treatment group s. Mean (SD) baseline CD4 cell counts were as follows: 
GS-9883+F/TAF 471 (190.9) cells/μL ; DTG+F/TAF 507 (271.0) cells/μL ; p=0.35. The mean 
(SD) change in CD4 cell count from baseline to Week 12 was similar between the 2 treatment 
groups as follows: GS -9883+F/TAF +170 (150.0) cells/μL ; DTG+F/TAF +173 (220.5) cells/μL 
(difference in L SM: 0; 95% CI : −76 to 76; p = 1.00).
Interim Virology Resistance Data
Through Week 12, no emergent drug resistance was detected.
[IP_ADDRESS]. Safety Results
Adverse Events
The overall inci dence of treatment-
emergent AEs was balanced between treatment groups as 
follows: GS- 9883+F/TAF 58.5%, 38 subjects; DTG+F/TAF 57.6%, 19 subjects). The most 
common TEAEs (occurring in > [ADDRESS_1010956]) by [CONTACT_110095]:
GS-9883+F/TAF: diarrhea and headache (6.2%, 4 subjects each); and fatigue and nausea (3.1%, 
2 subjects each)
DTG+F/TAF: nausea (12.1%, 4 subjects); diarrhea (9.1%, 3 subjects); and fatigue, flatulence, 
and furuncle (6.1%, 2 subjects each)
Most treatment -emergent AEs wer e Grade [ADDRESS_1010957] (diabetic ketoacidosis); this event was also reported as an SAE, and 1 other SAE 
(appendicitis) was reported. Neither SAE was considered related to study  drug by [CONTACT_1275], resulted in study  drug discontinuation, or required interruption of study  drug, and 
both SAEs resolved. 
The overall incidence of study  drug-related treatment -emergent AEs was balanced between 
treatment groups as follows: GS-9883+F/TAF 12.3%, 8 subjects; DTG+F/TAF 15.2%, 
5subjects. Most study  drug-related treatment- emergent AEs were Grade 1 in severit y. Grade2 
study drug-related treatment -emergent AEs (somnolence a nd headache) were reported in 
1subject. No Grade 3 or 4 treatment -emergent AEs or treatment -emergent SAEs were 
considered related to study  drug.
No deaths, pregnancies, or AEs leading to premature study drug discontinuation were reported.
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_1010958] 1 treatment- emergent laborat ory abnorma lity (ie, at least 
1grade level increase from baseline in graded abnormality ) was similar between treatment 
groups as follows: GS -9883+F/TAF 70.3%, 45 subjects; DTG+F/TAF 75.0%, [ADDRESS_1010959] 1 Grade 3 or 4 treatment- emergent laboratory abnormalit y 
was similar between treatment groups as follows: GS -
9883+F/TAF 10.9%, 7 subjects; 
DTG+F/TAF 12.5%, 4 subjects. Grade 4 treatment -emergent laboratory  abnormalities (creatine 
kinase) were reported in only  2subjects.
There were no clinicall y significant changes from baseline or differences between treatment 
groups in the median values for hematology , chemistry , or metabolic parameters. Changes from 
baseline in serum creatinine were similar between treatment groups. Median (Q1, Q3) changes in 
serum creatinine at Week 12 were as follows: GS -9883+F/TAF 0.11 (0.06,0.16)mg/dL; 
DTG+F/TAF 0.14 (0.06,0.24)mg/dL. Changes from baseline in eGFR were similar between 
treatment groups. Median (Q1, Q3) changes in eGFR at Week 12 were as follows: 
GS-9883+F/TAF −12.2 (−18.0,−6.4)mL/min; DTG+F/TAF −15.8 (−30.1, −9.5)mL/min.
1.3. Information about Emtricitabine (Emtriva®, FTC)
Emtricitabine ( 5-fluoro-1-[(2R, 5S)-2-(hydroxymethyl)-[1, 3]-oxathiolan -5-yl] cytosine, FTC) is 
a NRTI that has demonstrated potent and selective inhibition of the HI V. In HIV-infected adults, 
FTC is administered as a 200 mg QD dose concurrently  with other ARVdrugs. The 
200mg FTC 
capsule formulation was approved b y the US Food and Drug Administration (FDA) for 
marketing on 2 July 2003 and is available under the name [CONTACT_10881]®. In the European Union 
(EU), marketing authorization was granted for both the 200 mg Emtrivacapsule formulation 
and a 10mg/mL Emtrivaoral Solution formulation on 24 October2003, with indications for 
the treatment of HIV infection concurrently  with other antiretroviral drugs in bot h adult and 
pediatric patients.
Further information is available i n the current Prescribing Information for Emtriva®.
1.4. Information about Tenofovir alafenamide (TAF, GS -7340)
Tenofovir alafenamide (GS- 7340, TAF) is a second generation oral prodrug of tenofovir (TFV), 
a nucleotide analog that inhibits HI V-1 reverse transcri ption. Tenofovir is metabolized 
intracellularl y to the active metabolite, tenofovir diphosphate (TFV -DP), a competitive inhibitor 
of HIV-1 reverse transcriptase (RT) that terminates the elon gation of the viral DNA chain. The 
intracellular metabolism of TAF and TFV are consistent with the 600- fold enhancement in anti -
HIV activity  in cell culture of TAF over TFV.
Please refer to the GS -9883/F/TAF Investigator’s Brochure for further information.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page27 21 October [ZIP_CODE].4.1. Clinical Trials of Single Agent Tenofovir alafenamide (TAF, GS-7340) or 
Fixed Dose Combination emtricitabine/tenofovir alafenamide (FTC/TAF)
Clinical trials entailing the use of tenofovir alafenamide include:
GS-US-120-1101, a Phase 1/2 study  of the pharmacokinetics and antiviral activity  of 
GS-7340 (50 mg and 150 mg) in HIV -infected subjects (completed)
GS-US-
120-0104, a Phase 1b study  of the pharmacokinetics and antiviral activity  of 
GS-7340 (8 mg, 25 mg, 40 mg) in HIV infected subjects (completed)
GS-US-120-0107, a Phase 1, partially- blinded, randomized, placebo- and positive controlled 
study to evaluate the effect of GS- 7340 on the QT/QTc interval in healthy  subjects 
(completed)
GS-US-120-0108, a Phase 1, open- label, parallel -design stud y to evaluate the 
pharmacokinetics of GS -7340 in subjects with severe renal impairment (completed)
GS-US-120-0109, a Phase 1 study  to evaluate the pharmacokinetics, metabolism and 
excretion of GS -7340 (completed)
GS-US-120-0114, a Phase 1, open- label, parallel -group, single dose study  to evaluate the 
pharmacokinetics of tenofovir a lafenamide in subjects with normal and impaired hepatic 
function (completed)
GS-US-120-0117, a Phase 1 single -dose study  evaluating the pharmacokinetic drug 
interaction potential between rilpi[INVESTIGATOR_10790] (completed)
GS-US-120-0118, a Pharmacokinetic study  evaluating the drug interaction potential of 
tenofovir alafenamide with a boosted protease inhibitor or unboosted integrase inhibitor in 
healthy subjects (completed)
GS-US-311-1386, a Phase [ADDRESS_1010960] of food on th e pharmacokinetics of 
tenofovir alafenamide when administered as F/TAF FDC in health y volunteers (completed)
GS-US-311-0101, a Phase 1 healthy  volunteer study  evaluating the drug interaction potential 
between once -daily FTC/GS-7340 fixed -dose combination and efavirenz (EFV) or 
COBI-boosted darunavir (DRV) (completed)
GS-US-311-1088, a Phase 1, Relative Bioavailability  Study of Emtricitabine/Tenofovir 
Alafenamide Fixed Dose Combination Tablet to evaluate the formulation performance of 
emtricitabine (FTC) an d tenofovir alafenamide (TAF) fixed dose combination tablets relative 
to co-administration of individual agents (completed).
GS-US-311-1089, a Phase 3 study  of the safety  and efficacy  of FTC/TAF in HIV infected, 
virologicall y suppressed patients (ongoing).
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_1010961] of food (high- calorie, high- fat meal) on the PK of the TAF 
component of the F/TAF FDC was evaluated. The GL SM ratio of the AUClast of TAF when 
administered with a high -fat meal was 177% (90% CI: 166% to 188%), and the T AF Cmax 
GLSM ratio was 84.5% (90% CI:74.9% to 95.4%). This ~75% increase in TAF plasma 
exposure and ~15% decrease in TAF plasma Cmax when administered with food was 
accompanied b y a delay in Tmax (increase from 1.00 hour under fasted conditions to 2.00 ho
urs 
under fed conditions). The exposures of TAF observed under fed or fasted conditions in this 
study are within the range of exposures observed in the E/C/F/TAF clinical development 
program and are commensurate with safe and effective plasma levels of TAF (see investigator 
brochure for further details). Therefore, the changes in TAF exposures when F/TAF is 
administered with food should not result in differences in efficacy  and thus are not clinicall y 
relevant. TAF can be administered without regard for foo d and these findings can be 
extrapolated to F/TAF (as FTC can betaken without regard to food).
1.4.2. Clinical Trials of FTC/TAF as part of 
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF)
Clinical trials using tenofovir alafenamide, cofor mulated into the E/C/F/TAF STR include:
GS-US-292-0101, a Phase 1 healthy  volunteer study  evaluating the relative bioavailability  of 
EVG, FTC, TFV, and COBI administered as E/C/F/TAF STR relative to E/C/F/TDF or TAF 
(completed)
GS-US-
292-0103, a Phase 1 he althy volunteer study  to evaluate the pharmacokinetics and 
relative bioavailabilit y of the E/C/F/TAF STR relative to the individual components at 
GS-7340 doses of 10 mg (STR) or 25 mg Single Agent (SA) (completed)
GS-US-292-0102, a Phase 2 randomized, doub le-blinded study  of the safet y and efficacy of 
E/C/F/TAF STR versus E/C/F/TDF STR in HIV
-1 infected, antiretroviral treatment -naive 
adults (ongoing)
GS-US-292-0104 and GS -US-
292-0111, Phase 3 randomized, double -blinded study  of the 
safety and efficacy of E /C/F/TAF STR versus E/C/F/TDF STR in HIV-1 infected, 
antiretroviral treatment- naive adults (ongoing)
GS-US-292-0109, a Phase 3 open- label study  to evaluate switching from a TDF- containing 
combination regimen to a TAF -containing combination single tablet re gimen (STR) in 
virologicall y-suppressed, HIV -
1 positive subjects (ongoing)
GS-US-292-0112, a Phase 3 Open -label Safet y Study of 
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenami de single-tablet Regimen in HIV -1 
positive patients with mild to modera
te renal impairment (ongoing)
GS-US-292-0117, a Phase 3, two-part study to evaluate the efficacy of Tenofovir 
Alafenamide versus placebo added to a failing regimen followed by  [CONTACT_10841]/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HI V-1 positive, 
antiretroviral treatment-
experienced adults (ongoing)
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page29 21 October 2015GS-US-292-0119, a Phase 3 open- label study  to evaluate switching from optimized stable 
antiretroviral r egimens containing darunavir to 
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafe namide (E/C/F/TAF) single tablet 
regimen (STR) plus darunavir (DRV) in treatment experienced HIV- 1 positive adults 
(ongoing)
GS-US-292-
0106, a Phase 2/3, open-label stud y of the pharmacokinetics, safety, and 
antiviral activity  of the Elvitegravir/Cobicista t/Emtricitabine/Tenofovir Alafenamide 
(E/C/F/TAF) single tablet regimen (STR) in HIV- 1 infected antiretroviral treatment -naive 
adolescents (ongoing)
Study GS-US-
292-0101 is a Phase 1 study  of 40 subjects evaluating the relative bioavailability  
of two diffe rent formulations of E/C/F/TAF STR, each with TAF dose of 25 mg or 40 mg, versus 
E/C/F/TDF STR or TAF 25 mg alone. Exposures of EVG, COBI, and FTC were comparable 
between E/C/F/TAF vs E/C/F/TDF regardless of formulation (monolay er or bi-layer). In 
contrast, TAF exposures were ~2.2 -fold higher (and corresponding tenofovir exposures ~ 3 -fold 
higher) when administered as E/C/F/TAF (25 mg) vs TAF single agent (SA) 25 mg for both 
formulations of the E/C/F/TAF, likely mediated by [CONTACT_10842] P -gp-mediated intestinal 
secretion of TAF b y COBI.
Study GS
-US-292-0103 is a completed Phase 1 healthy  volunteer study  which evaluated the PK 
and relative bioavailability  of the E/C/F/TAF STR relative to the individual components at TAF 
doses of 10 (STR) or 25 mg SA. Results indicate that when dosed as the E/C/F/TAF 10 mg STR, 
TAF and TFV exposures were comparable to those observed with TAF 25 mg dosed alone. 
Exposures of EVG, COBI, and FTC were also comparable between the STR and individually  
dosed formulations.
Study GS-US-292-0102 is an ongoing, randomized, active -controlled Phase 2 study, compares 
E/C/F/TAF (10 mg) versus Stribild®(STB, E/C /F/TDF) in treatment -naïve, HIV -
1 infected 
subjects. At Week 48, the E/C/F/TAF demonstrated potent antiviral efficacy  (HIV-1 RNA 
<50copi[INVESTIGATOR_014]/mL) similar to STB (88.4% [99/112] vs 87.9% [51/58] using the snapshot 
algorithm); in the E/C/F/TAF group, no patient had emergent resistance to 1 or more components 
of the E/C/F/TAF. Importantly , E/C/F/TAF demonstrated a potential benefit over E/C/ F/TDF in 
terms of renal and bone safet y: smaller median decreases in eGFR (mL /min) (at Week 48, 
E/C/F/TAF 
-5.5 vs E/C/F/TDF -10.0 [P<0.001) and smaller median percentage decreases in 
BMD (at Week 48, spi[INVESTIGATOR_050] E/C/F/TAF - 1.00 vs E/C/F/TDF -3.37 [p<0.001], hip -0.62 
vs -2.39[p<0.001]).
Studies GS -US-292-0104 and GS-US -292-0111 are ongoing , Phase 3 randomized, 
double-blinded studies of the safet
yandefficacyof E/C/F/TAF versus E/C/F/TDF in HI V-1 
infected, antir etroviral treatment -naive adults. The interim Week 48 keyconclusions from pooled 
data showed that E/C/F/TAF once dai ly was noninferior to STB once daily when administered 
for48 weeks to HIV- infected, ART -naive adults, as asse ssed using the US Food and Drug 
Administration (FDA )-defined snapshot algorithm with H I
V-1 RNA < 50copi[INVESTIGATOR_014]/mL  
(E/C/F/TAF 92.4%; STB 90.4%; diff erence in percentages: 2.0%, 95%CI: - 0.7% to 4.7%). 
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page30 21 October 2015Administration of E/C/F/TAF resulted in > 90% lower plasma TFV and higher intracellular 
TFV-DP relative to STB.  E/C/F/TAF showed an improv ed renal and bone safe typrofile with 
significant ly less decline in hip and spi[INVESTIGATOR_9210], less increase in serum creatinine and reduction 
in estimated glomerular filtration rate (eGFR). 
1.5. Information about GS -9883/emtricit abine/tenofovir alafenamide 
(GS-9883/F/TAF)
Please refer to the GS -9883/F/TAF Investigator’s Brochure for further information.
1.5.1. GS-US-141-1233: Study of the Relative Bioavailability of GS -9883, FTC, and 
TAF between GS -9883/F/TAF and GS -9883 + F/TAF
Study GS
-US-141-1233 is an ongoing Phase 1, open-label,2-cohort, multiple -period,
fixed-sequence, crossover study  conducted at a single center in the US to evaluate 1) the relative 
bioavailability  (BA) of 2 GS -9883/F/TAF (75/200/25 mg and 50/200/25 mg) FDC tablets 
compared with the GS -9883 (75 mg) tablet and the F/TAF (200/25 mg) FDC tablet administered 
simultaneously  and 2) the effect of food on the PK of GS -9883, FTC, and TAF when 
administered as GS -9883/F/TAF (75/200/25 mg and 50/200/25 mg) FDC tablets.
Cohort [ADDRESS_1010962] of GS- 9883/F/TAF (75/200/25 mg) FDC 
tablet in a [ADDRESS_1010963] of GS -9883/F/TAF ( 50/200/25 mg) FDC tablet in a 4 -period sequence.
The in
-life portion of Cohort 1 is complete; preliminary  results are summarized below. The 
in-life portion of Cohort 2 is ongoing.
Cohort 1 Results:
Pharmacokinetic Results
Under fasted conditions, GS -9883 AUCinfand Cmaxwere 27% and 31% higher, respectivel y, 
following GS -9883/F/TAF (75/200/25 mg) FDC administration than following administration of 
single-agent GS-9883 (75 mg ) with the F/TAF (200/25 mg) FDC. FTC and TAF exposure was 
similar following admini stration of GS -9883/F/TAF (75/200/25 mg) or single -agent GS-9883 
(75 mg) with the F/TAF (200/25 mg) FDC. 
Compared with administration under fasted conditions, administration of the GS -9883/F/TAF 
(75/200/25 mg) FDC with a high-fat meal resulted in a 46% hi gher GS-9883 AUC infand a 27% 
higher GS -[ADDRESS_1010964] of food on TAF and FTC exposure was similar to that 
previously  observed for F/TAF (Study  GS-US-311-1386). GS -9883/F/TAF may  be taken 
without regard to food.  Based on these results, Cohort 2 wasadded to the study  via protocol 
amendment to evaluate the relative BA of the GS -9883/F/TAF (50/ 200/25mg) FDC tablet 
compared with the single -agent GS-9883 (75 mg) tablet and the F/TAF (200/25 mg) FDC tablet 
administered simultaneously .
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page31 21 October 2015Safety Results
Of the 28 subjects included in the Safet y Analysis Set for Cohort 1, 12 subjects (43%) had at 
least 1treatment -emergent AE. All treatment emergent AEs were assessed as Grade [ADDRESS_1010965] discontinued the 
study due to an AE.
1.6. Rationale for this Study
As treatment guidelines recommend earl y treatment of HIV -1 infection, there is need for 
regimens that maximize long-term efficacy , safety,tolerability , and convenience. These features 
are determined b y the specific formulation of the regimen (fixed -dose, or multi -tablet regimens), 
the nucleos(t)ide backbone, and the thir d agents (PI , NNRTI, or INSTI).
Switching to GS-9883/F/TAF may  offer the advantages of a single- tabletFDC containing the 
unboosted, next -generation INSTI, GS -9883, combined with a TAF
-containing nucleotide 
backbone. This regimen has the potential to avoid unwanted side effects from PI -based therapy  
(such as h yperbilirubinemia, rash, gastrointestinal upset , and dyslipi[INVESTIGATOR_035]), decrease the 
potential for drug -drug interactions by  [CONTACT_739914] a boosting agent , avoiding potential 
long term renal and bone side effects from TDF, and avoiding potential long -term cardiovascular 
risk from ABC.
FourFDCs are currently  approved in the US and EU for once -daily administration as a complete 
regimen for the treatment of HIV -1 infection, EFV/FTC/TDF, FTC/RPV/TDF, E/C/F/TDF, and 
ABC/DTG/3TC. There is no PI -containing FDC currentl y available. Studies have shown that a 
once-daily FDC significantly  improved adherence, treatment satisfaction, and virologic 
outcomes for patients infected with HIV -1 {[ZIP_CODE]
}, {[ZIP_CODE]}, {[ZIP_CODE]}, {[ZIP_CODE]}. Due to longer 
duration of high adherence, patients taking FDCs also have better clinical outcomes, such as 
fewer hospi[INVESTIGATOR_602], compared with multiple- tablet regimens {[ZIP_CODE]}.
Boosted protease inhibitors still represent a sizeable portion of the treated HIV-1-infected 
population and are viewed as the class with the greatest barrier to resistance. Boosted DRV is the 
only PI [INVESTIGATOR_739896] a preferred agent, though ATV is still 
widely prescribed. Use of DRV/r and ATV/r in this study  will allow comparison of the 
GS-9883/F/TAF FDC with these third agents, regardless of NRTI backbone. The study has the 
potential to demonstrate benefits such as decreased pi[INVESTIGATOR_739897], and improved 
patient reported outcomes.
This study  will evaluate the safet y, efficacy  and tolerability  of switching from boosted PI  
[INVESTIGATOR_739898]-9883/F/TAF, thereby  [CONTACT_739915]-9883/F/TAF as a FDC option 
forHIV-infected patients.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page32 21 October [ZIP_CODE].7. Rationale for Dose Selection
FTC
The 200 mg dose of FTC represents the marketed dose for this agent that is currentl y available as 
single agent capsules (EMTRIVA) and as a component of a number of fixed -dose combination 
tablets, including: TRUVADA, ATRIPLA, COMPLERA (EVIPLERA), and STRI BILD.
TAF
Based upon results of the Phase 1 Study  GS-US-120-0104, in which various doses of TAF 
(8mg, 25 mg, and 40 mg) were administered to HIV -infected subjects in 10 day s of 
monotherap y, the range of exposure achieved with TAF 25 mg was chosen as the reference 
exposure. I n this study , TAF 25 mg resulted in near -maximal antiviral activity  and plasma TFV 
exposure > 90% low er relative to TDF.
The recommended dose of TAF is based on ensuring that patients have a TAF s ystemic exposure 
that is within the range of the reference exposure achieved with TAF 25 mg, or with TAF 10 mg 
when administered with the boosting agent COBI as E/C/F/TAF, for which an extensive safet y 
and efficacy  database exists. Specifically , TAF [ADDRESS_1010966] on TAF exposure. Therefore, the dose of TAF 
25 mg is appropriate for the GS -9883/F/TAF FDC.
GS-9883
The dose of GS -9883 for Phase 2 was selected based upon data from Study GS-US-141-1219 
(Table1-5), in which HIV-1 -infectedsubjects wereadministered 5, 25, 50, or 100 mg doses of 
GS-9883 monotherap y under fasting conditions for 10 day s.
Table1-5. GS-US-141-1219: Trough GS -9883 Plasma Concentrations at Steady 
State Following GS -9883 Administration Under Fasting Conditions 
and Corresponding Protein -Adjusted IQ 95Values
GS-9883 dose nMedian (range) C tau,SS(ng/mL) Median (range) paIQ 95a
5 mg 4 206.5 (146.0 –342.0) 1.3 (0.9 –2.1)
25 mg 4 797.5 (714.0 –1900.0) 4.9 (4.4 –11.7)
50 mg 4 2170.0 (852.0 –3020.0) 13.4 (5.3 –18.6)
100 mg 4 4190.0 (3730.0 –5970.0) 25.9(23 –36.9)
aThe paIQ 95value is estimated based on steady -state C tauvalues and the in vitro paIC 95value for wild -type HIV -1 
(162ng/mL).
Source: Data on File
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page33 21 October 2015Single-agent GS-9883 was well toleratedatall doses admi nistered.The range of GS-9883 
plasma exposure at steady  state (C tau,SS) observed in the 50 -mg cohort correlated with protein 
adjusted 95% inhibitory  quotient (paIQ 95) values ranging from 5 .3to19, while the range of 
GS-9883 plasma exposure at stead y state (C tau,SS) observed in the 100 -mg cohort correlated with 
paIQ95values ranging from 23 to 37 ( Table1-5).
Based on PK/PD analy ses, exposure following a 75-mg dose of single- agent GS-9883 is 
expected to provide near
-maximal virologic response, with a predicted paIQ 95of approximately
 
20, providing considerable coverage above the target concentration of 162 ng/mL (paI C95).
GS-9883 (75 mg) single agent coadministered with F/TAF (200/25 mg) is currentl y being 
evaluated in a Phase 2 study , GS-US-141-1475 (GS -9883+F/TAF vs DTG+F/TAF). The 
Week12 interim data from this study , support the safet y and efficacy of GS -9883 exposures 
obtained with the 75 mg dose of the single agent .
GS-9883/F/TAF FDC Dose Selection
A fixed dose formulation of GS -9883/F/TAF is being developed for use in Phase 3 studies. 
Preliminary  results from the relative bioavailability  (rBA) study  (GS-US-141-1233) of 
GS-9883/F/TAF (75/200/25 mg) showed that GS -9883 plasma exposure was higher (w ith Cmax
and AUC infincrease of 31% and 27%, respectively) following administration of the FDC as 
compared with exposure following administration of GS
-9883 (75 mg) + F/TAF (200/25 mg) 
under fasted conditions. The increase in GS -9883 exposures associated w ith the FDC 
formulation results in an estimated mean paIQ 95of 24.3, compared to an estimated mean paIQ 95
of 19.2 for the GS -9883 (75 mg) single agent coadministered with F/TAF , in the fasted state.
In order to bridge exposures of GS -9883 in the FDC to the exposure observed with GS -9883 
75mg administered as a single agent, and to bridge to the safe and effective exposures observed 
in the Phase 2 study  GS-US-141-1475, a lower strength GS -9883/F/TAF FDC is being 
developed for use in the Phase 3 studies. Comp arability of GS-9883 exposures will be confirmed 
in an rBA stud y of GS-9883/F/TAF (50/200/25 mg) and GS -9883 (75 mg) + F/TAF prior to 
initiation of dosing in the Phase 3 studies.
1.8. Risk Benefit Assessment for this Study
All patients with HI V-1 infection shou ld receive effe ctive anti-retroviral therap y. Potential risks 
associated with all classes of ARVs include immune reconstitution sy ndrome, lipody strophy, and 
lactic acidosis with steatosis.  The risk of class effects is considered to be low.  I mportant 
iden
tified risks appropriately  managed by  [CONTACT_10844]/exclusion criteria as well as through 
close clinical and laboratory  monitoring during the study are as follows:  hy persensitivity  
reaction to abacavir and allergy  to any components of the tablets.  Some observational studies 
have shown increased risk of cardiovascular disease with abacavir.  Protease inhibitors may  be 
associated with increased lipid levels and gastrointestinal side effects. If patients are currentl y 
infected with hepatitis B and disconti nue their existing or new therap y, there is a risk of severe 
acute exacerbations of hepatitis B.
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_1010967] fewer side effects than alternative therapi[INVESTIGATOR_014].  Other potential 
benefits include provisions of fixed dose combination therapy , and the knowledge that patient 
participation will contribute to the body  of knowledge of HIV therapi[INVESTIGATOR_014].
The overall benefit- risk assessment for GS -9883/F/TAF is fav orable at this time.
1.9. Compliance
This study  will be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regulatory  requirements.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page35 21 October [ZIP_CODE]. OBJECTIVES
The primary  objective of this study  is:
To evaluate the efficacy  of switching to a FDC of  GS -9883/F/TAF versus continuing on a 
regimen consisting of boosted atazanavir or darunavir plus either FTC/TDF or ABC/3TC in 
HIV-1 infected adult subjects who are virologically  suppressed as determined by  [CONTACT_739916] (HIV-1 RNA≥ 50copi[INVESTIGATOR_014]/mL )at Week48
The secondary  objective of this study  
is:
To evaluate the safet y and tolerability  of the two treatment groups through Week 48
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page36 21 October [ZIP_CODE]. STUDY DESIGN
3.1. Endpoints
The primary  efficacy endpoint is:
The proportion of subjects with virologic failure (HIV- 1 RNA ≥ 50 copi[INVESTIGATOR_014]/mL ) at Week 48 
as defined b y the modified US FDA snapshot algorithm
The secondary  efficacy endpoints include:
The proportion of subjects with HI V-1 RNA < 50 copi[INVESTIGATOR_014]/mL  at Week 48 as defined by  [CONTACT_110098]
The change from baseline in CD4+ cell counts at Week 48
3.2. Study Design
This protocol describes a randomized, open -label, multicenter, active -controlled study  to
evaluate the safet y and effi cacy of switching to a FDC of GS -9883/F/TAF in HIV -
1 infected 
adult subjects who are virologically suppressed (HIV -1 RNA < 50 copi[INVESTIGATOR_014]/mL ) on a regimen 
consisting of ritonavir or cobicistat boosted ATV or DRV plus either FTC/TDF or ABC/3TC for 
≥6 months pri or to screening.
3.3. Study Treatments
Subjects who provide written informed consent and meet all eligibility  criteria will be 
randomized in a 1:1 ratio to one of the following two treatment groups:
Treatment Group 1:Switch to FDC of GS -9883 50 mg/ emtricitabi ne 200mg/tenofovir 
alafenamide 25 mg (GS-9883/F/TAF) administered orall y,once daily without regard to food
(n=260)
Treatment Group 2: Remain on current antiretroviral regimen consisting of ritonavir or 
cobicistat boosted ATV or DRV plus either FTC/TDF or ABC/3TC administered orall y
,
oncedaily with food (n=260)
3.4. Duration of Treatment
The treatment duration is 48 weeks.
At the Week 48 Visit , treatment group 1 and 2 subjects in a country  where GS -9883/F/TAF FDC 
is not available will be given the option to receive GS-9883/F/TAF FDC for additional [ADDRESS_1010968].
GS-9883/Fff AF 
Protocol GS-US-380-1878 
[COMPANY_009] Sciences, Inc. Final 
Original 
After Week 48 Visi t, subjects in the [LOCATION_008] ([LOCATION_006]) will stop taking study dmg and 
complete a [ADDRESS_1010969] of care. 
Figure 3-1. 
Screening 
S30da,·s 
prior 
to Dayl Study Schema 
Day 1* 
T1·E!atment Group 1: GS-9883/F/TAF FDC 
QD (n-260) Week 4Sb,c 
Treatment Grouo 2: Remain on current regimen of 
boosted ATV or DRV plus FTC/TDF or ABC/3TC 
QD (n=260) 30Day 
FlU" 
a. Following the Day 1 visit, subjects will be required to retum for study visits at Weeks 4, 8, 12, and then every 12 weeks 
through Week 48. 
b. After Week 48, subjects in a cmmtry where GS-9883/F/TAF FDC is not available will be given the option to receive 
GS-9883/F!T AF FDC for additional [ADDRESS_1010970]. 
c. Subjects who complete the study through the Week 48 Visit and do not wish to receive GS-9883/F !TAF FDC and subjects 
in the [LOCATION_008] ([LOCATION_006]) who complete the study through the Week 48 Visit w'ill be required to retwn to the clinic 
30 days after the completion of study dmgs for a 30-Day Follow-Up Visit. 
3.5. Biomarker Testing 
3.5.1. Biomarker Samples for Optional Pharmacogenomic Research 
[COMPANY_003] 
CONFIDENTIAL Page 37 21 October 2015 
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page38 21 October [ZIP_CODE].5.2. Additional Sample Storage
Forsubjects who provide additional consent , residual blood and urine samples taken throughout 
the study will be stored. Stored samples may  be used by  [CONTACT_739917], and HIV disease and its associated conditions, or to 
provide additional safet y data.  At the conclusion of this study , these samples may  be retained in 
storage by [CONTACT_10846] a period up to 15 years.
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_1010971] be obtained 
prior to initiation of study procedures
2.Age 18years
3.Currently  receiving antiretroviral regimen consisting of ritonavir or cobicistat boosted ATV
or DRV plus either FTC/TDF or ABC/3TC for 6 months preceding the screening visit
4.HIV RNA < 50 copi[INVESTIGATOR_014]/mL at the screening visit
5.Normal ECG (or if abnormal, determined b y the Investigator to be not clinically significant)
6.Adequate renal function:
Estimated glomerular filtration rate ≥ 50mL/min(
≥ 0.83mL/sec)according to the 
Cockcroft -Gault formula {2202}:
a.Male: (140–age in years) (wt in kg) CLcr (mL/min)
72(serum creatinine in mg/dL)
         (140 –age in years) (wt in kg) CLcr (mL/sec)
72(serum creatinine in umol/L) 0.6786
b.Female: (140–age in years) (wt in kg)  0.85CLcr (mL/min)
72(serum creatinine in mg/dL)
        (140–age in years) (wt in kg)  0.85 CLcr (mL/sec)
72(serum creatinine in umol/L) 0. 6786
7.Hepatic transaminases (AST and ALT) 5upper limit of normal (ULN)
8.Total bilirubin 1.5mg/dL(26 umol/L) , or normal direct bilirubin
9.Adequate hematologic function (absolute neutrophil count ≥ 750/mm3(≥0.75 GI/L); 
platelets ≥50,000/mm3(≥ 50 GI/L); hemoglobin ≥ 8.5 g/dL(
≥85 g/L))
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page40 21 October 201510.Serum amy lase ≤ 5 × ULN (subjects with serum amy lase > 5 ×ULN will remain eligible if 
serum lipase is ≤ 5
×ULN)
11. Femalesof childbearing potential must agree to utilize protocol recommended highl y 
effective contraceptive methods or be non -heterosexually  active or practice sexual abstinence 
(as defined in Appendix 6) from screening, throughout the duration of the study  period, and 
for [ADDRESS_1010972] dose of study  drug.
a)Female subjects who utilize hormonal contraceptive as one of their birth cont rol methods 
must have used the same method for at least [ADDRESS_1010973] agree to use protocol specified 
method(s) of contraception (as described in Appendix 6) throughout the st udy period and for 
[ADDRESS_1010974] study  drug dose
14.Life expectancy  ≥ [ADDRESS_1010975] or second antiretroviral regimen with documented plasma HIV- 1 RNA 
< 50 copi[INVESTIGATOR_014]/mL on a stable regimen (or undetectable HIV- 1 RNA level according to the local 
assay being used if the limit of detection is ≥ 50 copi[INVESTIGATOR_014]/mL ) for ≥ 6 months preceding the 
Screening visit. 
Prior changes in antiretroviral regimen are onl y allowed due to tolerabilit y issues or for 
regimen simplification. 
Unconfirmed virologic elevation sof ≥ 50 copi[INVESTIGATOR_014]/mL  (transient 
detectable viremia, or “blip”) prior to screening are acceptable .(If the lower limit of 
detection of the local HIV- 1 RNA assay  is <50 copi[INVESTIGATOR_014]/mL  [e.g., <20 copi[INVESTIGATOR_014]/mL ], the plasma 
HIV-1 RNA level cannot exceed 50 c opi[INVESTIGATOR_014]/mL on two consecutive HIV -1 RNA tests)
16.Have no documented or suspected resistance to FTC, TFV, ABC or 3TC ,including but not 
limited to the reverse transcriptase resistance 
mutations K65R and M184V/I
17.No previous use of an y approved or experimental integrase st rand transfer inhibitor (INSTI)
4.3. Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study .
1. An opportunistic illness indicative of stage 3HIVdiagnosed within the 30 days prior to 
screening (refer to Appendix 5)
2.Subjects experiencing decompensated cirrhosis (e .g, ascites, encephalopathy , or variceal 
bleeding)
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_1010976] been treated with immunosuppressant therapi[INVESTIGATOR_10793] 
3months of study  screening, or expected to receive these agents or s ystemic steroids during 
the study (e.g, corticosteroids, immuno globulins, and other immune -or cytokine-based 
therapi[INVESTIGATOR_014])
4.Current alcohol or substance use judged b y the Investigator to potentiall y interfere with 
subject study  compliance
5.A history of or ongoing malignancy  (including untreated carcinoma in -situ) other th an 
cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non -invasive cutaneous 
squamous carcinoma. Subjects with biopsy -confirmed cutaneous KS are eligible, but must 
not have received an y systemic therap y for KS within 30 days of Day 1and are not 
anticipated to require s ystemic therap y during the study
6.Active, serious infections (other than HIV -1 infection) requiring parenteral antibiotic or 
antifungal therap y within [ADDRESS_1010977] unsuitable for the stud y or unabl e to comply  with the dosing requirements
9.Any known allergies to the excipi[INVESTIGATOR_10794] -9883/F/TAF FDC or AT V, RTV, DRV, COBI, 
FTC/TDF or ABC/3TC
10.Females who are pregnant (as confirmed b y positive serum pregnancy  test)
11. Females who are breastfeeding
12.Subjects r eceiving ongoing therap y with any of the medica tions listed in the Table 5-1and 
Table5-2. Administration of any  Prohibited Medication ( Table5-1andTable5- 2) must be 
discontinued at least 30 day s prior to the Day  1 visit and for the duration of the study.
13. Acute hepatitis in the 30 day s prior to study  entry
14. Chronic hepatitis B infection in subjects not on a TDF containing regimen, as determined b y 
either:
Positive HBV surface antigen and negative HBV surface antibod y, regardless of HBV 
core antibod y status, at the screening visit
Positive HBV core antibody  and negative HBV surface antibody , regardless of HBV 
surface antigen status, at the screening visit
15.Active tuberculosis infection
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_1010978] using the Interactive Web Response System (IWRS). Once a 
subject number has been assigned to a subject, it will not be reassigned to any  other subject. The 
subject number assignment and randomization may be performed up to 3days prior to the 
in-clinic Day [ADDRESS_1010979] 
eligibility  has been confirmed.
Subjects will be randomized in a 1:1 ratio to Treatment Group1 or Treatment Group 2.
Treatment Group 1
: Switch to a FDC of GS -9883/emtricitabine/tenofovir alafenamide 
(GS-9883/F/TAF) administered orall y once dail ywithout regard to food (n=260)
Treatment Group 2: Remain on current antiretroviral regimen consisting of ritonavir or 
cobicistat boosted ATV or DRV plus either FTC/TDF or ABC/3TC administered orall y once 
daily with food (n=260)
Randomization will be stratified b y the prior treatment regimen group (ie, TDF containing 
regimens [ ritonaviror cobicistat boosted 
ATV or DRV plus FTC/TDF] and non- TDF containing 
regimens [ ritonaviror cobicistat boosted 
ATV or DR V plus ABC/3TC]) at screening.
Subjects randomized in Treatment Group 1 will be assignedstudy drug bottle numbers of 
GS-9883/F/TAF FDC at study visitsby [CONTACT_10966].
Investigators must provide a pres cription to the subjects in Treatment Group2. Those subjects 
are responsible for obtaining their ARV treatment prior to or during the study  visit.
5.2. Description and Handling 
5.2.1. Formulation
[IP_ADDRESS]. GS-9883/Emtricitabine/Tenofovir alafenamide (GS-9883/F/TAF) 
50mg/200mg/25 mg Tablets
GS-9883 50 mg/Emtricitabine 200 mg/Tenofovir alafenamide 25 mg tablets are capsule -shaped, 
film-coated purplish -brown, debossed with "GSI" on one side of the tablet and "9883" on the 
other side of the tablet. Each tablet core contains 50 m g of GS-9883, 200 mg of emtricitabine, 
and 25 mg of tenofovir alafenamide. In addition to the active ingredients, the GS -9883/F/TAF 
tablets contain croscarmellose sodium, magnesium stearate, and microcry stalline cellulose. The 
tablet cores are film- coated 
with iron oxide red, iron oxide black, polyethylene glycol, polyvinyl 
alcohol, talc, and titanium dioxide.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page43 21 October [ZIP_CODE].2.2. Packaging and Labeling
[IP_ADDRESS]. GS-9883/Emtricitabine/Tenofovir alafenamide (GS-9883/F/TAF) 
50mg/200mg/25mg Tablets
GS-9883/F/TAF  tablets are packaged in white, high densit y polyethylene (HDPE) bottles. Each 
bottle contains 30 tablets, silica gel desiccant and poly ester packing material. Each bottle is 
enclosed with a white, continuous thread, child
-resistant poly propylene screw cap with an 
induction- sealedand aluminum- faced liner.
Study drug(s) to be distributed to centers in the US and other participating countries shall be 
labeled to meet applicable requirements of the [LOCATION_002] Food and Drug Administration 
(FDA), EU Guideline to Good Manufacturing P ractice -Annex 13 (I nvestigational Medicinal 
Products), and/or other local regulations.
5.2.3. Storage and Handling
Study drug GS-9883/F/TAF should be stored at controlled room temperature of 25°C (77°F); 
excursions are permitted between 15°C and 30°C (59°F and 86°F).  Storage conditions are 
specified on the label. Until dispensed to the subjects, all bottles of study  drugs should be stored 
in a securely  locked area, accessible only  to authorized site personnel.
To ensure the stabilit y and proper identification, study drug(s) should not be stored in a container 
other than the container in which they  were supplied.
Consideration should be given to handling, preparation, and disposal through measures that 
minimize drug contact [CONTACT_10850] . Appropriate precautions should be followed to avoid direct 
eye contact [CONTACT_10851].
5.3. Dosage and Administration of GS-9883/Emtricitabine/Tenofovir alafenamide
GS-9883/F/TAF tablets will be provided by  [CONTACT_10869].
GS-9883/Emtricitabine/Tenofovir alafenamide (GS-9883/F/TAF) 50 mg/200 mg/[ADDRESS_1010980] be accounted for b y the stud y monitor prior to destruction 
or return.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page44 21 October [ZIP_CODE].4. Prior and Concomitant Medications
The use of medications for the treatment of HIV, othe r than study  drug, is prohibited.
Medications listed in the following table and use of herbal/natural supplements are excluded or 
should be used with caution while subjects are participating in the study , depending on subject’s 
treatment regimen . Subjects will refrain from consumption of grapefruit juice and Seville orange 
juice throughout participation in the study .
Table5-1. Prior and Concomitant Medications (GS-9883/F/TAF Regimen)
Drug Class Agents Disallowed*Use Discouraged and To Be Used With 
Caution
Acid Reducing Agents
Antacids
Buffered medications Concentration of study drug may 
decrease w ith antacids. Subjects may not 
take antacids (eg, Tums or Rolaids); the 
ulcer medication sucralfate (Carafate); or 
vitamin or mineral supplements that 
contain calcium, iron or zinc for a 
minimum of 2 hours before and 6 hours 
after any dose of study drug.
Antiarrhythmic Agent Dofetilide
AnticonvulsantsPhenobarbital, Phenytoin, 
Carbamazepi[INVESTIGATOR_050], Oxcarbazepi[INVESTIGATOR_10795], Rifapentine
AntiretroviralsAny antiretroviral drug that is not part of 
the study regimen
GI Motility Agents Cisapride
Herbal/Natural 
SupplementsSt. John’s Wort, Echinaccea
Oral Hypoglycemic AgentMetformin: close monitoring is 
recommended. A dose adjustment of 
Metformin may be necessary. Limit total 
daily doses of Metformin to 1000mg 
either when starting or at study entry.
*Administration of any of the above medications must be discontinued at least 30 days prior to the Day 1 visit and for the 
duration of the study.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page45 21 October 2015Table5-2. Prior and Concomitant Medications (Boosted ATV and DRV 
regimen)
Drug Class Agents Disallowed*
Alpha-[ADDRESS_1010981] Alfuzosin
Antiarrhythmic Agent Amiodarone , Dronedarone
Anticonvulsants Phenobarbital, Phenytoin, Carbamazepi[INVESTIGATOR_739899], Pi[INVESTIGATOR_739900]/Natural Supplements St. John’s Wort
Anticancer drugs Irinotecana
Ergot DrivativesErgotamine, Ergonovine
Dihydroergotamine
Methylergonovine
Ergometrine
HMG-CoA Reductase Inhibitors Simvastatin, Lovastatin
Phosphodiesterase -5 Inhibitors Sildenafil ( for PAH)
Sedatives/Hypnotics Orally administered Midazolam, Triazolam
Calcium Channel Blockers Bepridil
Chronic angina Ranolazine
aApplied to ATV regimen only
*Administration of any of the above medications must be discontinued at least [ADDRESS_1010982] notify  [COMPANY_009] Sciences as soon as he/she is aware of the use of the excluded 
medication.
Additionally, Investigators should refer to the current product/package inserts of the 
antiretroviral medications for contraindications related to their use .
5.5. Accountability for Investigational Medicinal Product (IMP)
The investigator is responsible for ensuring a dequate accountability  of all used and unused IMP.
This includes acknowledgement of receipt of each shipment of IMP(quantity and condition). All 
used and unused IMPdispensed to subjects must be returned to the site.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page46 21 October 2015Study Drug accountability records will be provided to each stud y site to:
Record the date received and quantity  of IMPkits
Record the date, subject number, subject initials, the IMPkit number dispensed
Record the date, quantity of used and unused IMPreturned, along with the initials of the 
person recording the information
5.5.1. I nvestigational M edicinal Product Return or Disposal
Return and disposal of study drug GS-9883/F/TAF will be performed as outlined in 
Section9.1.7.
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_1010983] research organization (CRO).
6.1. Subject Enrollment and Treatment Assignment
It is the responsibility  of the Investigator to ensure that subjects are eligible for study  prior to 
enrollment. Please refer to Section 6.3for details about randomization a nd treatment assignment.
6.2. Pretreatment Assessments
6.2.1. Screening Visit
Subjects will be screened within 30-days before Day 1 to determine eligibility  for participation in 
the study. The following will be performed and documented at screening:
Obtain written informed consent
Obtain medical history  including history  of HIV-1 disease-related events, smoking history  
and prior medications within 30 days of the screening visit . 
If available, obtain historical genot ype(s)(not required for entry to study)
Complete physical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)
12-lead ECG performed supi[INVESTIGATOR_050]
Height
Vital signs measurement (blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature), including 
weight
Urine collect ion for the following laboratory  procedures:
Urinalysis
Blood sample collection for the following laboratory  analyses:
Serum pregnancy  test (females of childbearing potential only ). If the test is positive, the 
subject will not be enrolled
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page48 21 October 2015Chemistry  profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, 
amylase (reflex lipase testing is performed in subjects with total amy lase 1.5ULN) 
and TSH.
Estimated glomerular filtration rate according to the Cockcroft -Gault formula:
■Male: (140–age in years) (wt in kg) CLcr (mL/min)
72(serum creatinine in mg/dL)
        (140 –age in years) (wt in kg) CLcr (mL/sec)
72(serum creatinine in umol/L) 0.6786
■Female: (140–age in years) (wt in kg) 0.85CLcr (mL/min)
72(serum creatinine in mg/dL)
       (140 –age in years) (wt in kg) 0.85 CLcr (mL/sec)
72(serum creatinine in umol/L) 0. 6786
Hematology  profile: complete blood count (CBC) with differential and platelet count
CD4+ cell count
Plasma HIV -1 RNA
Hepatitis B Virus (HBV) blood panel: Hepatitis B virus surface antigen (HBsAg), 
Hepatitis B virus surface antibody  (HBsAb) and Hepatitis B virus core antibody  (HBcAb)
The following will be conducted b y the central laboratory if the following criteria are 
met:
■ If positive HBsAg, reflex testing for plasma HBV DNA, HBeAg (if negative, re flex 
HBeAb), and quantitative HBsAg
■If positive HBcAb with negative HBsAg  and negative HBsAb, reflex testing for 
plasma HBV DNA (if positive, reflex HBeAg). If HBeAg is performed and found to 
be negative, reflex HBeAb.
Hepatitis C virus (HCVAb) serology . Subjects who are HCVAb positive will have a 
HCV RNA test performed.
Review of adverse events and concomitant medications
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_1010984] all serious adverse events (SAEs), as well as any adverse events 
related to protocol -mandated procedures on the adverse e vents case report form (eCRF). All 
other untoward medical occurrences observed during the screening period, including 
exacerbation or changes in me dical 
historyare to be captured on the medical history  eCRF. See 
Section7Adverse Events and Toxicity  Management for additional details.
6.2.2. Day [ADDRESS_1010985]’s eligibility before proceeding with the Day [ADDRESS_1010986] 
complete all study  procedures before being administered the study  drug:
Review of AEs and changes in concomitant medications
Complete phy sical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)
Vital signs measurement (blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature), including 
weight
12-lead ECG performed supi[INVESTIGATOR_050]
Short Form 36 Health Survey  (SF-36), HIV Sy mptoms Distress Module, Work Productivity  
and Activity  Impairment Questionnaire (WPAI), UCL A Scleroderma Clinical Trial 
Consortium Gastrointestinal Tract (UCLA SCTC GIT 2.0) and VAS Adherence 
Questionnaire to be completed by  [CONTACT_423]. Subject is to read questionnaire b y 
himself/herself and write/mark answers directl y onto questionnaires.
Urine collection for the following laboratory  procedures:
Urinalysis 
Urine albumin, urine creatinine, urine protein, retinol binding protein and 
beta-2-microglobulin 
Urine pregnancy  test (females of childbearing potential only ); positive urine pregnancy  
tests will be confirmed with a serum test. If the test is positive, the subject will not be 
able to participate
Urine storage sample for possible additional clinical testing
GS-9883/F/T AF 
Protocol GS-US-380-1878 
[COMPANY_009] Sciences, Inc. Final 
Original 
• Blood sample collection for the following laborat01y analyses: 
-Chemis1:Iy profile: alkaline phosphatase, AST, ALT, GGT, total bilimbin, direct and 
indirect bilimbin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, phosphoms, magnesium , potassium, sodium, uric acid, and amylase 
(reflex lipase testing is perf01med in subjects with total amylase> 1.[ADDRESS_1010987]) and TSH 
-Metabolic assessments: Fasting (no food or drinks, except water, at least 8 hours prior to 
blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL, and 
u·iglycerides). If the subject has not fasted prior to the visit, the visit may proceed, but the 
subject must retu.m within 72 hours in a fasted state to draw blood for the metabolic 
assessments. 
-Estimated glomemlar filu·ation rate according to the Cockcroft -Gault f01mula 
- Hematology profile: complete blood cmmt (CBC) with differential and platelet cmmt 
- Plasma HIV-1 RNA 
-CD4+ cell count 
- Plasma storage sample for safety, virology, or PK testing 
-Whole blood sample for potential HIV DNA genotypi[INVESTIGATOR_007] 
- Subjects who m eet the defmition of HBV infection below at Screening Visit (positive 
sennn HBsAg or Positive HBcAb with quantifiable HBV DNA), will have plasma HBV 
DNA tested. 
• Optional blood sample collection for the following laboratory analyses if 
pharmaco genomic consent is obtained 
I 
I 
I 
I 
CONFIDENTIAL Page 50 21 October 2015 
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_1010988] using the Interactive Web Response System (IWRS). Once a 
subject number has been assigned to a subject, it will not be reassigned to any  other subject. The 
subject number assignment and randomization may be performed up to [ADDRESS_1010989] 
eligibility  has been confirmed.
6.4. Treatment Assessments (Week 4 -48)
The following evaluations are to be completed at the end of Weeks 4, 8, 12, 24, 36, and 48 unless 
otherwise specified .
Study visits are to be completed within ± 2 day s of the protocol -specified visit date based on the 
Day 1 visit through Week 12 and completed within ± 6 days of the protoc ol-specified visit date 
through Week 36, unless otherwise specified.  The visit window at Week 48 will be ± 6 weeks of 
the protocol -specified visit date and this clinical visit window coincideswith the Week 48 
statistical analy sis window for HIV- 1 RNA.
Regularly scheduled evaluations will be made on all subjects whether or not they  continue to 
receive study  drug.
Review of AEs and changes in concomitant medications
Complete physical examination (Weeks24 and 48) (urogenital/anorectal exams will be 
performed at the discretion of the Investigator) or sy mptom-directed phy sical examination as 
needed 
Vital signs measurement (blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature), including 
weight
12-leadECG performed supi[INVESTIGATOR_050] (Weeks 24 and 48)
Short Form 36 Health Survey  (SF-36), HIV Sy mptoms Distress Module, Work Productivity  
and Activity  Impairment Questionnaire (WPAI) and UCL A Scleroderma Clinical Trial 
Consortium Gastrointestinal Tract (UCLA SCTC GIT 2.0) to be completed by  [CONTACT_739918] 4, 12, an d 48.Subject is to read questionnaire b y himself/herself and write/mark 
answers directl y onto questionnaires.
VAS Adherence Questionnaire. Subject is to read questionnaire b y himself/herself and 
write/mark answers directly  onto questionnaires.
Urine colle ction for the following laboratory  procedures:
Urinalysis
Urine albumin, urine creatinine, urine protein, retinol binding protein and 
beta-2-microglobulin (Weeks24 and 48)
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page52 21 October 2015Urine pregnancy  test (females of childbearing potential only ); positive urine pregnancy  
tests will be confirmed with a serum test. If the test is positive, the subject will be 
discontinued
Urine storage sample for possible additional clinical testing
Blood sample collection for the following laboratory  analyses:
Chemistry  profile: alkali ne phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, and 
amylase (reflex lipase testi ng is performed in subjects with total amy lase 1.5ULN). 
At Weeks 12, 24 and 48, anal yses of glucose will be done as part of the fasting metabolic 
assessments and not as part of the chemistry  profile. At Weeks 24 and 48, TSH will also 
be analyzed.
Metabolic assessments: Fasting (no food or d rinks, except water, at least 8 hours prior to 
blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL , and 
triglycerides). If the subject has not fasted prior to the visit, the visit may  proceed, but the 
subject must return within 72 hours in a fasted state to draw blood for the metabolic 
assessments. (Weeks 12, 24 and 48)
Estimated glomerular filtration rate according to the Cockcroft -Gault formula
Hematology  profile: complete blood count (CBC) with differential and platelet count
Plasma HIV -1 RNA
CD4+ cell count
Plasma storage sample for safet y, virology , or PK testing
Plasma HBV DNA (for subjects who meet the definition of HBV infection)
■At Weeks 12, 24 and 48 (for subjects who meet the definition of HBV infection), the 
following will be conducted by  [CONTACT_2237] : HBsAb, HBsAg (qualitative 
and quantitative) and HBeAg (if negative ,reflex HBeAb)
Pharmacokinetic Bloo d Collection for subjects who are on stud y drugin Treatment Group 1 
only. 
Details of pharmacokinetic blood sampling procedures and sample management will be 
documented in the Pharmacokinetic Sample Collection, Processing, Storage, and Shipment 
Manual.
Single Anytime ,Troughand Post Dose PK Sample sfor all subjects on study drug in 
Treatment Group 1 :
■Subjects will have a single an ytime pre or post -dose PK blood at Weeks8, 24 and 
36.
GS-9883/F/T AF 
Protocol GS-US-380-1878 
[COMPANY_009] Sciences, Inc. Final 
Original 
I 
I 
I • Observed dosing at the clinic: Subjects will have a trough PK blood sample collected 
between 20-[ADDRESS_1010990] be 
instructed to not take their study <hugs on the mo ming of their visit for the tr·ough 
sample collection. Subjects will then take an observed dose of study <hug at the clinic. 
A single post dose PK blood sample will be collected between [ADDRESS_1010991] has taken their dose of study <hugs prior to the visit, the visit may 
proceed, but the subject must retum within 72 hours for the tr·ough PK blood sample 
collection. In the event a subject routinely takes their study dmg in the evening, a 
single post-dose sample may be <h·awn at Weeks [ADDRESS_1010992] will not be 
instructed to change their dosing time to accommodate this tr·ough PK <h·aw. 
• Dosing diaries will be collected from subjects for the single anytime PK and tr·ough 
PK collection. If a dosing diaty is not retumed the site may ask the subject for the 
time of the last dose and if it was taken with or without food. 
-Optional Pharmacokinetic (PK) Substudy: 
CONFIDENTIAL Page 53 21 October 2015 
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page54 21 October [ZIP_CODE].5. Treatment Assessments (Post Week 48)
6.5.1. Post Week 48 Assessments
At the Week 48 visit, subjects who completed 48 weeks of stud y drug treatment and are in a 
country where GS-9883/F/TAF FDC is not available will be given the option to receive 
GS-9883/F/TAF FDC for additional [ADDRESS_1010993].
Subjects who further continue participation in the study  and receives GS-9883/F/TAF FDC will 
return for stud y visits every 12 weeks. Stud y visits are to be completed within ±[ADDRESS_1010994] Week 48 will be required to return for study  visits 
according to the schedule presented in Appendix 1.StudyProcedures Table and descr ibed in the 
text below:
Review of AEs and changes in concomitant medications
Symptom-directed phy sical examination as needed
Vital signs measurement (blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature), including 
weight
Urine collection for the following laboratory  procedures:
Urinalysis
Urine albumin, urine creatinine, urine protein, retinol binding protein and 
beta-
2-microglobulin (Weeks 72 and 96)
Urine pregnancy  test (females of childbearing potential only ); positive urine pregnancy  
tests will be confirmed with a serum test. If the test is positive, the subject will be 
discontinued.
Urine storage sample for possible additional clinical testing
Blood sample collection for the following laboratory  analyses:
Chemistry  profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, and 
amylase (reflex lipase testing is perform ed in subjects with total amy lase 1.5ULN). 
Every 24 weeks, analy ses of glucose will be done as part of the fasting metabolic 
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page55 21 October 2015assessments and not as part of the chemistry  profile. In addition, TSH will also be 
analyzed every 24 weeks.
Metabolic assessm ents: Fasting (no food or drinks, except water, at least 8 hours prior to 
blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL , and 
triglycerides). If the subject has not fasted prior to the visit, the visit may  proceed, but the 
subject must return within 72 hours in a fasted state to draw blood for the metabolic 
assessments. (Every 24 weeks)
Estimated glomerular filtration rate according to the Cockcroft -Gault formula
Hematology  profile: complete blood count (CBC) with differential and platelet count
Plasma HIV -1 RNA
CD4+ cell count
Plasma storage sample for safet y, virology  or PK testing
Plasma HBV DNA (for subjects who meet the definition of HBV infection)
Subjects who meet the criteria for virologic failure will be managed accord ing to the 
Management of Virologic Rebound Section 6.13.
Document study  drug dispensation and accountability  for all study  drugs dispensed.
6.6. Post-treatment Assessments
6.6.1. Early Study Drugs Discontinuation Assessments
At the Early Study Drugs Discontinuation Visit, any evaluations showing abnormal results 
indicating that there is a possible or probable causal relationship with the study drug , will 
be repeated weekly (or as often as deemed prudent by [CONTACT_737]) un til the 
abnormality is resolved, returns to baseline, or is otherwise explained.
The following evaluations are to be completed at the Earl y Study Drugs Discontinuation Visit:
Review of AEs and changes in concomitant medications
Complete phy sical examinatio n (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)
Vital signs measurement (blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature), including 
weight 
12-lead ECG performed supi[INVESTIGATOR_050]
VAS Adherence Questionnaire. Subject i s to read questionnaire b y himself/herself and 
write/mark answers directly  onto questionnaires.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page56 21 October 2015Urine collection for the following laboratory  procedures:
Urinalysis 
Urine pregnancy  test (females of childbearing potential only ); positive urine pregnancy  
tests will be confirmed with a serum test
Urine storage sample for possible additional clinical testing
Blood sample collection for the following laboratory  analyses:
Chemistry  profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, L DH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, and 
amylase (reflex lipase testing is performed in subjects with total amy lase 1.5ULN), 
and TSH
Estimated glomerular filtration rate according to the Cockcroft -Gault formula
Hematology  profile: complete blood count (CBC) with differential and platelet count
Plasma HIV -1 RNA
CD4+ cell count
Plasma storage sample for safet y, virology , or PK testing
Plasma HBV DNA (for subjects who meet the definition of HBV infection)
HIV-1 genotype/phenotype testing for subjects with virologic failure
Drug accountability
6.6.2. 30- Day Follow -Up
Subjects who complete the study  through Week [ADDRESS_1010995] of care.
Subjects who permanently discontinue stud y drug prior to Week 48 and refuse to continue in the 
study will be asked to return to the clinic 30 days after the completion of the Earl y Study Drugs 
Discontinuation Visit for the 30- Day Follow-Up Visit.
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_1010996] one subsequent visit after the Early Study Drug Discontinuation Visit will notbe 
required to complete the 30 -Day Follow -Up Visit.
For the purpose of scheduling a 30 -Day Follow-Up Visit, a  6 days window may  be used. 
Thefollowing evaluations are to be completed at the 30 -Day Follow-Up Visit:
Review of AEs and changes in concomitant medications
Symptom-directed phy sical examination
Vital signs measurement (blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature), including 
weight
Urine collection for the following laboratory  procedures:
Urinalysis
Urine pregnancy  test (females of childbearing potential only ); positive urine pregnancy
tests will be confirmed with a serum test.
Blood sample collection for the following laboratory  analyses:
Chemistry  profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, L DH, CPK, bicarbonate , BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, and 
amylase (reflex lipase testing is performed in subjects with total amy lase 1.5ULN).
Estimated glomerular filtration rate according to the Cockcroft -Gault formula
Hematology  profile: complete blood count (CBC) with differential and platelet count
Plasma HIV -1 RNA
CD4+ cell count
At the 30-Day Follow-Up Visit, any  evaluations showing abnormal results believed to be a 
reasonable possibility  of a causal relationship with the study  drugs will be repeated weekl y (or as 
often as deemed prudent by  [CONTACT_737]) until the abnormality  is resolved, returns to 
baseline, or is otherwise explained.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page58 21 October [ZIP_CODE].7. Criteria for Discontinuation of Study Treatment
Study medicatio n may be discontinued in the following instances:
Intercurrent illness that would, in the judgment of the investigator, affect assessments of 
clinical status to a significant degree . Following resolution of intercurrent illness, the subject 
may resume stud y dosingat the discretion of the investigator
Unacceptable toxicity , or toxicity  that, in the judgment of the investigator, compromises the 
ability to continue study -specific procedures or is considered to not be in the subject’s best 
interest
Lack of eff icacy
Subject request to discontinue for an y reason
Subject noncompliance
Pregnancy  during the study ; refer to Appendix 6
Development of active tuberculosis infection
Discontinuation of the study  at the request of [COMPANY_009], aregulatory  agency or an institutional 
review board or independent ethics committee ( IRB/IEC)
6.8. O ther Evaluations
6.8.1. Markers of Renal Tubular Function
For all subjects, urine will be collected for selected evaluations of renal tubular function, which 
will include but not limited to urine albumin, ur ine creatinine, urine protein, retinol binding 
protein and beta -2-microglobulin at Day [ADDRESS_1010997] 
Week48.
6.9. Blood and Urine Storage
A portion of the blood and urine samples drawn at all visits (except the Sc reeningVisit, 30- day 
follow-up Visitand Unscheduled Visits) will be frozen and stored. These stored blood and urine 
samples may  be used by  [CONTACT_10852]
-1 genotypi[INVESTIGATOR_007]/phenot ypi[INVESTIGATOR_10798], for retesting the amount of HIV- [ADDRESS_1010998] HIV -1 or clinical laboratory  testing to provide additional safety  data. No human 
genetic testing will be performed without expressed consent of stud y subjects. At the conclusion 
of this study , these samples may  be retained in storage by  [CONTACT_10846] a period up to 
15years.
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_1010999] discontinues study  dosing (for example, a s a result of an AE), every  attempt should 
be made to keep the subject in the study  and continue to perform the required study -related 
follow-up and procedures (see Section 6.7, Criteria for Discontinuation of Study  Treatment ). If 
this is not possible or a cceptable to the subject or investigator, the subject may  be withdrawn 
from the study .
6.11. End of Study
The end of stud y will be the last patient’s last observation (or visit).
6.12. Post Study Care
After a subject has completed/terminated their participation in the study, long-term care for the 
subject will remain the responsibility  of their primary  treating ph ysician.
6.13. Virologic Failure
Virologic failure is defined as virologic rebound or hav ing HIV-1 RNA ≥ 50copi[INVESTIGATOR_014]/mL  at study 
drug discontinuation or Week 48. 
6.13.1. Management of Virologic Rebound
Subjects who meet the criteria listed below will be considered to have virologic rebound:
At any 
post Day 1 visit, a rebound in HIV -1 RNA ≥ 50 copi[INVESTIGATOR_014]/mL, which is subsequently  
confirmed at the following scheduled or unscheduled visit;
OR
Any subject with HIV RNA ≥ 50 copi[INVESTIGATOR_014]/m L at study drug discontinuation
Following the unconfirmed virologic rebound, subjects will be asked to return to the clinic for a 
scheduled or unscheduled blood draw ([ADDRESS_1011000] that resulted 
in HIV-1 RNA virologic rebound) for confirmation of virologic rebound. If virologic rebound is 
confirmed at the scheduled or unscheduled visit and the HIV -1 RNA is ≥ 200copi[INVESTIGATOR_014]/mL , the 
blood sample from the confirmation visit wi
ll be the primary  sample used for HIV -[ADDRESS_1011001]’s first post -Day [ADDRESS_1011002] may  be discontinued at 
Investigator’s discretion or per local treatment guidelines.
If no resistance is detected from the genotypeor phenotype, 
the subject may  remain on study  
drugsand HIV-[ADDRESS_1011003] should be repeated ([ADDRESS_1011004] with HI V-1 RNA
≥50 copi[INVESTIGATOR_014]/mL ). Investigators should carefully  evaluate the benefits and risks of remaining on 
study drug for each individual subject and document this assessment in the on- site medical 
record.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page60 21 October 2015Subjects who are noncompliant on an ongoing basis will be considered for discontinuation per 
the Investigator’s discretion or local treatment guidelines . Investigators who opt to discontinue 
study drugs for an individual subject must discuss with theMedical Monitor prior to study  drug 
discontinuation.
For subjects who are off study  drug but remain on study , it will be the Investigator’s discretion to 
manage virologic rebound.
Please refer to Figure6-1for the management of subjects who meet the crit eria for virologic 
rebound.
Figure6-1. Virologic Rebound Schema
a.If virologic rebound is not confirmed, the subject will remain on their current regimen.
b.If virologic rebound is confirmed and the HIV -1 RNA is ≥ 200 copi[INVESTIGATOR_014]/mL , the HIV -
1 genotype and phenotype (reverse 
transcriptase, protease and integrase) will be analyzed.
c.Based on the results of the genotyp icand phenotypi[INVESTIGATOR_739901], the subject will remain on study drugs or study drugs will be 
discontinu ed. If genotypi[INVESTIGATOR_236690], a new ARV regimen may be configured at the discretion of the 
Investigator.
d.Ifno resistance is detected, HIV -1 RNA will be repeated (2 -3 weeks later).  Investigator reviews study drug 
continuation/discontinuati
on options and discuss with the Medical Monitor prior to study drug discontinuation
e.A new ARV regimen will be configured, at the Investigator’s discretion, and the subject will remain in the study.

GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page61 21 October [ZIP_CODE].13.2. Subjects with HIV -1 RNA ≥ 50 copi[INVESTIGATOR_014]/mL at Study DrugDiscontinuation, or 
Week48
Subjects with HI V-1 RNA ≥ 50 copi[INVESTIGATOR_014]/mL  at study drug discontinuation or last visit will be 
considered virologic failures. Subjects with H IV-1 RNA ≥ 50 copi[INVESTIGATOR_014]/mL  at Week [ADDRESS_1011005].
Subjects with HI V-1 RNA ≥ 200 copi[INVESTIGATOR_014]/mL  at study drug discontinuation, last visit or Week 48, 
will also have resistance testing conducted.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page62 21 October [ZIP_CODE]. ADVERSE EVENTS AND TOXICITY  MANAGEMENT
7.1. Definitions of Adverse Events, Adverse Reactio ns, and Serious Adverse 
Events
7.1.1. Adverse Events
An adverse event (AE) is any  untoward medical occurrence in a clinical study  subject 
administered a medicinal product, which does not necessarily  have a causal relationship with the 
treatment. An AE can therefo re be any unfavorable and/or unintended sign, sy mptom, or disease 
temporally  associated with the use of a medicinal product, whether or not considered related to 
the medicinal product. AEs may  also include pre -or post-treatment complications that occur as a 
result of protocol specified procedures, lack of efficacy, overdose, drug abuse/misuse reports, or 
occupational exposure. Preexisting events that increase in severit y or change in nature during or 
as a consequence of participation in the clinical study  will also be considered AEs.
An AE does not include the following:
Medical or surgical procedures such as surgery , endoscopy , tooth extraction, and transfusion. 
The condition that led to the procedure may be an adverse event and must be reported.
Pre-existing diseases, conditions, or laboratory  abnormalities present or detected before the 
screening visit that do not worsen
Situations where an untoward medical occurrence has not occurred (e.g., hospi[INVESTIGATOR_10800] , social and/or convenience admissions)
Overdose without clinical sequelae (see Section 7.6.1)
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol -associated procedure is not an 
AE. It is considered to be pre -existing and should be documented on the medical history  
e
CRF.
7.1.2. Serious Adverse Events
A serious adverse event (SAE) is defined as an event that, at an y dose, results in the following:
Death
Life-threatening (Note: The term “life -threatening” in the definition of “serious” refers to an 
event in w hich the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it were more severe.)
In-patient hospi[INVESTIGATOR_10801]-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page63 21 October 2015Persistent or signific ant disability /incapacit y
A congenital anomal y/birth defect
A medicall y important event or reaction: such events may not be immediately 
life-threatening or result in death or hospi[INVESTIGATOR_110080]. Medical and 
scientific judgment must be exercised to determine whether such an event is reportable under 
expedited reporting rules. Examples of medically  important events include intensive 
treatment in an e mergency  room or at home for allergic bronchospasm; blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059]; and development of drug dependency  or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal 
product will be considered a medicall y important event and subject to expedited reporting 
requirements.
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory  abnormalities (eg, clinical chemistry , hematology , and urinaly sis) that 
require medical or surgical intervention or lead to IMP interruption, modification, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. I n addition, 
laboratory  or other abnormal assessments (eg, electrocardiogram, x- rays, vital signs) that are 
associated with signs and/or symptoms must be recorded as an AE or SAE if they  meet the 
definition of an AE o r SAE as described in Sections 7.1.1and7.1.2. If the laboratory  
abnormality is part of a sy ndrome, record the s yndrome or diagnosis (eg, anemia), not the 
laboratory  result (ie, decreased hemoglobin).
For specific information on handling of clinical labor atory abnormalities in this study , please 
refer to Section 7.5.
7.2. Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified sub
-investigator is responsible for assessing AEs and SAEs for 
causality and severity , and for final review and confirmation of accuracy  of event information 
and assessments.
7.2.1. Assessment of Causality for Study Drugs and Procedures
The investigator or qualified sub
-investigator is responsible for assessing the relationship to IMP 
therapy using clinical judg ment and the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the IMP. For SAEs, an 
alternative causality must be provided (eg, pre -existing condition, underl ying disease, 
intercurrent illness, or concomitant medication).
Yes: There is reasonable possibility  that the event may  have been caused by [CONTACT_10853].
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page64 21 October 2015It should be emphasized that ineffective treatment should not be considered as causall y related in 
the context of adverse event reporting. 
The relationship to study  procedures (eg, invasive procedures such as venipuncture or biops y) 
should be assessed using the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the study  procedure.
Yes:The adverse event occurred as a result of protocol procedures (eg, venipuncture)
7.2.2. Assessment of Severity
AE severit y should be recorded and graded according to the GSI Grading Scale for Severity of 
Adverse Events and Laboratory  Abnormalities ( Appendix 4)For adverse events associated with 
laboratory  abnormalities, the event should be graded on the basis of the clinical severit y in the 
context of the underly ing conditions; this may  or may not be in agreement with the grading of 
the laboratory abnormality .
The distinction between the seriousness and the severity of an adverse event should be noted. 
Severe is a measure of intensity ; thus, a severe reaction is not necessaril y a serious reaction. For 
example, a headache may be severe in intensity , but would not b
e classified as serious unless it 
met one of the criteria for serious events.
For AEs associated with laboratory  abnormalities, the event should be graded on the basis of the 
clinical severit y in the context of the underlying conditions; this may or may no t be in agreement 
with the grading of the laboratory  abnormality .
7.3. Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to [COMPANY_009]
Requirements for collection prior to study  drug initiation:
After informed consen t, but prior to initiation of study  medication, the following t ypes of events 
should be reported on the eCRF:
all SAEs and adverse events related to protocol -mandated procedures.
7.3.1. Adverse Events 
Following initiation of study  medication, collect all AEs, regardless of cause or relationship, 
until 30-days after last administration of study  IMP must be reported to the eCRF database as 
instructed.
All AEs should be followed up until resolution or until the adverse event is stable, if possible. 
[COMPANY_009] Sciences may request that certain AEs be followed bey ond the protocol defined follow up 
period.
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_1011006] consents to 
participate in the stud y (i.e, signing the informed consent) and throughout the duration of the 
study, including the protocol -required post treatment follow -up period, must be reported to the 
eCRF database and [COMPANY_009] Drug Safet y and Public Health (DSPH) as instructed. This also 
includes an y SAEs re sulting from protocol -associated procedures performed after informed 
consent is signed.
Any SAEs and deaths that occur after the post treatment follow -up visit but within 30- days of the 
last dose of study  IMP, regardless of caus ality, should also be report ed.
Investigators are not obligated to activel y seek SAEs after the protocol defined follow up perio d
; 
however, if the investigator learns of an y SAEs that occur after stud y participation has concluded 
and the event is deemed relevant to the use of IMP, he/she should promptly  document and report 
the event to [COMPANY_009] DSPH . 
Electronic Serious Adverse Event (eSAE) Reporting Process
Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
information to [COMPANY_009] DSPH within 24 hours of the investigator’s knowledge of the event. 
Detailed instructions can be found in the eCRF completion guidelines.
If it is not possible to record and submit the SAE information electronicall y, becausethe 
eCRF database cannotbe accessed or is not available (including at study  start),  record the 
SAE on the paper serious adverse event reporting form and submit by [CONTACT_37392] 
24hours of the investigator’s knowledge of the event to:
[COMPANY_009] DSPH contact [CONTACT_3031]: Email:[EMAIL_201]
Fax:+[PHONE_212]
As soon as it is possible to do so, any SAE reported via paper must be transcribed into the 
eCRF Database according to instructions in the eCRF completion guidelines.
If an SAE has been reported via a paper form because the eCRF databas e has been locked, no 
further action is necessary.
All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in the 
eCRF completion guideline.
Additional information may  be requested to ensure the timely  completion of accurate sa fety 
reports.
Any medications necessary  for treatment of the SAE must be recorded onto the concomitant 
medication section of the subject’s CRF/eCRF and the event description section of the SAE 
form.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page66 21 October 2015For fatal or life -threatening events, copi[INVESTIGATOR_3103], autops y reports, and other 
documents are also to be submitted by  e-mail or fax when requested and applicable. 
Transmission of such documents should occur without personal subject identification, 
maintaining the traceability  of a document to t he subject identifiers.
7.4. [COMPANY_009] Reporting Requirements
Depending on relevant local legislation or regulations, including the applicable US FDA Code of 
Federal Regulations, the EU Clinical Trials Directive (2001/20/EC) and relevant updates, and 
other country -specific legislation or regulations, [COMPANY_009] may be required to expedite to 
worldwide regulatory  agencies reports of SAEs, serious adverse drug reactions (SADRs), or 
suspected unexpected serious adverse reactions (S[LOCATION_003]Rs). I n accordance with the EU Clinica l 
Trials Directive (2001/20/EC), [COMPANY_009] or a specified designee will notify worldwide regulatory  
agencies and the relevant I EC in concerned Member States of applicable S[LOCATION_003]Rs as outlined in 
current regulations.
Assessment of expectedness for SAEs will be determined by  [CONTACT_143367]’s brochure or relevant local label as applicable .
All investigators will receive a safet y letter notifying them of relevant S[LOCATION_003]R reports associated 
with any study IMP. The investigator should notify  the IRB or IEC of S[LOCATION_003]R reports as soon as 
is practical, where this is required b y local regulatory agencies, and in accordance with the local 
institutional policy .
7.5. Toxicity Management 
All clinical and clinicall y significant laboratory  toxicities will be managed according to uniform 
guidelines detailed in Appendix 3as outlined below.
Clinical events and clinically significant laboratory  abnormalities will be graded according to 
the GSIGrading Scale for Severit y of Adverse Ev ents and Laborat ory Abnormalities 
(Appendix 4).
Grade [ADDRESS_1011007] discontinuation, u nless such a delay  is not consistent with good medical practice
Any questions regarding toxicity  management should be directed to the [COMPANY_009] Medical 
Monitor.
7.5.1. Grades 1 and 2 Laboratory Abnormality or Clinical Event
Continue study  drug at the discretion of t he Investigator.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page67 21 October [ZIP_CODE].5.2. Grade 3 Laboratory Abnormality or Clinical Event
For Grade [ADDRESS_1011008].
For a Grade [ADDRESS_1011009] should be withheld until the toxicity  returns to Grade2.
When restarting investigational medicinal product following resolution of the adverse event, 
the investigational medicinal product should be restarted at full dose upon discussion with 
the [COMPANY_009] Sciences Medical Monitor.
If a laboratory  abnormality  recurs to Grade [ADDRESS_1011010] may not require permanent discontinuation but 
requires discussion with the [COMPANY_009] Sciences Medical Monitor.
7.5.3. Grade4 Laboratory Abnormality or Clinical Event
For a Grade [ADDRESS_1011011]. A clinic ally significant Grade 4 laboratory abnormalit y that is not confirmed b y 
repeat testing should be managed according to the algorithm for the new toxicity  grade.
Investigational medicinal product may  be continued without dose interruption for a clinically  
non-significant Grade 4 laboratory  abnormality  (eg, Grade 4 CK after strenuous exercise, or 
triglyceride elevation that is nonfasting or that can be medicall y managed) or a clinical event 
considered unrelated to investigational medicinal product requires di scussion with the 
[COMPANY_009]Sciences Medical Monitor.
7.5.4. On-Treatment ALT Flare and Post -Treatment Exacerbation of Hepatitis B 
Management
In On-Treatment ALT Flare is defined as:
Confirmed (within 3 days of receipt of initial laboratory  results) serum ALT > 2 ×Day1 
value and >10 × ULN, with or without associated sy mptoms
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page68 21 October [ZIP_CODE].5.4.1. Management of ALT Flare in Subjects Receiving Study  Medication
If laboratory  results indicate elevation of ALT  2 × Day 1 value and 10 × ULN, the following 
is recommended:
Schedule the subject to return to the clinic as soon as possible (ideall y within 3 days after 
initial laboratory  results were drawn). During the visit, a clinical assessment of the subject 
will be performed. The assessment should include a phy sical examination and eval uation of 
the subject’s mental status.
If the ALT elevation is confirmed, request the central clinical laboratory  to conduct reflex 
testing for plasma HBV DNA, HBV serology  (HBsAg and HBsAb), HDV, HAV IgM, and 
HCV serology
Check the following laboratory  parameters: serum AL T and AST, total bilirubin, I NR, and serum 
albumin. Based on the results of the confirmatory  tests, the following treatment modifications are 
recommended:
Elevated Liver Enzymes, Normal or Stable relative to Day 1 Liver Function Tests
If ALT levels are elevated (i.e., 2 ×Day 1 and 10 ×ULN) with normal or stable total 
bilirubin and I NR relative to Day  1, the subject may  remain on study  medication and should be 
monitored weekl y as long as ALT levels re turn to normal or Day  1 level. During monitoring, if 
the ALT values remain persistently  elevated, the Investigator should discuss with the [COMPANY_009] 
Medical Monitor whether the stud y drug should be discontinued.
Elevated Liver Enzymes, Elevated Liver Function Tests
If ALT values are elevated (i.e.,  2 ×Day 1 and 10 ×ULN), and total bilirubin is confirmed to 
be 2 x Day  1 value, and INR is 0.5 above Day  1, provided both are > ULN,  the investigator 
should consider discontinuing stud y medication (upon discussion with the [COMPANY_009] Medical 
Monitor, unless the safety of the patient is of immediate concern).  The subject should be 
monitored weekl y as long as ALT, total bilirubin, and INR values remain elevated or above 
Day1 values.
During monitoring, if the AL T values and the liver function tests remain persistently  elevated, 
the Investigator should discuss with the [COMPANY_009] Medical Monitor whether the study  drug should 
be discontinued.
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_1011012] Discontinued 
Study Medication
If laboratory  results indicate (1) an ALT elevation 2 ×Day 1 and 10 ×ULN alone OR 
associated with (2) abnormal laboratory parameters suggestive of worsening hepatic function 
(total bilirubin 2 × Day  1, INR 0.5 above Day  1, provided both are > ULN) and the subject is on 
nopost-study therapy for HBV, the following is recommended:
Schedule the subject to return to the clinic as soon as possible (ideall y no later than 3 days 
after the initial laboratory values were drawn). During the visit, perform a clinical assessment 
of the subject.
Check the following laboratory  parameters: serum AL T and AST, bilirubin, INR, and 
albumin.
If the ALT elevation is confirmed, request the clinical laboratory  to conduct reflex testing for 
plasma HBV DNA, HBV serology  (HBsAg and HBsAb), HDV, HAV IgM and HCV. If 
serum HBV DNA is increasing, the investigator should consider immediate initiation of 
approved therap y.
The subject should be followed until laboratory  parameters (ALT, total bilirubin, I NR) return 
to normal or Day  [ADDRESS_1011013] 
(unconjugated) bilirubin related to inhibition of UDP- glucuronyl transferase (UGT). Hepa tic 
transaminase elevations that occur with h yperbilirubinemia should be evaluated for alternative 
etiologies. Dose modification of atazanavir sulfate is not permitted. Subjects who experience 
unacceptable jaundice/scleral icterus can be discontinued from study at the discretion of the 
Investigator.
Subjec
tswithbilirubinlevelsof5-10x UL N,ifisol atedandnotacc ompaniedby 
[CONTACT_739919](scleralicterusorcutaneous jaundice)mayc ontinueon study,
ifagreeduponby[CONTACT_739920].Allsubjectswithserum bilir ubinlevels
5-10x ULN musthavebilirubin,ASTandALT repeatedatleastonce within7daysof the
Investigatorbeingnotifiedoftheeleva tedbilirubinlevel. Thereaf t er,serumbilirubin
levels5-10xULNwit houtclinicallysignific antelevation in AST orALTshouldbe
followedaccor dingtothec linical judgmentof the Investigator .
Subjectswhosehyperbilirubinemia (5-10x ULN)isaccompanied by≥ Grade2 AL T orAST
elevation orwhoexperienceaoneGradeworseninginALTorASTdonot qualifyashaving
isolate
dhyperbilirubinemiaandwillbedis continued.
Confirmedhyp erbilirubinemia>10x ULN willrequirediscontinuation.
Elevationofconjugated (direct)bili rubin>2 mg/dLinassociationwithGrade2 ALTor AST
elevationwillrequirediscontinuation.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page70 21 October [ZIP_CODE].5.6. Management of Possible Abacavir Hypersensitivity Reaction
Abacavir should not be used in patients known to carry the HLA -B*5701 allele due to increased 
risk of hy persensitivity  reaction, unless no other therapeutic option is available based on the 
treatment history  and resistance testing.
In a clinical stud y, 3.4 % of subjects with a negative HLA -B*5701 status receiving abacavir 
developed a h ypersensitivity  reaction. Therefore, even in the absence of HLA- B*5701allele, it is 
important to permanently discontinue abacavir and not rechallenge with abacavir if a 
hypersensitivity  reaction cannot be ruled out on clinical grounds, due to the potential for a severe 
or even fatal reaction.
Hypersensitivity  reactions are characterized b y the appearance of s ymptoms indicating 
multi-organ system involvement. Almost all hy persensitivity  reactions will have fever and/or 
rash as part of the s yndrome. Other signs and s ymptoms may  include respi[INVESTIGATOR_739902], sore throat, cough, and abnormal chest x -ray findings 
(predominantl y infiltrates, which can be localized), gastrointestinal symptoms, such as nausea, 
vomiting, diarrhea, or abdominal pain, and may  lead to misdiagnosis of hypersensitivity  as 
respi[INVESTIGATOR_23715] (pneumonia, bronchitis, pharyngitis), or gastroenteritis. Other frequentl y 
observed signs or s ymptoms of the hy persensitivity  reaction may  include lethargy  or malaise and 
musculoskeletal sy mptoms (my algia, rarely  myolysis, arthralgia). T he symptoms related to this 
hypersensitivity  reaction worsen with continued therapy  and can be life -threatening. 
Thesesymptoms usually  resolve upon discontinuation of abacavir.
Hypersensitivity  reaction sy mptoms usua lly appear within the first six weeks of initiation of 
treatment with abacavir, although these reactions may  occur at any  time during therapy . Patients 
should be monitored closely , especiall y during the first two months of treatment with abacavir.
Regardless of their HLA -B*[ADDRESS_1011014] be permanentl y 
discontinued if hy persensitivity  cannot be ruled out, even when other diagnoses are possible 
(respi[INVESTIGATOR_96613], flu -like illness, gastroenteritis or reactions to other medicinal products) 
{[ZIP_CODE]}.
7.5.7. On-Treatment Hepatitis C Management
If a subject tests positive for HCV RNA at screening or develops signs or sy mptoms of active 
Hepatitis C virus ,[COMPANY_009] recommends that local medical practice is followed at the discretion of 
the Investigator. Investigational medicinal product may  be continued without dose 
interruption. Should the Investigator feel the need to initiate Hepatitis C treatment the 
Investigator must contact [CONTACT_110102] -drug interactions 
are expected. Subjects should return to the clinic for scheduled or unscheduled follow up visit(s) 
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_1011015] labelling (as it applies to the daily  dose of the subject in 
question). In cases of a discrepancy  in drug accountability , overdose will be established only  
when it is cl ear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for the discrepancy  except in cases in which the investigator has 
reason to suspect that the subject has taken the additional dose(s).
Productcomplaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or distribu tion of the medicinal product.
7.6.2. Instructions for Reporting Special Situations
[IP_ADDRESS]. Instructions for Reporting Pregnancies
The investigator should repo rt pregnancies in female study  subjects that are identified after 
initiation of study  medication and throughout the study , including the post study  drug follow -
up 
period, to the [COMPANY_009] DSPH using the pregnancy report form within 24 hours of b ecoming aware 
of the pregnancy .
Refer to the 
belowand theeCRF completion guidelines for full instructions on the mechanism of 
pregnancy  reporting.
The pregnancy  itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy  without medical reasons.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page72 21 October 2015Any premature termination of pregnancy  (eg, a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must be reported with in 24hours as an 
SAE. The underl ying medical reason for this procedure shouldbe recorded as the AE term.
A spontaneous abortion is alway s considered to be an SAE and will be reported as described in 
Sections7.3.2. Furthermore, an y SAE occurring as an adverse pregnancy  outcome post study  
must be reported to [COMPANY_009] DSPH.
The subjec t should receive appropriate monitoring and care until the conclusion of the 
pregnancy . The outcome should be reported to [COMPANY_009] DSPH using the pregnancy  outcome report 
form. If the end of the pregnancy  occurs after the study  has been completed, the outcom e should 
be reported directl y to [COMPANY_009] DSPH. [COMPANY_009] DSPH contact [CONTACT_10856]:
Email: Safety _FC@gilead. com and Fax: +1 (650) [ADDRESS_1011016] should 
continue until the conclusion of the pregnancy . If the end of the pregnancy  occurs after the study 
has been completed, the outcome should be reported directl y to [COMPANY_009] DSPH, fax number 
+[PHONE_2520] or email Safety [EMAIL_202].
Refer to Appendix 6for Pregnancy  Precautions, Definition for Female of Childbearing Potential, 
and Contraceptiv e Requirements.
[IP_ADDRESS]. Reporting Other Special Situations
All other special situation reports must be reported on the special situations report form and 
forwarded to [COMPANY_009] DSPH within [ADDRESS_1011017] of situations that involve study  IMP and/or [COMPANY_009] concomitant 
medications, but do not apply
 to non-[COMPANY_009] concomitant medications.
Special situations involving non -[COMPANY_009] concomitant medications does not need to be reported on 
the special situations report form; however, for special situations that result in AEs due to a 
non-[COMPANY_009] concomitant medication, the AE should be reported on the AE form.
Any inappropriate use of concomitant medications prohibited by  [CONTACT_10857] “misuse,” but may  be more appropriately  documented as a protocol deviation.
Refer to Section 7.6.2.1and the eCRF completion guidelines for full instructions on the 
mechanism of special situations reporting.
All clinical sequelae in rela tion to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE eCRF and/or the SAE report form. Details of the sy mptoms and 
signs, clinical management, and outcome will be reported, when available.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page73 21 October [ZIP_CODE]. STATISTICAL  CONSIDE RATIONS
8.1. Analysis Objectives and Endpoints
8.1.1. Analysis Objectives
The primary  objective of this study  is to evaluate the efficacy of switching to a FDC of 
GS-9883/F/TAF versus continuing on a regimen consisting of boosted ATV or DRV plus either 
FTC/TDF or ABC/ 3TC (i.e., boosted PI  + 2NRTIs) in HIV-1 infected subjects who are 
virologicall y suppressed as determined b y the proportion of subje cts with virologic failure 
(HIV-1 RNA ≥ 50 copi[INVESTIGATOR_014]/mL ) at Week 48 .
The secondary  objective of this study  is toevaluate the safety  and tolerab ility of the 
twotreatment groups through Week 48 .
8.1.2. Primary Endpoint
The primary  endpoint is the proportion of subjects with virologic failure ( HIV-1 RNA 
≥ 50copi[INVESTIGATOR_014]/mL ) at Week 48 as defined 
by [CONTACT_739921] a lgorithm.
8.1.3. Secondary Endpoint
The secondary  endpoints include:
The proportion of subjects with HIV-1 RNA < 50copi[INVESTIGATOR_014]/mL  at Week 48 as defined by  [CONTACT_110098]
The changefrom baseline in CD4+ cell count at Week 48
8.2. Analysis Conventions
8.2.1. Analysis Sets
[IP_ADDRESS]. All randomized
The randomized anal ysis set includes all subjects who are randomized into the study . This is the 
primary analysis setfor by-subject listings.
[IP_ADDRESS]. Efficacy
[IP_ADDRESS].1. Full Anal ysis Set (FAS)
The primary  analysis set for efficacy  analyses is defined as full anal ysis set (FAS), which wi ll 
include all subjects who (1) are randomized into the study and (2)have received at least 1 dose 
of study drug. 
Subjects will be grouped according to the treatment to which they  were 
randomized.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page74 21 October [ZIP_CODE].[IP_ADDRESS]. Per- Protocol ( PP) Analysis Set
The secondary  analysis set for efficacy  analyses is defined as per -protocol (PP) analy sis set, 
which will include all subjects who (1) are randomized into the stud y, (2)have received at least 
1dose of study  drug, and (3) have not committ ed any major protocol violation, including the 
violation of key  entry criteria. Subjects will be grouped according to the treatment they  actually 
received.
Subjects meeting an y of the following criteria will be excluded from the Week 48 PP analy sis 
set:
Subjects who do not have on -treatment HIV -1 RNA in the Week 48 anal ysis window, except 
when missing is due to discontinuation of study  drug for lack of efficacy .
Subjects who do not meet the inclusion criterion for no previous use of an y approved or 
experimental integrase strand transfer inhibitor (INSTI)
Subjects who meet the exclusion criterion for receiving ongoing therap y with any of the 
medications listed in the table in protocol Section 4.3including drugs not to be used with 
FTC, TAF, GS -9883, ATV , RTV,COBI,DRV, FTC/TDF and ABC/3TC
[IP_ADDRESS]. Safety
The primary  analysis set for safety anal yses is defined as safety analysis set, which will include 
all subjects who (1) are randomized into the study  and (2) have received at least 1 dose of stud y 
drug. All the da ta collected up to 30 days after subjects permanently  discontinue their study  drug 
will be included in the safety  summaries, unless specified otherwise. Subjects will be grouped 
according to the treatment they  actually received.
[IP_ADDRESS]. Pharmacokinetics
[IP_ADDRESS].1. Pharmacoki netic (PK) Substudy  Analysis Set
The primary  analysis set for intensive PK anal yses is defined as the PK substudy  analysis set, 
which will include all subjects who (1)arerandomized into the study , (2)enrolled into the PK 
Substudy, (3)have received at l east 1dose of study  drug, and (4) have at least 1 nonmissing 
intensive PK concentration data for the anal yte under evaluation rep orted by [CONTACT_10858].
[IP_ADDRESS].2. Pharmacokinetic (PK) Analy sis Set
The primary  analysis set for general PK analy ses is defined as the pharmacokinetic ( PK)analysis 
set, which will include all subjects who (1)are randomized into the study , (2)have received at 
least 1dose of stud y drug, and (3)have at least 1 nonmissing PK concentration data for the 
analyte under evaluation reported b y thePK lab.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page75 21 October [ZIP_CODE].3. Data Handling Conventions
HIV-1 RNA results of ‘No HIV -1 RNA detected’ and “< 20cp/mL HIV-1 RNA Detected” will 
be imputed as 19 copi[INVESTIGATOR_014]/mL  for analysis purpose.
Natural logarithmic transformation of plasma concentrations and PK parameters will be applied 
for PK anal ysis.
Laboratory  data that are continuous in nature but are less than the lower limit of quantitation or 
above the upper limit of quantitation will be imputed to the value of the lower or upper limit plus 
or minus one significant digit, respectively (e.g., if the result of a continuous laboratory test is 
<20, a value of 19 will be assigned).
Missing data can have an impact upon the interpretation of the trial data. In general, values for 
missing data will not be imputed. However, a missi ng pre-treatment laboratory  result would be 
treated as normal (i.e., no toxicity  grade) for the laboratory  abnormality  summary .
All available data for subjects that do not complete the study will be included in data listings.
8.4. Demographic Data and Baseline Characteristics
Demographic and baseline characteristics will be summarized using standard descriptive 
methods including sample size, mean, SD, median, Q1, Q3, minimum, and maximum for 
continuous variables and frequency  and percentages for categorical vari ables.
Demographic data will include sex, race, ethnicity , and age.
Baseline characteristics will include body  weight, height, body mass index, and eGFR, HIV-1 
infection, and enrollment distribution by
 [CONTACT_10859].
For categorical demographic and baseline characteristics, the Cochran–Mantel–Haenszel (CMH)
test will be used to compare treatment group s. For continuous demographic and baseline 
characteristics, the Wilcoxon rank sum test will be used to compare treatment groups.
8.5. Efficacy Analysis
8.5.1. Primary Analysis
The primary  efficacy endpoint is the proportion of subjects with virologic failure (HIV -1 RNA 
≥ 50copi[INVESTIGATOR_014]/mL ) at Week 48 as defined by  [CONTACT_739922]. The 
primary analysis of the efficacy  will be based on the FAS.
[IP_ADDRESS]. Modified FDA Snapshot Algorithm
The US FDA snapshot algorithm has been modified to classify  subjects who discontinue study  
drug due to a dverse event or death and have the last available on- treatment HIV -1 RNA value 
≥
50copi[INVESTIGATOR_014]/mL  as a Virologic Failure. , In the original US FDA snapshot algorithm, t hese 
subjects would be classified as having No Virologic Data in the Week 48 Analy sis Window.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page76 21 October 2015The modified US FDA sn apshot algorithm appears below.
The analysis window at Week 48 is defined as from Study  Day 294 to Study  Day377, inclusive . 
All HIV-1 RNA data collected on -treatment (ie, including data collected up to [ADDRESS_1011018] 
dose date of study drug) will be used in the snapshot algorithm. Virologic outcome will be 
defined as the following categories:
Virologic Success: this includes subjects who have the last available on -treatment HIV -
1 
RNA < 50 copi[INVESTIGATOR_014]/mL in the Week 48 anal ysis window
Virologic Failure : this include subjects
Who have the last available on- treatment HIV-1 RNA ≥ 50 copi[INVESTIGATOR_014]/mL  in the Week 48 
analysis window , or
Who do not have on- treatment HIV -1 RNA data in the Week 48 anal ysis window and
■Who discontinue study  drug prior to or in the Week 48 anal ysis window due to lack 
of efficacy , or
■Who discontinue study  drug prior to or in the Week [ADDRESS_1011019] available on -treatment HIV -1 
RNA ≥
50copi[INVESTIGATOR_014]/mL
No Virologic Data in the Week 48 Analysis Window : this includes subjects who do not 
have on-treatment HIV -1 RNA data in the Week 48 anal ysis window because of the 
following:
Discontinuation of study  drug prior to or in the Week [ADDRESS_1011020] available on-treatment HI V-1 RNA is 
<50copi[INVESTIGATOR_014]/mL , or
Missing data during the window but on study  drug
[IP_ADDRESS]. Analysis of Primary  Efficacy Endpoint
The null hy pothesis is that the proportion of subje cts with virologic failure (HIV -1 RNA 
≥ 50copi[INVESTIGATOR_014]/mL ) atWeek 48 in the GS -9883/F/TAF group is at least 4% higher than the 
virologic fa ilure rate in the boosted PI + 2NRTIs group; the alternative hypothesis is that the 
virologic failur e rate in the GS -9883/F/TAF group is less than 4% higher than that in the 
boosted-PI + 2NRTIs group.
Non-inferiority will be assessed using the confidence interval (CI) approach. The point estimate 
of treatment difference ( GS-9883/F/TAF –
boosted PI + 2NRTIs ) and the associated 2-sided 
95% CIs will be constructed based on the 
exact method . It will be concluded that 
GS-9883/F/TAF is non- inferior to boosted PI + 2NRTIsif the upper bound of the 2- sided 95% 
CI of the difference between treatment groups (GS -9883/F/TAF –boosted PI +2NRTIs) in the 
virologic failure rate is less than 4% (ie, a margin of 4% is applied to non
-inferiority assessment).
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page77 21 October 2015If non-inferiority  of GS-9883/F/TAF to boosted PI + 2NRTIs is established, the upper bound of 
the 95% CI will be compared to 0; if the upper bound of the 95% CI is less than 0, superiority  of 
GS-9883/F/TAF over boosted PI + 2NRTIs will be established.
8.5.2. Secondary Analyses
The proportion of subjects with HI V-1 RNA 
< 50 copi[INVESTIGATOR_014]/mL  at Week 48 as defined by [CONTACT_739923]. The 95% CIs will be constructed in the same 
manner as for the primary  efficacy endpoint. However, non- inferiority will be assessed using a 
margin of 10%. It will be concluded that GS -9883/F/TAF is noninferior to boosted PI  +2NRTIs
if the lower bound of th e 2-sided 95% CI of the difference between treatment groups 
(GS-9883/F/TAF –boosted PI  + 2NRTIs ) in the respo nse rate is greater than -10%.
The change from baseline in CD4 +cell count at Week 48 will be summarized by  [CONTACT_113998] . The differences in changes from baseline in CD4 +cell count between
treatment groups and the associated 95% CIs will be constructed using ANOVA models, 
including treatment (GS -9883/F/TAF vs. b oosted PI + 2NRTIs )as a fixed effect in the model.
In additio n, missing CD4+ cell count will be imputed using Last Observation Carried Forward 
(LOCF) method and analyzed similarly .
8.6. Safety Analysis
All safety analyses will be performed using the safety  analysis set.
All safety data collected on or after the date that the study drug was first administered up to the 
date of the last dose of study  drug plus [ADDRESS_1011021]’s extent of exposure to study  drug will be generated from the study  drug 
administration page in CRF. Exposure data will be summarized by  [CONTACT_3148].
Duration of exposure to study  drug will be expressed as the number of weeks between the first 
and last dose of the stud y drug, inclusive, regardless of temporary interruptions in study  drug 
administration and summarized by  [CONTACT_3148].
Dosing information for individual subjects will be listed.
8.6.2. Adverse Events
Clinical and laboratory  adverse events will be coded using the Medical Dictionary  for 
Regulatory  Activities (MedDRA). Sy stem Organ Class (SOC), High -Level Group Term 
(HLGT), High -Level Term (HL T), Preferred Term (PT), and Lower -Level Term (LLT) will be 
attached to the clinical database.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page78 21 October 2015Events will be summarized on the basis of the date of onset for the event. A treatment -emergent 
adverse event will be de fined as an y adverse event with onset date on or after the stud y drug start 
date and no later than 30 day s after the study  drug stop date; or any  adverse event leading to 
study drug discontinuation.
Summaries (number and percentage of subjects) of treatmen t-emergent adverse events (b y SOC, 
HLT [if applicable], and PT) will be provided by  [CONTACT_3148]. Additional summaries will include 
summaries for adverse events by  [CONTACT_479], Investigator’s assessment of relationship to study  drug, 
and effect on stud y drug dosing .
On an ongoing basis adverse events will be reviewed for events that might meet the definition of 
Stage 3 Opportunistic I llnesses in HIV are indicative of an AIDS -Defining Diagnoses. The 
[COMPANY_009] medical personnel will review the possible Stage 3 events and approve the events t hat 
meet the definition. Those events that do meet the Stage 3 Opportunistic I llness definition of an 
AIDS-Defining Diagnosis will be listed.
A listing of Stage 3 Opportunistic I llnesses in HIV can be found in Appendix 5.
8.6.3. Laboratory Evaluations
Selected laboratory  data (using conventional units) will be summarized using onl y observed data. 
Absolute values and changes from baseline at all scheduled visits will be summarized.
Graded laboratory  abnormalities will be defined using the grading scheme defined in Grading of 
laboratory  abnormalities attached in Appendix 4.
Incidence of treatment -emergent laboratory  abnormalities, defined as values that increase at least 
[ADDRESS_1011022] dose 
of study drug plus 30 days, will be summarized by [CONTACT_3148]. If baseline data are missing, then 
any graded abnormalit y (i.e., at least a Grade 1) will be consid ered treatment emergent. The 
maximum postbaseline toxicity  grade will be summarized by  [CONTACT_10862].
Laboratory  abnormalities that occur before the first dose of study  drug or after the last dose of 
study drug plus 30 day s will be included in a dat a listing.
8.6.4.
Other Safety Evaluations
Vital signs and safety ECG data will be summarized as appropriate.
8.7. Pharmacokinetic Analysis
For the intensive PK substudy , plasma concentrations of GS-9883 maybe summarized by  
[CONTACT_10863]. Pharmacokinetic parameters (C max, Tmax, Ctau, 
AUCtau,and T½, as appropriate) may be listed and summarized using descriptive statistics (eg, 
sample size, arithmetic mean, geometric mean, coefficient of variation %, SD, median, Q1, Q3, 
minimum, and maximum). Plasma concentrations over time will be plotted in semi -logarithmic 
and linear formats as mean ± standard deviation, and median (Q1, Q3).
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page79 21 October 2015For the general PK anal yses, the pharmacokinet ics of GS-9883 may  be evaluated using 
descriptive statistics or population approaches.
TAF and FTC concentrations may  be analyzed and PK parameters summarized as applicable.
8.8. Patient Reported Outcomes (PRO)
The PRO measures based on questionnaires (eg, SF- 36 and HIV Sy mptoms Distress Module ) 
will be summarized by [CONTACT_388156].
8.9. Sample Size
A total of approximately  520 HIV -1 infected subjects, randomized in a 1:1 ratio to 2 treatment 
groups (260 subjects per treatment group), achieves at least 90% power to detect a 
non-inferiority margin of 4% in Week 48 virolog ic failure rate (HIV -1 RNA ≥ 50copi[INVESTIGATOR_014]/mL  as 
defined by  [CONTACT_739924]) differen ce between the two treatment 
groups. For sample size and power computation, it is assumed that both treatment group s have a 
virologic failure rate of 2% (based on the historical [COMPANY_009] E/C/F/TAF and STB studies ), that a 
non-inferiority margin is 4%, and that the signif icance level of the test is at a one -sided 
0.025level.
8.10. Independent Data Monitoring Committee
An external Independent Data Monitoring Committee (IDMC) will review the progress, efficacy , 
and safety data of this study while the stud y is ongoing. The committ
ee will convene after all 
subjects enrolled complete Week [ADDRESS_1011023] subjects enrolled 
completes Week 24 of the study .  ForeachIDMC anal ysis performed prior to analy sis for the 
primary efficacy endpoint, an alpha penalty  of0.[ZIP_CODE] will be applied for the primary  analysis 
of the primary  efficacyendpoint.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page80 21 October [ZIP_CODE]. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The investigator will ensure that this study  is conducted in accordance with the principles of the 
Declaration of Helsinki (as amended in Edinburgh, Toky o, Venice, Hong Kong, and 
SouthAfrica), International Conference on Harmonisation (I CH) guidelines, or with the laws and 
regulations of the country in which the research is conducted, whichever affords the greater 
protection to the study  subject:These standards are consistent with the European Union Clinical 
Trials Directive 2001/20/EC and Good Clinical Practice Directive 2005/28/EC.
The investigator will ensure adherence to the basic principles of Good Clinical Practice, as 
outlined in 21 CFR312, subpart D, “Responsibilities of Sponsors and Investigators,” [ADDRESS_1011024] be provided prior to 
the investigator’s (and any  subinvestigator’s) participation in the study . The investigator and 
subinvestigator agree to notify  [COMPANY_009] of an y change in reportable interests during the study  and 
for [ADDRESS_1011025] (IRB)/Independent Ethics Com
mittee (IEC) 
Review and Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this 
protocol, informed consent form, and an y accompanying material to be provided to the subject 
(such as advertisements, subject info rmation sheets, or descriptions of the study  used to obtain 
informed consent) to an IRB/IEC. The investigator will not begin an y study subject activities 
until approval from the IRB/IEC has been documented and provided as a letter to the 
investigator.
Before implementation, the investigator will submit to and receive documented approval from 
the IRB/IECany modifications made to the protocol or any accompan ying material to be 
provided to the subject after initial IRB/IECapproval, with the exception of those necessary  to 
reduce immediate risk to study  subjects.
9.1.3. Informed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives , and 
potential hazards of the study  and before undertaking an y study
-related procedures. The 
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_1011026] current IRB-or IEC-approved consent form for documenting 
written informed consent. Each informed consent (or assent as applicable) will be appropriatel y 
signed and dated b y the subject or the subject’s legally authorized representative and the person 
conducting the consent discussion, and also by  [CONTACT_10865]. The consent form w ill inform subjects about pharmacogenomic testing and 
sample retention, and their right to receive clinically relevant pharmacogenomic anal ysis results.
9.1.4. Confidentiality
The investigator must assure that subjects’ anon ymity will be strictly  maintained and that their 
identities are protected from unauthorized parties. Only  subject initials, date of birth, another 
unique identifier (as allowed b y local law) and an identifica tion code will be recorded on an y 
form or biological sample submitted to the Sponsor ,or laboratory . Laboratory  specimens must 
be labeled in such a way as to protect subject identity  while allowing the results to be recorded to 
the proper subject. Refer to specific laboratory  instructions . NOTE:The investigator must keep a 
screening log showing codes, names, and addresses for all subjects screened and for all subjects 
enrolled in the trial. Subject data will be processed in accordance w ith all applicable r egulations.
The investigator agrees that all information received from [COMPANY_009], including but not limited to the 
investigator brochure, this protocol, 
eCRF, the IMP, and any other study  information, remain the 
sole and exclusive property  of [COMPANY_009] during the conduct of the study  and thereafter. This 
information is not to be disclosed to any  third party  (except employ ees or agents directl y 
involved in the conduct of the study  or as required by  [CONTACT_2371]) without prior written consent from 
[COMPANY_009]. The investigator f urther agrees to take all reasonable precautions to prevent the 
disclosure b y any employee or agent of the stud y site to any  third party  or otherwise into the 
public domain.
9.1.5. Study Files and Retention of Records
The investigator must maintain adequate and a ccurate records to enable the conduct of the study  
to be fully  documented and the study data to be subsequently  verified. These documents should 
be classified into at least the following two categories: (1) investigator’s study  file, and 
(2)subject clinic al source documents.
The investigator’s stud y file will contain the protocol/amendments, eCRF and query  forms, IRB 
or IEC and governmental approval with correspondence, informed consent, drug records, staff 
curriculum vitae and authorization forms, and oth er appropriate documents and correspondence.
The required source data should include sequential notes containing at least the following 
information for each subject:
Subject identification (name, date of birth, gender);
Documentation that subject meets eli gibility criteria, ie, history , physical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria);
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page82 21 October 2015Documentation of the reason(s) a consented subject is not enrolled
Participation in study (including study number);
Study discussed and date of informed consent;
Dates of all visits;
Documentation that protocol specific procedures were performed;
Results of efficacy  parameters, as required b y the protocol;
Start and end date (including dose regimen) of IMP, including dates of dispensing and return;
Record of all adverse events and other safety  parameters (start and end date, and including 
causality and severity);
Concomitant medication (including start and end date, dose if relevant; dose changes);
Date of study completion and re ason for earl y discontinuation, if it occurs.
All clinical study  documents must be retained b y the investigator until at least [ADDRESS_1011027] approval of a marketing application in 
an ICH region (ie, [LOCATION_002], Europe, or Japan) and until there are no pending or planned 
marketing applications in an I CH region; or, if no application is filed or if the application is not 
approved for such indication, until [ADDRESS_1011028] consented, an eCRF casebook will be completed b y an authorized study staff 
member whose training for this function is completed in EDC. The eCRF casebook will only  
capture the data required per the protocol schedule of events and procedur es.The 
Inclusion/Exclusion Criteria and Enrollment eCRFs should be completed only  after all data 
related to eligibility  have been received. Subsequent to data entry , a study monitor will perform 
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_1011029] or updating the original entry , and providing the 
reason for the update (e.g. data entry  error). Original entries as well as any  changesto data fields 
will be stored in the audit trail of the sy stem.Prior to any  interim time points or database lock 
(as instructed b y [COMPANY_009]), the investigator will use his/her log in credentials to confirm that the 
forms have been reviewed, and that the e ntries accuratel y reflect the information in the source 
documents. At the conclusion of the trial, [COMPANY_009] will provide the site with a read -only archive 
copy of the data entered by  [CONTACT_10867]. This archive must be stored in accordance with the records 
retention requirements outlined in Section 9.1.5.
9.1.7. Investigational Medicinal Product Accountability and Return
[COMPANY_009] recommends that used and unused IMP supplies be returned to the shippi[INVESTIGATOR_10803]. The stud y monitor will provide instructions for return. If 
return is not possible, the study  monitor will evaluate each study  center’s IMP disposal 
procedures and provide appropriate instruction for destruction of unused IMP supplies. I f the site 
has an appropriate stand ard operating procedure (SOP) for drug destruction as determined b y 
[COMPANY_009] QA, the site may  destroy used (empt y or partially empty) and unused I MP supplies in 
accordance with that site’s approved SOP. A cop y of the site’s approved SOP will be obtained 
for central files.
If IMP is destro yed on site, the investigator must maintain accurate records for all IMP
destroyed. Records must show the identification and quantity  of each unit destroy ed, the method 
of destruction, and the person who disposed of the I MP. Upon study  completion, copi[INVESTIGATOR_143346]. Another copy  will be returned to [COMPANY_009].
The study  monitor will review IMP supplies and associated records at periodic intervals.
9.1.8. Inspections
The investigator will make available all source documents and other records for this trial to 
[COMPANY_009]
’s appointed stud y monitors , to IRBs or IECs, or to regulatory  authority  or health authorit y 
inspectors.
9.1.9. Protocol Compliance
The investigator is responsible for ensuring the study is conducted in accordance with the 
procedures and evaluations described in this protocol.
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_1011030] submit a ll protocol modifications to the IRB or IEC 
in accordance with local requirements and receive documented IRB or IEC approval before 
modifications can be implemented.
9.2.2. Study Report and Publications
A clinical study  report (CSR) will be prepared and provided to the regulatory agency (ies). [COMPANY_009] 
will ensure that the report meets the standards set out in the I CH Guideline for Structure and 
Content of Clinical Study Reports (I CHE3). Note that an abbreviated report may  be prepared in 
certain cases.
Investigators in this study  may communicate, orally  present, or publish in scientific journals or 
other scholarl y media only after the following conditions have been met:
the results of the study
 in their entiret y have been publicly disclosed b y or with the consent of 
[COMPANY_009] in an abstract, manuscript, or presentation form or the stud y has been completed at all 
study sites for at least [ADDRESS_1011031] 30 day s before submission of t he 
publication or presentation.
No such communication, presentation, or publication will include [COMPANY_009]’s confidential 
information (see Section 9.1.4).
The invest igator will comply  with [COMPANY_009]’s request to delete references to its confidential 
information (other than the study  results) in any  paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obtain patent protection if 
deemed necessary .
9.3. Joint Investigator/Sponsor Responsibilities
9.3.1. Payment Reporting
Investigators and their study  staff may  be asked to provide services performed under this 
protocol, e.g. attendance at I
nvestigator's Meetings.  If required unde r the applicable statutory  
and regulatory  requirements, [COMPANY_009] will capture and disclose to Federal and State agencies any  
expenses paid or reimbursed for such services, including an y clinical trial payments, meal, travel 
expenses or reimbursements, consul ting fees, and any  other transfer of value.
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_1011032] access to the 
investigator’s source documentation in order to verify  the accuracy of the data recorded in the 
eCRF.
The monitor is responsib le for routine review of the eCRFat regular intervals throughout the 
study to verify adherence to the protocol and the completeness, consistency, and accuracy  of the 
data being entered on them. The monitor sh ould have access to any subject records needed to 
verify the entries on the eCRF . The investigator agrees to cooperate with the monitor to ensure 
that any problems detected through an y type of monitoring (central, on site) are resolved.
9.3.3. Access to Information for Auditing or Inspections
Representatives of regulatory  authorities or of [COMPANY_009] may  conduct inspections or audits of the 
clinical study . If the investigator is notified of an inspection by  a regulatory authority  the 
investigator agrees to no tify the [COMPANY_009] medical monitor immediately . The investigator agrees to 
provide to representatives of a regulatory  agency or [COMPANY_009] access to records, facilities, and 
personnel for the effective conduct of an y inspection or audit.
9.3.4. Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the stud y at any time. Should 
this be necessary , both parties will arrange discontinuation procedures and notify  the appropriate 
regulatory  authority(ies), IRBs, and IECs. In terminating the study, [COMPANY_009] and the investigator 
will assure that adequate consideration is given to the protection of the subjects’ interests.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page86 21 October 201510. REFERENCES
2202 Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum 
creatinine. Nephron 1976;16:31 -41.
5125 Mocroft A, Vella S, Benfield TL , Chiesi A, Miller V, Gargalianos P, et al. 
Changing patterns of mortality  across Europe in patients infected with HIV -1. 
Lancet 1998;352 (9142):1725-30.
8284 Sterne J, Hernán M, Ledergerber B, Tilling K, Weber R, Sendi P, et al. Long -term 
effectiveness of potent antiretroviral therapy  in preventing AIDS and death: a 
prospective cohort study . Lancet 2005;366 (9483):378-84.
[ADDRESS_1011033] DJ, Flahert y JF, et al. . 
Simplification of Antiretroviral Therap y to a Single -Tablet Regimen Consisting 
of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate Versus 
Unmodified Antiretroviral Therap y in Virologically  Suppressed HIV-1- Infected 
Patients. Acquir I mmune Defic S yndr2009;51 (2):163 -74.
[ZIP_CODE] Hodder SL, Mounzer K, Dejesus E, Ebrahimi R, Grimm K, Esker S, et al. Patient -
Reported Outcomes in Virologicall y Suppressed, HIV -1-Infected Subjects After 
Switching to a Simplified, Single- Tablet Regimen of Efavirenz, Emtricitabi ne, 
and Tenofovir DF. AIDS Patient Care STDS 2010;24 (2):[ADDRESS_1011034], Ragland K, Monk A, Deeks SG. A one
-pi[INVESTIGATOR_4382], once-daily, fixed-
dose combination (FDC) of efavirenz, emtricitabine, and tenofovir disoproxil 
fumarate (EFV/FTC/TDF) regimen is as sociated with higher unannounced pi[INVESTIGATOR_739903] -one pi[INVESTIGATOR_4382], once -daily [Poster]. 17th Conference on 
Retroviruses and Opportunistic I nfections (CROI); 2010 February  16-19; San 
Francisco, CA. 
[ZIP_CODE] Airoldi M, Zaccarelli M, Bisi L , Bini T, Antin ori A, Mussini C, et al. One -pi[INVESTIGATOR_739904]-a-day HAART: a simplification strategy  that improves adherence and 
quality of life of HIV -
infected subjects. Patient preference and adherence 
2010;4:115-25.
[ZIP_CODE] Sax PE, Mey ers J, Mugavero M, Davis KL. Adherence to A ntiretroviral 
Treatment Regimens and Correlation with Risk of Hospi[INVESTIGATOR_739905] [Poster O113]. 10th 
International Congress on Drug Therap y in HIV Infection; 2010 November 7 -11; 
Glasgow, [LOCATION_006]. 
[ZIP_CODE] Sterrantino G, Santoro L, Bartolozzi D, Trotta M, Zaccarelli M. Self -reported 
adherence supports patient preference for the single tablet regimen (STR) in the 
current cART era. Patient preference and adherence 2012;6:427 -33.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page87 21 October 201525149 Ezzati M, L opez AD. Estim ates of global mortality attributable to smoking in 
2000. Lancet 2003;362 (9387):847-52.
[ZIP_CODE] Palella FJ, Delaney  KM, Moorman AC, L oveless MO, Fuhrer J, Satten GA, et al. 
Declining Morbidity  and Mortality  Among Patients With Advanced Human 
Immunodeficienc y Virus Infection. N Eng J Med 1998;338 (13):853-60.
[ZIP_CODE] Aldir I, Horta A, Serrado M. Single -tablet regimens in HI V: does it reall y make a 
difference? Curr Med Res Opin 2013;30 (1):89 -97.
[ZIP_CODE] Costagliola D. Demographics of HIV and aging. Curr Opin HIV AIDS 2014;9 
(4):294-301.
[ZIP_CODE] Department for Health and Human Services (DHHS). Guidelines for the Use of 
Antiretroviral Agents in HIV -1-Infected Adults and Adolescents. Developed by  
[CONTACT_10868] –A 
Working Group of the Office of AIDS Research Advisory  Council (OARAC). 
Downloaded from http://aidsinfo.nih.gov/guidelines on 5/11/2015. L ast Updated 
08 April, 2015.
[ZIP_CODE] Selik RM, Mokotoff ED, Branson B, Owen SM, Whitmore S, Hall HI . Morbidity  
and Morta lity Weekly Report (MMWR). Revised Surveillance Case Definition 
for HIV Infection -[LOCATION_002] 2014. Centers for Disease Control and 
Prevention,  2014.
[ADDRESS_1011035] Sheet: 2014 Global Statistics. 
Available at: 
http://www.unaids.org/sites/default/files/media_asset/20150714_FS_MDG6_Rep
ort_en.pdf . 2014.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page88 21 October 201511. APPENDICES
Appendix 1.Investigator Signature [CONTACT_10882] 2.Study Procedures Table
Appendix 3.Management of Clinical and Laboratory Adverse Events
Appendix 4.GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Appendix 5.Definitions of Stage 3 Opportunistic Illnesses in HIV (CDC Guidelines)
Appendix 6.Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Require ments
GS-9883/Frf AF 
Protocol GS-US-380-[ADDRESS_1011036] 
FOSTER CITY, CA [ZIP_CODE] 
STUDY ACKNOWLEDGEMENT 
A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of 
Switching from Regimens Consisting of Boosted Atazanavir or Darunavir plus either 
Emtricitabineffenofovir or Abacavir!Lamivudine to GS-9883/Emtricitabineffeoofovir 
Alafenamide in Virologically Suppressed HIV-1 Infected Adults 
GS-US-380-1878 Original, 21 October 2015 
This protocol has been approved by [CONTACT_10869], Inc. The following signature [CONTACT_10883]. 
1:1_ o L h orL~ £;., b. ors~ .I( Fbal7 tc_ P P D 
Marshall For dyce, MD (Printed) ........,,..--------------' 
Author 
Date 
INVESTIGATOR STATEMENT 
I have read the protocol, including all appendices, and I agree that it contains all necessary 
details for me and my staff to conduct this study as described. [ADDRESS_1011037] this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated. 
I will provide all study personnel under my supervision copi[INVESTIGATOR_739906], Inc. I will discuss this material with them to ensure 
that they are fully informed about the drugs and the study. 
Principallnvestigator Name (Printed) Signature 
[CONTACT_279395] 89 21 October 2015 
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_1011038]-Week 48e, w
30-Day Follow-upuEarly Study 
Drugs DCc4 8 12 24 36 48 Every 12 Weeksx
Informed Consent X
Medical History X
Concomitant Medications X X X X X X X X X X X
Adverse Events X X X X X X X X X XfXf
Complete /Symptom -Directed 
Physical Exam X X XdXdXdXXdX XdXd,fXf
12-Lead ECG (performed 
supi[INVESTIGATOR_050])X X X X X
SF-36, HIV Symptoms Distress 
Module, WPAI, and UCLA 
SCTC GIT 2.0 QuestionnairesX X X X
VAS Adherence Questionnaire X X X X X X X X
Height X
Vital signs (blood pressure, 
pulse, respi[INVESTIGATOR_1487], and 
temperature), including Weight X X X X X X X X X X X
Urinalysis X X X X X X X X X XfXf
Urine Pregnancy TestgX X X X X X X X X X
Serum Pregnancy Test X
Chemistry ProfilehX X X X X X X X X XfXf
Metabolic AssessmentsiX X X X Xj
GS-9883/F/T AF 
Protocol GS-US-380-1878 
[COMPANY_009] Sciences, Inc. 
Study Procedures 
Estimated Glomemlar Filtration 
Rate (eGFR) 
Hematology Profilek 
Plasma HIV -1 RNA 
CD4+ Cell Connt 
Evaluation of renal tubular 
fimction1 
Plasma and Urine Storage 
Sample 
Whole Blood sample for 
potential HIV DNA genotypi[INVESTIGATOR_739907] -1 Genotype/Phenotype e 
Single PK Samplen 
Trough and post dose PK 
Sample0 
Optionali[COMPANY_003] I 
r 
Randomiza tionY 
Provide subject dosing diary to 
Treatment Group I subjects 
Optional PK Substudy" 
CONFIDENTIAL Screening • Day 1b 4 
X X X 
X X X 
X X X 
X X X 
X 
X X 
X 
X 
X 
X 
X 
X X 
X End ofWeek•,v 
[ADDRESS_1011039]-Week 48e,w 
Every 12 Weeks" 30-Day Follow-up0 
X X 
X xr 
X X 
X X 
xm 
X Final 
Original 
Early Study 
Drugs DC< 
X 
xr 
X 
X 
X 
x< 
21 October 2015 
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_1011040] discontinues study drug.
d.Symptom-directed phy sical examination as needed.
e.HIV-1 genotype and phenotype testing for subjects with virologic failure. Following virologic rebound, subjects will be a sked to return to the clinic (2-3 weeks later) prior to 
the next scheduled visit or at the next scheduled study visit, for a HIV -1 RNAandHIV-1 genotype and phenotype (reverse transcriptase ,protease and integrase genotype and 
phenotype ) blood draw. Based on the results of this testing, subjects should be managed according to the Virologic Rebound Schema (Sections6.13)
f.Any adverse event or test showing abnormal results that is believed to have a possible or probable causal relationship with t he study drug will be repeated weekly (or as often 
as deemed prudent by [CONTACT_737]) until the abnormality is re solved, returns to baseline, or is otherwise explained.
g.Females of childbearing potential only. Positive urine pregnancy tests will be confirmed with a serum test.
h.Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid and amylase (reflex lipase testing is performed in subjects with total amylase 
1.5ULN)At Day1, Weeks 12, 24, [ADDRESS_1011041] Week 48, and Early Study Drugs 
Discontinuation visit.
i.Fasting (no food or drinks, except water, at least 8 hours prior to blood collection) glucose and lipid panel (total choleste rol, HDL, direct LDL, triglycerides).  If the subject 
has not fasted prior to the visit, the visit may proceed, but the subject must return within [ADDRESS_1011042] dose.
p.A PK substudy will be performed in a subset of Treatment Group 1 subjects (n= 24) at selected study sites.  The pharmacokinetic substudy visit must occur at the Week4 or
Week 8visits. The substudy will include intensive PK profiling in plasma .
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page93 21 October 2015q.HBV blood pa nel will be performed at Screening (Hepatitis B virus surface antigen (HBsAg), Hepatitis B virus surface antibody (HBsAb) and Hepatitis B virus core antibody 
(HBcAb)). 
r. To be performed for subjects who meet the definition of HBV infection
s.At Weeks 12, 24 a nd 48 the following will be performed by [CONTACT_2237]: HBsAb, HBsAg (qualitative and quantitative) and HBeAg ( if negative reflex, HBeAb)
t.Study drug GS -9883/F/TAF to be dispensed to Treatment Group [ADDRESS_1011043] one subsequent visit after 
the Early Study Drugs Discontinuation Visit. For the purpose of scheduling a 30 -Day Follow -Up Visit, a 6days window m ay be used.
v.Study visits are to be completed within ± 2 days of the protocol -specified visit date based on the Day 1 visit through Week 12 a nd completed within ± 6 days through to
Week36,unless otherwise specified. The visit window at Weeks 48 will be ± 6 weeks of the protocol -specified visit date. After Week 48 Visit, subjects in the United 
Kingdom ([LOCATION_006]) will stop taking study drug and complete a 30 day follow up visit
w.Visit window of 6days for study visits post Week 48.
x.GS-9883/F/TAF FDC will be dispensed to subjects participating in the study post Week [ADDRESS_1011044] eligib ility has been 
confirmed.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page94 21 October 2015Appendix 3. Management of Clinical and Laboratory Adverse Events
Grade 1 
~------G-r-ad- e-2------~~ ~~------G-r-ad-e-3------~~~ ~ ___________ G_r_a_d_e-4----------~ 
~ ~ 
May continue dosing Repeat lab to 
at the discretion of confirm toxicity 
the investigator grade 
If confirmed and possibly and/or probably related to investigational 
medicinal products: 
1. Withhold investigational medicinal products until :s; Grade 2 
2. Restart all investigational medicina l products at full dose 
l 
If Grade 3 or 4 recurrence that is confirmed and possibly or probably 
related to investigational medicinal products, discontinue all 
investigational medicinal products dosing permanently l 
Ifc Repeat lab to 
confirm toxicity 
grade 
l 
mve onfirmed and unrelated to 
stigational medicinal products, 
mg may continue at the discretion 
he investigator dos 
oft If confirmed and 
possibly or probably 
----+ related to 
investigational 
medicinal products, 
discontinue 
investigational 
medicinal products 
dosing permanently and 
follow at periodic 
intervals at least weekly 
until a return to 
baseline or is otherwise 
explained 
If Grade 3 or 4 recurrence that is considered unrelated to 
investigational medicinal products, continue all investigational 
medicina l products at the same dose at the discretion of the 
investigator 
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page95 21 October 2015Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalit ies
Antiviral Toxicity Grading Scale Version: 01 April 2015
HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Hemoglobin
HIV POSITIVE
Adult and Pediatric 57 Days8.5to10.0g/dL 
85 to 100 g/L7.5to 8.5g/dL 
75to85g/L6.5 to 7.5g/dL 
65 to 75g/L6.5g/dL
65g/L
HIV NEGATIVE
Adult and Pediatric 57 Days 10.0to10.9g/dL
100to109g/L
OR
Any decrease from Baseline
2.5 to 3.5g/dL
25 to 35g/L9.0 to 10.0g/dL
90 to 100g/L
OR
Any decrease from Baseline
3.5 to 4.5g/dL
35 to 45g/L7.0 to 9.0g/dL
70 to 90g/L
OR
Any decrease from Baseline
4.5g/dL
45g/L7.0g/dL
70g/L
Infant, 36 –56 Days
(HIV POSITIVE OR
NEGATIVE )8.5 to 9.4 g/dL
85 to 94g/L7.0 to 8.5g/dL
70 to 85g/L6.0 to 7.0 g/dL
60 to < 70 g/L6.0 g/dL
< 60 g/L
Infant, 22 –35 Days
(HIV POSITIVE OR
NEGATIVE )9.5 to 10.5 g/dL
95 to 105 g/L8.0 to 9.5g/dL
80 to 95g/L7.0 to 8.0g/dL
70 to 80g/L7.0g/dL
70g/L
Infant, 1–21 Days
(HIV POSITIVE OR
NEGATIVE )12.0 to 13.0 g/dL
120 to 130g/L10.0 to 12.0g/dL
100 to 120g/L9.0 to 10.0g/dL
90 to 100g/L9.0g/dL
90g/L
Absolute Neutrophil Count  
(ANC)
Adult and Pediatric, 
≥ 7 Months# 1000to1300/mm3750to1000/mm3500to750/mm3500/mm3
1.00to 1.30GI/L 0.75to 1.00 GI/L 0.50to0.75 GI/L 0.50 GI/L
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page96 21 October 2015HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Absolute CD4+ Count
HIV NEGATIVE ONLY
Adult and Pediatric 
>13Years300to400/mm3
300to400/μL200to300/mm3
200to 300/μL100to200/mm3
100to200/μL100/mm3
100/μL
Absolute Lymphocyte Count
HIV NEGATIVE ONLY
Adult and Pediatric 
13Years600 to 650/mm3
0.60 to 0.65 GI/L500 to 600/mm3
0.50 to 0.60 GI/L350 to 500/mm3
0.35 to 0.50 GI/L350/mm3
0.35 GI/L
Platelets 100,000 to < 125,000/mm3
100to125 GI/L50,000 to 100,000/mm3
50to 100 GI/L25,000 to 50,000/mm3
25 to 50 GI/L25,000/mm3
25GI/L
WBCs 2000/mm3to 2500/mm31,500 to  2,000/mm31000 to 1,500/mm31000/mm3
2.00GI/Lto 2.50GI/L 1.50to 2.00GI/L 1.00 to 1.50GI/L 1.00 GI/L
Hypofibrinogenemia 100to200mg/dL 75 to 100mg/dL 50to 75mg/dL 50mg/dL
1.00to2.00g/L 0.75to 1.00g/L 0.50 to 0.75g/L 0.50g/L
Hyperfibrinogenemia ULN to 600 mg/dL 600mg/dL — —
ULN  to 6.0 g/L 6.0g/L — —
Fibrin Split Product 20 to 40μg/mL 40to 50μg/mL 50to 60μg/mL 60μg/mL
20 to 40mg/L 40 to 50mg/L 50 to 60mg/L 60mg/L
Prothrombin Time (PT) 1.00 to 1.25 ULN 1.25 to 1.50 ULN 1.50 to 3.00 ULN 3.00 ULN 
International Normalized Ratio 
of prothrombin time (INR)1.[ADDRESS_1011045] >1.[ADDRESS_1011046] >2.[ADDRESS_1011047] >3.[ADDRESS_1011048]
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page97 21 October 2015HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Activated Partial
Thromboplastin Time (APTT) 1.00to 1.66ULN 1.66to 2.33ULN 2.33to 3.00ULN 3.00 ULN
Methemoglobin 5.0to10.0% 10.0to15.0% 15.0to20.0% 20.0% 
#An overlap between the Grade 1 scale and the Lab’s normal range for absolute neutrophils may result for pediatric subjects.  Please follow the [COMPANY_009] convention of grading 
any result within the LLN and ULN a 0.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page98 21 October 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hyponatremia 130 to <LLN mEq/L 125 to130mEq/L 121 to125mEq/L 121 mEq/L
130 to<LLN mmol/L 125 to130mmol/L 121 to125mmol/L 121 mmol/L
Hypernatremia >ULN  to 150 mEq/L 150 to 154 mEq/L 154 to 159 mEq/L 159 mEq/L
>ULN  to 150 mmol/L 150 to 154 mmol/L 154 to 159 mmol/L 159 mmol/L
Hypokalemia 
Adult and Pediatric
1 Year3.0 to  <LLN mEq/L 2.5 to3.0mEq/L 2.0 to2.5mEq/L 2.0 mEq/L
3.0 to<LLN mmol/L 2.5 to3.0mmol/L 2.0 to2.5mmol/L 2.0 mmol/L
Infant  <1 Year 3.0 to 3.4 mEq/L
3.0 to 3.4 mmol/L2.5 to3.0mEq/L                
2.5 to <3.0 mmolL2.0 to2.5mEq/L                 
2.0 t o <2.5 mmolL2.0 mEq/L                         
<2.0 mmolL
Hyperkalemia 
Adult and Pediatric
1 Year5.6 to 6.0 mEq/L
5.6 to 6.0 mmol/L6.0 to 6.5 mEq/L
6.0 to 6.5 mmol/L6.5 to 7.0 mEq/L
6.5 to 7.0 mmol/L7.0 mEq/L
7.0 mmol/L
Infant  <1 Year >ULN to 6.0 mEq/L           
>ULN to 6.0 mmol/L> 6.0 to 6.5 mEq/L
> 6.0 to 6.5 mmol/L6.5 to 7.0 mEq/L             
6.5 to 7.0 mmol/L7.0 mEq/L                  
7.0 mmol/L
Hypoglycemia
Adult and Pediatric
1Month55 to 64mg/dL
3.03 to 3.58 mmol/L40 to55mg/dL
2.20 to3.03mmol/L30 to40mg/dL
1.64 to2.20mmol/L30 mg/dL
1.64 mmol/L
Infant,1Month 50 to 54mg/dL
2.8 to 3.0 mmol/L40 to 50mg/dL
2.2 to 2.8mmol/L30 to 40mg/dL
1.7 to 2.2mmol/L30 mg/dL
1.7 mmol/L
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page99 21 October 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hyperglycemia, Nonfasting 116to 160mg/dL 160 to 250 mg/dL 250 to 500 mg/dL 500 mg/dL
6.42 to 8.91 mmol/L 8.91 to 13.90 mmol/L 13.90 to 27.79 mmol/L 27.79 mmol/L
Hyperglycemia, Fasting 110 to 125 mg/dL
6.08 to 6.96 mmol/L>125 to 250 mg/dL
>6.96 to 13.90 mmol/L>250to 500 mg/dL
>13.90 to 27.79 mmol/L>500 mg/dL
>27.79 mmol/L
Hypocalcemia 
(corrected for albumin if 
appropriate*)
Adult and Pediatric
2 Years7.8 <LLN mg/dL
1.94 to <LLN mmol/L7.0 to7.8 mg/dL
1.74 to1.94 mmol/L6.1 to7.0mg/dL
1.51 to1.74 mmol/L6.1mg/dL
1.51mmol/L
Pediatric ≥7 days -2 Years 7.8 to 8.4 mg/dL                               
1.94 to 2.10 mmol/L7.0 to <7.8 mg/dL              
1.74 to <1.94 mmolL6.1 to  <7.0 mg/dL                         
1.51 to < 1.74 mmolL< 6.1mg/dL                           
< 1.51 mmol/L
Infant,7Days 6.5 to 7.5 mg/dL
1.61 to 1.88  mmol/L6.0 to 6.5 mg/dL
1.49 to < 1.61 mmol/L5.5 to 6.0 mg/dL
1.36 to < 1.49 mmol/L 5.5 mg/dL
< 1.36 mmol/L
Hypercalcemia (corrected 
for albumin if appropriate*)
Adult and Pediatric 
7Days>ULN to 11.5 mg/dL 11.5 to 12.5 mg/dL 12.5 to 13.5 mg/dL 13.5 mg/dL
>ULN to 2.88 mmol/L 2.88 to 3.13 mmol/L 3.13 to 3.38 mmol/L 3.38 mmol/L
Infant,7Days 11.5 to 12.4 mg/dL
2.86 to 3.10  mmol/L12.4 to 12.9 mg/dL
> 3.10 to 3.23  mmol/L12.9 to 13.5 mg/dL
> 3.23 to 3.38  mmol/L13.5 mg/dL
> 3.38 mmol/L
Hypocalcemia (ionized) 3.0 mg/dL to LLN 2.5 to < 3.0 mg/dL 2.0 to2.5 mg/dL 2.0 mg/dL
0.74 mmol/L to LLN 0.62 to0.74 mmol/L 0.49 to0.62 mmol/L 0.49 mmol/L
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page100 21 October 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hypercalcemia (ionized) ULN to 6.0 mg/dL 6.0 to 6.5 mg/dL 6.5 to 7.0 mg/dL 7.0 mg/dL
ULN to 1.50 mmol/L 1.50 to 1.63 mmol/L 1.63 to 1.75 mmol/L 1.75 mmol/L
Hypomagnesemia 1.40 to  <LLN mg/dL
1.2 to <LLN mEq/L1.04 to1.40 mg/dL
0.9 to   1.2 mEq/L0.67 to1.04 mg/dL
0.6 to 0.9 mEq/L0.67 mg/dL
0.6 mEq/L
0.58 to <LLN mmol/L 0.43 to0.58 mmol/L 0.28 to0.43 mmol/L 0.28 mmol/L
Hypophosphatemia
Adult and Pediatric
14Years2.0 to < LLN mg/dL
0.63  to LLN mmol/L1.5 to 2.0 mg/dL
0.47 to 0.63 mmol/L1.0 to 1.5 mg/dL
0.31 to 0.47 mmol/L1.0 mg/dL
0.31 mmol/L
Pediatric 1 Year– 14 Years 3.0 to <LLN mg/dL
0.96 to <LLN mmol/L2.5 to 3.0 mg/dL
0.80 to <0.96mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L1.5 mg/dL
<0.47 mmol/L
Pediatric 1Year 3.5 to <LLN mg/dL
1.12 to <LLN mmol/L2.5 to 3.5mg/dL
0.80 to < 1.12mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L1.5 mg/dL
<0.47 mmol/L
Hyperbilirubinemia 
Adult and Pediatric 
>14Days1.0 to 1.5 ULN 1.5 to 2.5 ULN 2.5 to 5.0 ULN 5.0 ULN 
Infant, 14Days
(non-hemolytic)NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 to 30.0 mg/dL
> 428 to 513 μmol/L30.0 mg/dL
> 513 μmol/L
Infant, 14Days
(hemolytic)NA NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 mg/dL
> 428 μmol/L
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page101 21 October 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Blood Urea Nitrogen 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
Hyperuricemia >ULN to 10.0 mg/dL 10.0 to 12.0 mg/dL 12.0 to 15.0 mg/dL 15.0 mg/dL
>ULN to 597 μmol/L 597 to 716 μmol/L 716 to 895 μmol/L 895 μmol/L
Hypouricemia               
Adult and Pediatric           
≥ 1 year   
Infant  < 1 Year1.5 mg/dL to LLN
87 μmol/L to LLN1.0 to1.5 mg/dL
57 to87 μmol/L0.5 to1.0 mg/dL
27 to57 μmol/L0.5 mg/dL
27 μmol/L
N/A 1.0 mg/dl to <LLN -
57 μmol to <LLN0.5 to1.0 mg/dL
27 to57 μmol/L0.5 mg/dL
27 μmol/L
Creatinine** 1.50 to 2.00 mg/dL
133 to 177 μmol/L2.00 to 3.00 mg/dL
177 to 265 μmol/L3.00 to 6.00 mg/dL 
265 to 530 μmol/L6.00 mg/dL
530 μmol/L
Bicarbonate
Adult and Pediatric 
≥ 4 Years16.0 mEq/L to LLN 11.0 to16.0 mEq/L 8.0 to11.0 mEq/L 8.0 mEq/L
16.0 mmol/L to LLN 11.0to16.0 mmol/L 8.0 to11.0 mmol/L 8.0 mmol/L
Pediatric < 4 Years NA 11.0 mEq/Lto <LLN 8.0 to11.0 mEq/L 8.0 mEq/L
11.0 mmol/L to <LLN 8.0 to11.0 mmol/L 8.0 mmol/L
Triglycerides
(Fasting)NA 500 to 750 mg/dL
5.64–8.47 mmol/L750 to 1200 mg/dL
8.47–13.55 mmol/L1200 mg/dL
13.55 mmol/L
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page102 21 October 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
LDL (Fasting)
Adult130 to 160 mg/dL >160 to 190 mg/dL > 190 mg/dL NA
3.35 to 4.15 mmol/L >4.15 to 4.92 mmol/L >4.92 mmol/L
LDL (Fasting)
Pediatric >2 to <18 years110 to 130 mg/dL >130 to 190 mg/dL > 190 mg/dL NA
2.84 to 3.37 mmol/L >3.37 to  4.92 mmol/L >4.92 mmol/L
Hypercholesterolemia
(Fasting)200 to 239 mg/dL 239 to 300 mg/dL 300 mg/dL NA
5.16 to 6.19 mmol/L 6.19 to 7.77 mmol/L 7.77 mmol/L
Pediatric 18 Years 170 to 199 mg/dL
4.39 to 5.15 mmol/L199 to 300 mg/dL
5.15 to 7.77 mmol/L300 mg/dL
7.77 mmol/LNA
Creatine Kinase 3.0 to6.0 ULN 6.0 to10.0 ULN 10.0 to20.0 ULN 20.0 ULN
* Calcium should be corrected for albumin if albumin is < 4.0 g/dL
**An overlap between the Grade 1 scale and the Lab’s normal range for creatinine may result for Male subjects >[ADDRESS_1011049] a 0.
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_1011050] (SGOT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
ALT (SGPT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
GGT 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
Alkaline Phosphatase 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
Total Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Pancreatic Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Lipase 1.0 to 1.5 ULN 1.5 to 3.0 ULN 3.0 to 5.0 ULN 5.0 ULN
Albumin
Pediatrics <16 years 
≥ 16 years- 2.0 to LLN g/dL
20 to LLN g/L2.0 g/dL
20 g/LNA
3.0 g/dL to LLN
30 g/L to LLN2.0 to 3.0 g/dL
20 to 30 g/L2.0 g/dL
20 g/LNA
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page104 21 October 2015URINALYSIS
Grade 1 Grade 2 Grade 3 Grade 4
Hematuria (Dipstick) 1 2 3-4+ NA
Hematuria (Quantitative) 
See Note below
                              Females >ULN -10RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
                              Males 6-10 RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
Proteinuria (Dipstick) 1 2–3 4 NA
Proteinuria, 24 Hour Collection
Adult and Pediatric 
10 Years200 to999 mg/24 h >999 to1999 mg/24 h >1999to3500 mg/24 h 3500 mg/24 h
Pediatric 3 Mo to 
<10Years201 to499 mg/m2/24h >499to799 mg/m2/24 h >799to1000 mg/m2/24 h 1000 mg/ m2/24 h
Glycosuria (Dipstick) 1+ 2-3 4 NA
Notes:
Toxicity grades for Quantitative and Dipstick Hematuria will be assigned by [CONTACT_10870], however for other laboratories, toxicity grades will only be assigned to 
Dipstick Hematuria.
With the exception of lipid tests, any graded laboratory test with a result that is between the LLN and ULN should be assigne d Grade 0.
If the severity of a clinical AE could fall under either one of two grades (e.g., the severity of an AE could be either Grade 2 or Grade 3), select the higher of the two grades for 
the AE.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page105 21 October 2015CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Cardiac Arrhythmia (general)
(By [CONTACT_10871])Asymptomatic AND No 
intervention indicatedAsymptomatic AND Non -
urgent medical intervention 
indicatedSymptomatic, non -life-
threatening AND Non -
urgent medical intervention 
indicated Life-threatening arrhythmi a 
OR Urgent intervention 
indicated
Cardiac-ischemia/Infarction NA NA Symptomatic ischemia 
(stable angina) OR Testing 
consistent with ischemia Unstable angina OR Acute 
myocardial infarction
Hemorrhage (significant acute 
blood loss)NA Symptomatic AND No 
transfusion indicatedSymptomatic AND 
Transfusion of 2units 
packed RBCs (for children 
10cc/kg) indicated Life-threatening hypotension 
OR Transfusion of 2units 
packed RBCs indicated (for 
children 10cc/kg) indicated
Hypertension (with repeat 
testing at same visit)140–159mmHg systolic 
OR 
90–99 mmHg diastolic159–179 mmHg systolic 
OR 
99–109 mmHg diastolic179mmHg systolic 
OR 
109mmHg diastolicLife-threatening consequences 
(eg, malignant hypertension) 
OR Hospi[INVESTIGATOR_059] (other than 
ER visit) indicated
Pediatric 17Years (with 
repeat testing at same visit)NA 91st–94th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)≥95th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)Life-threatening consequences 
(eg, malignant hypertension) 
OR Hospi[INVESTIGATOR_374] 
(other than emergency room 
visit)
Hypotension NA Symptomatic, corrected w ith 
oral fluid replacementSymptomatic, IV fluids 
indicatedShock requiring use of 
vasopressors or mechanical 
assistance to maintain blood 
pressure
Pericardial Effusion Asymptomatic, small 
effusion requiring no 
interventionAsymptomatic, moderate or 
larger effusion requiring no 
interventionEffusion with non -life-
threatening physiologic 
consequences OR Effusion 
with nonurgent intervention 
indicatedLife-threatening consequences 
(eg, tamponade) OR Urgent 
intervention indicated
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page106 21 October 2015CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Prolonged PR Interval PR interval 
0.21 to 0.25 secPR interval
0.25 secType II 2nd degree AV 
block OR Ventricular pause 
3.0 secComplete AV block 
Pediatric [ADDRESS_1011051] degree AV block
(PR > normal for age and 
rate)Type I 2nd degree AV block Type II 2nd degree AV 
block Complete AV block
Prolonged QTc Asymptomatic, QTc interval 
0.45 to 0.47 sec OR Increase 
interval 0.03 sec above 
baselineAsymptomatic, QTc interval 
0.48 to 0.49 sec OR Increase 
in interval 0.03 to 0.05 sec 
above baselineAsymptomatic, QTc interval 
0.50sec OR Increase in 
interval 0.06sec above 
baselineLife-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Pediatric 16Years Asymptomatic, QTc interval 
0.450 to 0.464 sec Asymptomatic, QTc interval 
0.465 to 0.479 sec Asymptomatic, QTc interval 
0.480 sec Life-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Thrombosis/Embolism NA Deep vein thrombosis AND 
No intervention indicated (eg, 
anticoagulation, lysis filter, 
invasive procedure) Deep vein thrombosis AND 
Intervention indicated (eg, 
anticoagulation, lysis filter, 
invasive procedure) Embolic event (eg, pulmonary 
embolism, life -threatening 
thrombus) 
Vasovagal Epi[INVESTIGATOR_1865] (associated 
with a procedure of any kind)Present without loss of 
consciousness Present with transient loss of 
consciousnessNA NA
Ventricular Dysfunction 
(congestive heart failure, 
CHF)NA Asymptomatic diagnostic 
finding AND intervention 
indicatedNew onset with symptoms 
OR Worsening symptomatic 
CHFLife-threatening CHF
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page107 21 October 2015RESPI[INVESTIGATOR_10806] 1 Grade 2 Grade 3 Grade 4
Bronchospasm (acute) FEV1 or peak flow  reduced to 
70% to 80%FEV1 or peak flow  50% to 69% FEV1 or peak flow  25% to 
49% Cyanosis OR FEV1 or peak flow  
25% OR Intubation
Dyspnea or Respi[INVESTIGATOR_10807] & functional 
activities Dyspnea on exertion causing 
greater than minimal interference 
with usual social & functional 
activities Dyspnea at rest causing 
inability to perform usual 
social & functional activities Respi[INVESTIGATOR_10808] 14 Years Wheezing OR minimal 
increase in respi[INVESTIGATOR_10809] 
90% to 95%Dyspnea at rest causing 
inability to perform usual 
social & functional activities 
OR Pulse oximetry 90%Respi[INVESTIGATOR_422258]/VISUAL
Grade 1 Grade 2 Grade 3 Grade 4
Uveitis Asymptomatic but detectable 
on examSymptomatic anterior uveitis OR 
Medical intervention indicatedPosterior or pan -uveitis OR 
Operative intervention 
indicatedDisabling visual loss in affected 
eye(s) 
Visual Changes (from 
baseline)Visual changes causing no or 
minimal interference with 
usual social & functional 
activitiesVisual changes causing greater 
than minimal interference with 
usual social & functional 
activitiesVisual changes causing 
inability to perform usual 
social & functional activitiesDisabling visual loss in affected 
eye(s)
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page108 21 October 2015SKIN
Grade 1 Grade 2 Grade 3 Grade 4
Alopecia Thinning detectable by 
[CONTACT_10872] (for disabled 
adults)Thinning or patchy hair loss 
detectable by [CONTACT_10873] –Rash Localized macular rash Diffuse macular, 
maculopapular, or 
morbilliform rash OR Target 
lesions Diffuse macular, 
maculopapular, or morbilliform 
rash with vesicles or limited 
number of bullae OR 
Superficial ulcerations of 
mucous membrane limited to 
one siteExtensive or generalized 
bullous lesions OR 
Stevens-Johnson syndrome 
OR Ulceration of mucous 
membrane involving two 
or more distinct mucosal 
sites OR Toxic epi[INVESTIGATOR_7387] (TEN)
Hyperpi[INVESTIGATOR_10810] (itching –no skin 
lesions) 
(See also Injection Site 
Reactions: Pruritis associated 
with injection)Itching causing no or 
minimal interference with 
usual social & functional 
activitiesItching causing greater than 
minimal interference with 
usual social & functional 
activitiesItching causing i nability to 
perform usual social & 
functional activities NA
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page109 21 October 2015GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Anorexia Loss of appetite w ithout 
decreased oral intakeLoss of appetite associated with 
decreased oral intake without 
significant weight loss Loss of appetite associated 
with significant weight loss Life-threatening consequences 
OR Aggressive intervention 
indicated [eg, tube feeding or 
total parenteral nutri tion]
Ascites Asymptomatic Symptomatic AND Intervention 
indicated (eg, diuretics or 
therapeutic paracentesis)Symptomatic despi[INVESTIGATOR_10811]-threatening consequences
Cholecystitis NA Symptomatic AND Medical 
intervention indicatedRadiologic, endoscopic, or 
operative intervention 
indicatedLife-threatening consequences 
(eg, sepsis or perforation) 
Constipation NA Persistent constipation requiring 
regular use of dietary 
modifications, laxatives, or 
enemas Obstipation with manual 
evacuation indicatedLife-threatening consequences 
(eg, obstruction)
Diarrhea 
Adult and Pediatric 
1YearTransient or intermittent 
epi[INVESTIGATOR_10812] 3stools 
over baseline/24 hrPersistent epi[INVESTIGATOR_10813] 
4–6 stools over baseline per 
24hrs. Bloody diarrhea OR Increase 
of 7stools per 24 -hour 
period OR IV fluid 
replacement indicatedLife-threatening consequences 
(eg, hypotensive shock)
Pediatric 1Year Liquid stools (more 
unformed than usual) but 
usual number of stoolsLiquid stools with increased 
number of stools OR Mild 
dehydrationLiquid stools with moderate 
dehydrationLiquid stools resulting in 
severe dehydration with 
aggressive r ehydration 
indicated OR Hypotensive 
shock
Dysphagia-Odynophagia Symptomatic but able to eat 
usual dietSymptoms causing altered 
dietary intake without medical 
intervention indicatedSymptoms causing severely 
altered dietary intake with 
medical intervention indicatedLife-threatening reduction in 
oral intake
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page110 21 October 2015GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Mucositis/Stomatitis 
(clinical exam)
See also Proctitis, 
Dysphagia-OdynophagiaErythema of the mucosa Patchy pseudomembranes or 
ulcerations Confluent pseudomembranes 
or ulcerations OR Mucosal 
bleeding with minor traumaTissue necrosis OR Diffuse 
spontaneous mucosal bleeding 
OR Life-threatening 
consequences (eg, aspi[INVESTIGATOR_1516], 
choking)
Nausea Transient ( 24hours) or 
intermittent nausea with no 
or minimal interference with 
oral intakePersistent nausea resulting in 
decreased oral intake for 24 –48 
hoursPersistent nausea resulting in 
minimal oral intake for  48 
hours OR Aggressive 
rehydration indicated (eg, 
IVfluids)Life-threatening consequences 
(eg, hypotensive shock)
Pancreatitis NA Symptomatic AND 
Hospi[INVESTIGATOR_10814] 
(other than ER visit)Symptomatic AND 
Hospi[INVESTIGATOR_374] 
(other than ER visit)Life-threatening consequences 
(eg, sepsis, circulatory failure, 
hemorrhage)
Proctitis (functional -
symptomatic)
Also seeMucositis/ 
Stomatitis for Clinical 
ExamRectal discomfort AND No 
intervention indicatedSymptoms causing greater than 
minimal interference with usual 
social & functional activities OR 
Medical intervention indicated Symptoms causing inability to 
perform usual social/ 
functional activities OR 
Operative intervention 
indicated Life-threatening consequences 
(eg, perforation)
Vomiting Transient or intermittent 
vomiting with no or 
minimal interference with 
oral intakeFrequent epi[INVESTIGATOR_10815]-threatening consequences 
(eg, hypotensive shock)
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page111 21 October 2015NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Alteration in Personality -
Behavior or in Mood (eg, 
agitation, anxiety, 
depression, mania, 
psychosis)Alteration causing no or 
minimal interference with 
usual social & functional 
activities Alteration causing greater than 
minimal interference with 
usual social & functional 
activities Alteration causing inability to 
perform usual social & 
functional activities Behavior potentially harmful 
to self or others (eg, 
suicidal/homicidal ideation or 
attempt, acute psychosis) OR 
Causing inability to perform 
basic self-care functions
Altered Mental Status 
For Dementia, see Cognitive 
and Behavioral/Attentional 
Disturbance (including 
dementia and ADD)Changes causing no or 
minimal interference with 
usual social & functional 
activitiesMild lethargy or somnolence 
causing greater than minimal 
interference with usual social 
& functional activitiesConfusion, memory 
impairment, lethargy, or 
somnolence causing inability 
to perform usual social & 
functional activitiesDelirium OR obtundation, OR 
coma
Ataxia Asymptomatic ataxia 
detectable on exam OR 
Minimal ataxia causing no 
or minimal interference with 
usual social & functional 
activitiesSymptomatic ataxia causing 
greater than minimal 
interference with usual social 
& functional activitiesSymptomatic ataxia causing 
inability to perform usual 
social & functional activities Disabling ataxia causing 
inability to perform basic self -
care functions
Cognitive and 
Behavioral/Attentional 
Disturbance (including 
dementia and Attention 
Deficit Disorder) Disability cau sing no or 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources not indicatedDisability causing greater than 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources on part -time basis 
indicatedDisability causing inability to 
perform usual social & 
functional activities OR 
Specialized resources on a 
full-time basis indicatedDisability causing inability to 
perform basic self -care 
functions OR 
Institutionalization indicated
CNS Ischemia
(acute)NA NA Transient ischemic attack Cerebral vascular accident 
(CVA, stroke) with 
neurological deficit 
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page112 21 October 2015NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Developmental delay –
Pediatric 16 YearsMild developmental delay, 
either motor or cognitive, as 
determined by [CONTACT_7424] a developmental 
screening tool appropriate 
for the setting Moderate developmental 
delay, either motor or 
cognitive, as determined by 
[CONTACT_7425] a 
developmental screening tool 
appropriate for the setting Severe developmental delay, 
either motor or cognitive, as 
determined by [CONTACT_7424] a developmental 
screening tool appropriate for 
the setting Developmental regression, 
either motor or cognitive, as 
determined b y comparison 
with a developmental 
screening tool appropriate for 
the setting
Headache Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater 
than minimal interference with 
usual social & functional 
activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesSymptoms causing inability to 
perform basic self -care 
functions OR Hospi[INVESTIGATOR_373] (other than ER visit) 
OR Headache with significant 
impairment of alertness or
other neurologic function 
Insomnia NA Difficulty sleepi[INVESTIGATOR_10816]/functional activitiesDifficulty sleepi[INVESTIGATOR_10817] & functional activitiesDisabling insomnia causing 
inability to perform basic self -
care functions
Neuromuscular Weakness 
(including myopathy & 
neuropathy) Asymptomatic with 
decreased strength on exam 
OR Minimal muscle weak -
ness causing no or minimal 
interference with usual 
social & functional activitiesMuscle weakness causing 
greater than minimal 
interference with usual social 
& functional activitiesMuscle weakness causing 
inability to perform usual 
social & functional activities Disabling muscle weakness 
causing inability to perform 
basic self -care functions OR 
Respi[INVESTIGATOR_10818] 
(including paresthesia and 
painful neuropathy)Asymptomatic with sensory 
alteration on exam or 
minimal paresthesia causing 
no or minimal interference 
with usual social &
functional activities Sensory alteration or 
paresthesia causing greater 
than minimal interference with 
usual social & functional 
activities Sensory alteration or 
paresthesia causing inability to 
perform usual social & 
functional activitiesDisabling sen sory alteration or 
paresthesia causing inability to 
perform basic self -care 
functions
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page113 21 October 2015NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Seizure: (new onset) NA 1 seizure 2–4 seizures Seizures of any kind that are 
prolonged, repetitive (eg, 
status epi[INVESTIGATOR_7397]), or difficult 
to control (eg, refractory 
epi[INVESTIGATOR_002])
Seizure: (pre- existing) 
For Worsening of Existing 
Epi[INVESTIGATOR_10819]-
existing seizures (non -
repetitive) without change in 
seizure character OR 
infrequent breakthrough 
seizures while on stable meds 
in a previously controlled 
seizure disorderChange in seizure character 
from baseline either in 
duration or quality (eg, 
severity or focality) Seizures of any kind that are 
prolonged, repetitive (eg, 
status epi[INVESTIGATOR_7397]), or difficult 
to control (eg, refractory 
epi[INVESTIGATOR_002])
Seizure 
–Pediatric 18 YearsSeizure, generalized onset 
with or without secondary 
generalization, lasting 
< 5minutes with < 24hours 
post ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 5 –20 
minutes with 
< [ADDRESS_1011052] ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 
> 20 minutes Seizure, generalized onset 
with or witho ut secondary 
generalization, requiring 
intubation and sedation
Syncope (not associated 
with a procedure)NA Present NA NA
Vertigo Vertigo causing no or 
minimal interference with 
usual social & functional 
activitiesVertigo causing greater than 
minimal interference with 
usual social & functional 
activities Vertigo causing inability to 
perform usual social & 
functional activitiesDisabling vertigo causing 
inability to perform basic self -
care functions
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page114 21 October 2015MUSCULOSKELETAL
Grade 1 Grade 2 Grade 3 Grade 4
Arthralgia
See also ArthritisJoint pain causing no or 
minimal interference with 
usual social & functional 
activitiesJoint pain causing greater than 
minimal interference with usual 
social & functional activitiesJoint pain causing inability 
to perform usual social & 
functional activitiesDisabling joint pain causing 
inability to perform basic self -
care functions
Arthritis
See also ArthralgiaStiffness or joint sw elling 
causing no or minimal 
interference with usual 
social & functional activitiesStiffness or joint sw elling causing 
greater than minimal interference 
with usual social & functional 
activitiesStiffness or joint sw elling 
causing inability to perform 
usual social & functional 
activitiesDisabling joint stiffness or 
swelling causing inability to 
perform basic self -care 
functions
Bone Mineral Loss BMD t-score or z- score
–2.5 to –1.0 BMD t-score or z- score–2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences 
Pediatric 21Years BMD z-score 
–2.5 to –1.0BMD z-score < –2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences 
Myalgia
(non-injection site)Muscle pain causing no or 
minimal interference with 
usual social & functional 
activitiesMuscle pain causing greater than 
minimal interference with usual 
social & functional activitiesMuscle pain causing 
inability to perform usual 
social & functional activitiesDisabling muscle pain causing 
inability to perform basic self -
care functions
Osteonecrosis NA Asymptomatic with radiographic 
findings AND No operative 
intervention indicatedSymptomatic bone pain with 
radiographic findings OR 
Operative intervention 
indicatedDisabling bone pain with 
radiographic findings causing 
inability to perform basic self -
care functions
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page115 21 October 2015SYSTEMIC
Grade 1 Grade 2 Grade 3 Grade 4
Acute Systemic Allergic 
Reaction Localized urticaria 
(wheals) with no medical 
intervention indicatedLocalized urticaria with medical 
intervention indicated OR Mild 
angioedema with no medical 
intervention indicatedGeneralized urticaria OR 
Angioedema with medical 
intervention indicated OR 
Symptomatic mild 
bronchospasmAcute anaphylaxis OR Life -
threatening bronchospasm OR 
laryngeal edema
Chills Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activities Symptoms causing inability to 
perform usual social & 
functional activitiesNA
Fatigue
MalaiseSymptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesIncapacitating fatigue/malaise 
symptoms causing inability to 
perform basic self -care 
functions
Fever (nonaxillary) 37.7C to 38.6C
99.8F to 101.5F38.7C to 39.3C
101.6F to 102.8F39.4C to 40.5C
102.9F to 104.9F40.5C 
104.9F
Pain-Indicate Body Site
See also Injection Site 
Pain, Headache, 
Arthralgia, and MyalgiaPain causing no or 
minimal interference with 
usual social & functional 
activitiesPain causing greater than minimal 
interference with usual social & 
functional activitiesPain causing inability to 
perform usual social & 
functional activitiesDisabling pain causing 
inability to perform basic self -
care functions OR 
Hospi[INVESTIGATOR_059] (other than ER 
visit) indicated
Unintentional Weight 
LossNA 5% to 9% loss in body weight from 
baseline10% to 19% loss in body 
weight from baseline20% loss in body weight 
from baseline OR  Aggressive 
intervention indicated [eg, 
tube feeding or total parenteral 
nutrition]
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page116 21 October 2015INJECTION SITE REACTION
Grade 1 Grade 2 Grade 3 Grade 4
Injection Site Pain (pain 
without touching)
Or Tenderness (pain when 
area is touched) Pain/tenderness causing no 
or minimal limitation of use 
of limbPain/tenderness limiting use of 
limb OR Pain/tenderness 
causing greater than minimal 
interference with usual social 
& functional activitiesPain/tenderness causing 
inability to perform usual 
social & functional activitiesPain/tenderness causing inability 
to perform basi c self-care 
function OR Hospi[INVESTIGATOR_059] 
(other than ER visit) indicated 
for management of 
pain/tenderness
Injection Site Reaction 
(Localized), 15YearsErythema OR Induration
of 55cm to 99cm (or 
2581 cm2)Erythema OR Induration OR 
Edema 9cm any diameter 
(or 81cm2)Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR DrainageNecrosis (involving dermis and 
deeper tissue)
Pediatric 15Years Erythem a OR Induration 
OR Edema present but 
2.5cm diameterErythem a OR Induration 
OR Edema > 2.5cm 
diameter but < 50% surface 
area of the extrem ity 
segment (eg, upper 
arm/thigh)Erythem a OR Induration 
OR Edema involving 
50% surface area of the 
extremity segment (eg, 
upper arm/thigh) OR 
Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR 
DrainageNecrosis (involving dermis and 
deeper tissue)
Pruritis Associated with 
Injection 
See also Skin: Pruritis 
(itching—no skin lesions)Itching localized to injection 
site AND Relieved 
spontaneously or w ith 
48h treatment Itching beyond the injection 
site but not generalized OR 
Itching localized to injection 
site requiring 48h treatment Generalized itching causing 
inability to perform usual 
social & functional activitiesNA
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page117 21 October 2015ENDOCRINE/METABOLIC
Grade 1 Grade 2 Grade 3 Grade 4
Lipodystrophy (eg, back 
of neck, breasts, 
abdomen)Detectable by [CONTACT_10874] 
(for young children and 
disabled adults)Detectable on physical exam by 
[CONTACT_10875][INVESTIGATOR_10820]-threatening consequences 
(eg, ketoacidosis, 
hyperosmolar non -ketotic 
coma) 
Gynecomastia Detectable by [CONTACT_10874] 
(for young children and 
disabled adults)Detectable on physical exam by 
[CONTACT_10876] & functional activities OR 
Thyroid suppression therapy 
indicatedSymptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despi[INVESTIGATOR_10821]-threatening consequences 
(eg, thyroid storm)
Hypothyroidism Asymptomatic Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid replacement therapy 
indicatedSymptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despi[INVESTIGATOR_10821]-threatening consequences 
(eg, myxedema coma)
Lipoatrophy (eg, fat loss 
from the face, extremities, 
buttocks)Detectable by [CONTACT_10874] 
(for young children and 
disabled adults)Detectable on physical exam by 
[CONTACT_10877]-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page118 21 October 2015GENITOURINARY
Grade 1 Grade 2 Grade 3 Grade 4
Intermenstrual Bleeding 
(IMB)Spotting observed by [CONTACT_10878] -
threatening hypotension OR 
Operative intervention 
indicated
Urinary Tract 
obstruction (eg, stone)NA Signs or symptoms of urinary 
tract obstruction without 
hydronephrosis or renal 
dysfunctionSigns or symptoms of urinary 
tract obstruction with 
hydronephrosis or renal 
dysfunctionObstruction causing life -
threatening consequences
INFECTION
Grade 1 Grade 2 Grade 3 Grade 4
Infection (any other 
than HIV infection)Localized, no systemic antiμbial 
treatment indicated AND 
Symptoms causing no or 
minimal interference with usual 
social & functional activitiesSystemic antiμbial treatment 
indicated OR Symptoms 
causing greater than minimal 
interference with usual social 
& functional act ivitiesSystemic antiμbial treatment 
indicated AND Symptoms 
causing inability to perform 
usual social & functional 
activities OR Operative 
intervention (other than simple 
incision and drainage) indicatedLife-threatening 
consequences (eg, septic 
shock)
Basic Self-care Functions: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding.
Usual Social & Functional Activities: Adaptive tasks and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, use of transpor tation, pursuing a hobby, etc.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page119 21 October 2015Appendix 5. Definitions of Stage 3 Opportunistic Illnesses in HIV (CDC 
Guidelines)
1. Candidiasis of bronchi, trachea, or lungs 
2.Candidiasis of esophagus
3.Cervical cancer, invasive
4.Coccidioidomy cosis, disseminated or extrapulmonary
5.Cryptococcosis, extrapulmonary
6.Cryptosporidiosis, chronic intestinal ( 1 month duration)
7.Cytomegalovirus disease (other than liver, spleen or nodes)
8.Cytomegalovirus retinitis (with loss of vision)
9.Encephalopath y, HIV-related
10. Herpes simplex: chronic ulcer(s) ( 1month duration); or bronchitis, pneumonitis or 
esophagitis
11.Histoplasmosis, dis seminated or extrapulmonary
12.Isosporiasis, chronic intestinal ( 1month duration)
13.Kaposi’s sarcoma
14.Lymphoma, Burkitt’s (or equivalent term)
15.Lymphoma, immunoblastic (or equivalent term)
16.Lymphoma, primary , of brain
17.Mycobacterium avium complex or Myobacterium kansasii, disseminated or extrapulmonary
18.Mycobacterium tuberculosis , of any site,  pulmonary , disseminated or extrapulmonary
19.Mycobacterium , other species or unidentified species, disseminated or extrapulmonary
20.Pneumocy stis jirovecii (previously  known as “ Pneumocystis carinii ) pneumonia
21.Pneumonia, recurrent
22. Progressive multifocal leukoencephalopathy
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page120 21 October 201523.Salmonella septicemia, recurrent
24.Toxoplasmosis of brain
25.Wasting sy ndrome attributed to HIV infection
CDC Stage -3-Defining Opportunistic I llnesses in HIV Infection -2014 {[ZIP_CODE]}
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page121 21 October 2015Appendix 6.Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements
1)Definitions
a.Definition of Childbearing Potential
For the purposes of this study , a female born subject is considered of child bearing potential 
following the initiation of pubert y (Tanner stage 2) until becoming post -menopausal, unless 
permanentl y sterile or with medical ly documented ovarian failure.
Women are considered to be in a postmenopausal state when they  are >54years ofage with 
cessation of previously  occurring menses for > 12 months without an alternative cause. In 
addition, women of an y age with amenorrhea of >12 months may  also be considered 
postmenopausal if their follicle stimulating hormone (FSH) level is in the postmenopausal range 
and they are not using hormonal contraception or hormonal replacement therapy .
Permanent sterilization includes hy sterectomy , bilateral oophorectom y, or bilateral 
salpi[INVESTIGATOR_10822] a female subject of an y age.
b.Definition of Male Fertili ty
For the purposes of this study , a male born subject is considered to be fertile after the initiation 
of puberty unless permanently  sterile by [CONTACT_10879] y or medical documentation.
2)Contraception Requirements for Female Subjects
a.Study Drug Effe cts on Pregnancy and Hormonal Contraception
The data on GS -9883/F/TAF in pregnant women is limited or not available. There is no 
suspi[INVESTIGATOR_739908]. Relevant 
non-clinical reproductive studies for human pregnancy  do not indicate a strong suspi[INVESTIGATOR_143355] y/fetotoxicity .Data from clinical pharmacokinetic interaction studies of 
GS-9883 and F/TAF have demonstrated that there is no reduction in the clinical efficacy  of 
hormonal contrace ption or that the effect on hormonal contraception is insignificant. 
Please refer 
to the latest version of the GS -9883/F/TAF investigator’s brochure for additional information.
b.Contraception Requirements for Female Subjects of Childbearing Potential
The inclusion of female subjects of childbearing potential requires the use of highl y effective 
contraceptive measures.  They  must have a negative serum pregnancy  test at Screening and a 
negative pregnancy  test on the Day  [ADDRESS_1011053] 
will be performed at the end of relevant s ystemic exposure. I n the event of a delay ed menstrual 
period (over one month between menstruations), a pregnancy test must be performed to rule out 
pregnancy . This is even true for women of childbearing potential with infrequent or irregular 
periods. Female subjects must agree to one of the following from Screening until 30 days 
following the end of relevant sy stemic exposure.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page122 21 October 2015Complete abstinence from intercourse of reproductive potential .  Abstinence is an acceptable 
method of contraception only  when it is in line with the subject’s preferred and usual 
lifestyle.
Or
Consistent and correct use of 1 of the following methods of birth control listed below. 
Intrauterine device (IUD) with a fa ilure rate of <1% per y ear
Intrauterine hormone -releasing s ystem (IUS) with a failure rate of <1% per y ear
Tubal sterilization
Essure micro- insert system (provided confirmation of success 3 months after procedure)
Vasectom y in the male partner (provided that the partner is the sole sexual partner and 
had confirmation of surgical success 3 months after procedure)
Or
Consistent and correct use of one hormonal method and one barrier method
Barrier methods
■ Diaphragm with spermicide
■Cervical cap with spermicide
■Male condom (with or without spermicide)
Hormonal methods
■Oral contraceptives (either combined or progesterone only )
■Injectable progesterone
■Implants of levonorgestrel
■Transdermal contraceptive patch
■Contraceptive vaginal ring
Female subjects must also refrain from egg donation and in vitro fertilization during treatment 
and until at least 30 day s after the end of relevant sy stemic exposure.
GS-9883/F/TAF
Protocol GS -US-380-1878 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page123 21 October [ZIP_CODE]) Contraception Requirements for Male Subjects
It is theoreticall y possible that a relevant s ystemic concentration ma y be achieved in a female 
partner from exposure of th e male subject’s seminal fluid. Therefore, male subjects with female 
partners of childbearing potential must use condom s during treatment and until [ADDRESS_1011054] 90 days 
after the end of relevant systemic exposure.
4)Unacceptabl e Birth Control Methods
Birth control methods that are unacceptable include periodic abstinence (e.g., calendar, 
ovulation, sy mptothermal, post -ovulation methods), withdrawal (coitus interruptus), spermicides 
only, and lactational amenorrhea method (LAM). Female condom and male condom should not 
be used together.
5) Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify  the investigator if they  become pregnant at any  time during 
the study, or if they  become pregnant within [ADDRESS_1011055] report the information to 
the investigator.  Instructions for reporting pregnancy , partner pregnancy , and pregnancy  
outcome are outlined in Section 7.3.